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Gonadotrophin-releasing hormone (GnRH) can inhibit proliferation of multiple 
reproductive tissue cancer cell lines through direct interaction with GnRH receptors 
(GnRHR) on tumour cells. GnRH analogues may therefore have a role in treating 
some cancers. The signalling pathways associated with these inhibitory effects are 
poorly defined, and characterising them may help to understand therapeutic 
sensitivity. To elucidate these pathways, transcriptomic and proteomic approaches 
were used to compare the effects of the GnRH agonist Triptorelin in responsive 
GnRHR-transfected HEK293 cells (SCL60) and unresponsive (HEK293) cells both 
in vitro for up to 24h and in vivo for up to 7 days. Gene expression profiling 
demonstrated that SCL60 gene expression was temporally regulated with Triptorelin 
treatment, with expression of some genes increased at one time point but decreased 
at another. Early and mid-phase gene expression changes comprised mainly 
transcription factors and late changes included the hormonal signalling component 
CGA. Pathway analysis implicated mitogen-activated protein kinase and cell cycle 
pathways, supporting the detection of G2/M arrest. Signalling effects within SCL60 
xenografts, 4 and 7 days following Triptorelin treatment, were investigated using a 
phosphoproteomic antibody array. Changes included cell cycle and apoptosis 
regulators, as well as cell surface receptors and NFκB signalling pathway members. 
Reverse-phase protein arrays and western blotting also showed that pAkt was 
decreased and pNFκB-p65 was increased after Triptorelin treatment in vitro. An 
NFκB inhibitor enhanced the anti-proliferative effect of Triptorelin in SCL60 cells in 
vitro, suggesting that NFκB acts as a survival factor in the response to GnRHR 
stimulation. A range of GnRHR expression was observed in breast cancer tumours 
by immunohistochemistry, and on average GnRHR expression was significantly 
higher in the Triple Negative Phenotype (TNP) subgroup and in grade 3 tumours. A 
GnRHR-transfected breast cancer cell line, MCF7-h14, was developed. Despite this 
expressing a similar level of GnRHR to responsive SCL60 cells, MCF7-h14 cells 
were not inhibited by GnRHR activation, indicating that a high level of GnRHR is 
insufficient for the antiproliferative effects of Triptorelin. 
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1.1 Breast cancer 
1.1.1 The Hallmarks of Cancer 
Normal cell division is carefully controlled to ensure that cells do not divide 
inappropriately and cause harm to the host, such as when the cell is damaged. This 
regulation is sometimes lost as a result of mutations (either genetic or epigenetic) 
accumulating in the cell and can lead to tumour formation. Tumour-promoting 
mutations include the loss of tumour suppressor gene function [2] or the gain of 
function of oncogenes [3]. Tumour suppressors inhibit growth, for instance by 
implementing checkpoints in the cell cycle to prevent damaged DNA being 
replicated [2]. Oncogenes promote growth, for example by promoting the passage 
through cell cycle checkpoints, or by increasing the activity of particular growth 
factors in the cell [3]. It is the balance of tumour suppressor and oncogene activities 
that is important in maintaining the regulation of cell growth and proliferation. 
 
When regulation becomes aberrant, the surrounding cells usually recognise the rogue 
cell and destroy it as though it were an invading pathogen. However, since the rogue 
cell is derived from a normal host cell it may escape detection. In this rare event the 
cell may be permitted to survive in the tissue and proliferate without control. Many 
of the daughter cells will die, but due to the increased rate of proliferation and the 
competitive environment in which the cells are being produced, the number of 
surviving cells may increase, passing on the mutations required to survive in such an 
environment to their daughter cells. In this manner a tumour may be formed.  
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A tumour (or neoplasm) is defined as a mass of tissue resulting from abnormal 
growth of cells. For a tumour to be considered cancerous, additional features must be 
present. Hanahan and Weinberg suggested six hallmarks of cancer [4] to aid its 
definition; these are listed below [4]. 
1. Self-sufficiency in growth signals 
2. Insensitivity to anti-growth signals 
3. Ability to evade apoptosis 
4. Limitless potential for replication 
5. Sustained angiogenesis 
6. Tissue invasion and metastasis 
The authors have recently suggested the addition of a further two hallmarks: 
Deregulating cellular energetics and Avoiding immune destruction [5] and provide a 
detailed review of all eight hallmarks [5].  
 
These hallmarks are a useful way to think about the processes involved in cancer. A 
tumour may not necessarily become cancerous. Proliferation may be successfully 
limited by the tissue microenvironment, and equilibrium may be reached between the 
level of proliferation and death, that maintains the size of the tumour. Equally, a 
tumour may continue to grow, but grows so slowly that it may never cause 
pathological damage to the host. These tumours are referred to as being benign. They 
are self-limiting and do not invade surrounding tissues nor metastasise (spread to 
other parts of the body). 
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Figure 1: Breast Anatomy.  
Adapted from the original image by Patrick J. Lynch, medical illustrator and C. Carl Jaffe, 
MD, cardiologist [6] and permission for reproduction of the figure was granted under the terms 
of the Creative Commons Attribution 3.0 Unported license. 
 
A schematic of the human female breast anatomy is illustrated in Figure 1. The 
breasts are situated in front of the pectoralis muscle on the chest wall [7]. Each breast 
comprises a ductal system surrounded by stroma and fatty tissue [8]. The ducts meet 
at the nipple, from which milk is ejected during breastfeeding [8]. 
 
The breast is highly sensitive to hormones. It changes in composition and appearance 
during a woman’s life from puberty, through each menstrual cycle, pregnancy and 
the menopause [8, 9]. The breasts can also change in shape and size with variation in 
the woman’s body weight, since the breast is composed largely of adipose tissue [8, 
9]. 
 
The adult breast is comprised of 15-25 major (segmental) ducts that branch into 
smaller (subsegmental) ducts [8, 9]. Lobules (terminal duct lobular units, TDLUs) 
bud from subsegmental ducts [8, 9] and are composed of intralobular stroma and 
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acini (small tubules) [8]. As a woman continues to age, particularly past the third 
decade, her breasts become less dense (more fatty) [8]. For a detailed review of 
breast anatomy see references [8] and [9]. 
 
1.1.3 Breast Cancer Background 
1.1.3.1 Epidemiology 
Breast cancer is a heterogeneous disease from which 12,000 women in the UK died 
in 2008 [10]. It almost always occurs in the female breast, with nearly 46,000 women 
diagnosed with breast cancer in the UK in 2007 compared to less than 300 men [10].  
 
1.1.3.2 Risk factors 
Other than gender, factors that influence the risk of developing breast cancer include 
age, family history, exposure to radiation or other carcinogens such as certain 
chemicals or alcohol, ethnic group, and lifestyle factors such as diet and exercise [11, 
12]. Because breast tissue is highly sensitive to levels of circulating oestrogen, life 
events and choices such as the age at which a woman first gives birth, the number of 
children she has, early menarche, late menopause, breastfeeding, the use of the 




The majority of breast cancers are thought to originate in the epithelial lining of the 
TDLU [8] as ductal hyperproliferation. This develops into ductal carcinoma in situ 
(DCIS) as the cells acquire further genetic and epigenetic aberrations [8]. As the 
disease progresses it acquires the ability to invade and metastasize (invasive 
carcinoma) [8]. 
 
Tumours are composed, much like healthy tissues, of epithelial cells and stroma, but 
breast carcinomas have increased necrosis, vascularisation and invasion compared to 
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healthy breast tissue [8]. The cancerous epithelial tissues often appear poorly 
differentiated and more heterogeneous than healthy tissue [8]. 
 
1.1.3.4 Subtypes 
It is now generally accepted that there are five major molecular subtypes of breast 
cancer. The five subtypes are: Luminal A, Luminal B, Basal-like, Human Epidermal 
growth factor Receptor 2 (HER2) positive/Oestrogen Receptor (ER) negative, and 
normal breast-like [13]. This classification has been deduced from gene expression 
profiling of primary breast tumours and has been reproduced across different 
microarray platforms using multiple datasets [14, 15]. It is also supported by 
previous classifications based on histological and immunological characteristics of 
breast cancers [14]. Each subtype has distinct characteristics and responds differently 
to treatment [13]. 
 
1.1.3.5 Diagnosis 
Early detection of breast cancer is essential for improved prognosis [16]. Breast 
screening by mammography is currently in place in the UK for women 50-70 years 
of age [17]. Diagnosis is made following screening or through the identification of a 
palpable lump in the breast [17]. A breast biopsy is taken and the cells are tested for 
presence of oestrogen receptor, progesterone receptor and HER2 [17]. The presence 
or absence of each of these biomarkers can determine the subtype, and the most 
suitable treatment [17]. 
 
1.1.3.6 Treatment 
Surgery is usually the first treatment for breast cancer after diagnosis [17]. Only the 
tumour may be removed if it is small enough, or it may be necessary to remove the 
entire breast and surrounding lymph nodes [17]. Surgery can often be an effective 
treatment if the cancer has not yet metastasized, but surgery is not always possible 
and in many cases the disease recurs even after the apparent removal of all the cancer 
cells [18]. This may be due to the presence of cancer stem cells [18, 19].  
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1.1.3.6.1 Cytotoxic therapy 
All cancer cells originate from a host cell, so at least initially are very similar to 
healthy cells. The development of effective treatments depends on the ability to 
exploit subtle differences between the healthy and abnormal cells. Chemotherapy 
(treatment with cytotoxic drugs) and radiotherapy (treatment with radiation) exploit 
the higher growth rate of tumours [20]. They cause damage to all cells but have a 
greater impact on the cells that are rapidly dividing because cells are committed to 
apoptosis only after the damage is identified by checkpoints in the cell cycle. By 
giving this treatment in doses spread out over time, normal cells that are dividing at a 
slower rate have enough time to recover from this damage [20]. The side effects of 
this therapy result from damage to cells in the body that have a higher rate of 
proliferation such as bone marrow cells, which results in a compromised immune 
system and an increased risk of serious infection [20].  
 
1.1.3.6.2 Molecular targeted therapy 
The rationale for molecular targeted therapy is based on the premise that growth or 
invasion of the cancer cell is reliant on a particular pathway and therefore its 
inhibition would be of therapeutic benefit. It also stems from the concept of 
oncogene addiction i.e. the theory that cancer cells may become reliant on (addicted 
to) the activity of a single oncogene such that when this oncogene is inhibited the 
cancer cell dies [21]. A single oncogene can be targeted by designing drugs to 
specifically inhibit it. This is known as molecular targeted therapy [21].  
 
These treatments often have fewer side effects because they are more selective for 
the tumour cells over the host cells, since only the tumour cells are so dependent on 
the target molecule. Some targeted therapies for breast cancer and their drug targets 
are summarised in Table 1.  
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Drug (Brand Name) Target 
Tamoxifen (Nolvadex) Oestrogen Receptor Alpha (ERα) 
Exemestane (Aromasin) Aromatase cytochrome P450 
Anastrazole (Arimidex) Aromatase cytochrome P450 
Letrozole (Femara) Aromatase cytochrome P450 
Trastuzumab (Herceptin) Human Epidermal Growth Factor Receptor 2 (HER2) 
Pertuzumab (Omnitarg) Human Epidermal Growth Factor Receptor 2 (HER2) 
Lapatinib (Tykerb) Human Epidermal Growth Factor Receptor 1, 2 
(HER1, HER2) 
Table 1: Some targeted therapies for breast cancer in current clinical use 
 
Another important concept in cancer biology is synthetic lethality [22]. Two gene 
products are synthetically lethal if mutation or inhibition of one of them leaves the 
cell viable, but inhibition of both leads to cell death [22]. As in oncogene addiction, 
the cell is extremely dependent on one of these genes, but only when the other is not 
functional. The two gene products may [22]: 
– serve the same essential function (directly compensate each other’s 
loss) 
– be two subunits of an essential protein complex 
– be two interconnected components in an essential pathway 
– participate in parallel essential pathways 
Where it is possible to identify a synthetically lethal pair of genes, cell death may be 
induced by combining targeted treatments for the individual genes [22]. One 
example of this is the BRCA mutation. If either of the brca1 or brca2 genes is 
mutated such that the BRCA protein is unable to perform its usual role in DNA 
repair, the cell survives but becomes dependent on PARP-mediated DNA repair [23]. 
This makes the cells very sensitive to inhibition of PARP activity. PARP inhibitors 
have been shown to cause cell cycle arrest and apoptosis in BRCA-mutated breast 
cancer cells [23] . 
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1.1.3.6.3 Limitations of current therapies 
1.1.3.6.3.1 Heterogeneous response 
The response to treatment is heterogeneous both between patients and within the 
same patient or tumour [20]. Current biomarkers do not adequately select patients for 
response [24]. Drug side effects can have a large impact on a patient’s quality of life, 
often without guaranteeing an improvement in prognosis [20]. There is a need to 
identify patients who will respond to a drug more accurately, so that individuals who 
will not respond are not treated unnecessarily [20]. 
 
1.1.3.6.3.2 Resistance 
Cancers are often resistant to treatment, either from the outset (intrinsic resistance) or 
after time and with ongoing treatment (acquired resistance) [20]. Initially, the cells 
may appear only to be dependent on one molecule, but when this is inhibited the 
second molecule may begin to compensate for the loss of the first [20]. In this case 
combination treatment may be more effective than a single treatment [20]. 
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1.2 Gonadotrophin-releasing hormone in breast cancer 
Gonadotrophin-releasing hormone (GnRH) agonists and antagonists have been 
shown to have antiproliferative effects on breast cancer cells [25-32], but further 
research is required to improve efficacy and prediction of response [32]. To explore 
potential mechanisms of GnRH analogues, it is first necessary to understand the 
structure of GnRH and its receptor, and its role in the normal physiological context. 
 
1.2.1 GnRH 
1.2.1.1 GnRH Structure 
GnRH is a decapeptide, of which 23 forms have been identified across protochordate 
and vertebrate species [33]. There are often several isoforms present in one species; 
in mammals there are one or two isoforms per species [33]. The amino acid 
structures of GnRH-I and GnRH-II, the two forms present in humans, are shown in 
Figure 2. 
 
Figure 2: Amino acid structure of GnRH-I and GnRH-II 
Highly conserved residues are indicated in bold type. This figure was adapted from Millar et al 
[33] .  
 
The conserved amino and carboxyl termini (which are post-translationally modified 
to form pyroGlu and Glycine amide) are important for function, and the non-
conserved residues are thought to determine ligand-specificity or may be functionally 
redundant [33]. 
 
1.2.1.2 GnRH Receptor Structure 
The GnRH receptor (GnRHR) is a seven transmembrane G-protein coupled receptor 
(GPCR). There are three major subfamilies of GPCRs: A, B and C. The GnRHR 
belongs to family A, which includes receptors related to rhodopsin and the β2-




primary structure is that it lacks the carboxyl terminal intracellular tail normally 
found on GPCRs [35] (Figure 3). Other species do have a C-terminal tail, which acts 
as a regulatory domain and has a role in receptor internalisation [35]. Figure 3 also 
shows areas of the receptor that are believed to be involved in ligand binding, 














Figure 3: Human GnRH receptor structure.  
Adapted from Millar et al 2004: GnRH and GNRHRs [36]. The GnRHR lacks the intracellular 
carboxyl terminal tail present in other GPCRs. Other notable features shown above are 
domains for G-protein coupling (light blue and purple), disulphide bridges (dark blue), ligand 
binding sites (red), and receptor activation sites (green). 
 
Interestingly, a large percentage of human GnRH receptors are retained in the 
endoplasmic reticulum. This is thought to be a result of incorrect disulphide bridge 
formation [37]. This is not the case with rat and mouse GnRHR, of which most is 
efficiently directed to the plasma membrane [34]. Two disulphide bridges are 
required for effective routing of the human GnRHR to the plasma membrane, 
whereas only one of these bridges is required in rat and mouse GnRHR [37]. 
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1.2.2 The normal physiological functions of GnRH 
Most vertebrate species appear to have at least two of the structural variants of 
GnRH, but some have three. The different forms have diverse functions depending 
on the resident tissue and species [36]. They may operate in a neuroendocrine, 
paracrine, autocrine or neurotransmitter/neuroregulatory manner [36]. GnRH exists 
in two forms in humans, GnRH-I and GnRH-II [36]. GnRH-I is well-known to 
regulate gonadotrophin production and release in the pituitary [36], whereas the role 
of GnRH-II is less well defined. The GnRH-II system appears to have been adapted 
during evolution such that either one or both of GnRH-II and GnRH-II-R appear to 
be inactivated in a range of mammalian species [38].  
 
GnRH-I is released in pulses every 30-120min from nerve endings to stimulate 
synthesis and secretion of Luteinising Hormone (LH) and Follicle Stimulating 
Hormone (FSH) from the pituitary gland, resulting in the production of sex steroid 
hormones in the ovary or testes [36]. It is thought that GnRH-II may also have a role 
in reproductive behaviour [36]. 
 
Although GnRH-II appears to be functional, it does not interact with a specific 
GnRH-II receptor, since the gene encoding GnRH-II-R has a premature stop codon 
in humans [36]. It is therefore believed that GnRH-II couples to GnRH-I-R. The 
different ligands are thought to induce differential receptor conformations, which 
stabilise differential intracellular signalling complexes to mediate distinct cellular 
outcomes [39]. GnRH-II-R may help to modulate the expression of GnRH-I-R, since 
when both were transiently transfected in fibroblast-like COS-7 cells, expression of 
the GnRH-I-R was reduced, and signalling through the receptor was impaired [40]. 
 
1.2.3 Current role of GnRH in Therapy 
1.2.3.1 GnRH Agonists and Antagonists 
Aside from the endogenous GnRH-I and GnRH-II molecules, some synthetic 
analogues have been designed to target the GnRHR and have been studied in relation 
to manipulation of the reproductive system by targeting the pituitary gland. These 
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can be classified as agonists, antagonists, or inverse agonists. Figure 4 shows how 
the structures of GnRH agonists and antagonists are modified compared to the 
naturally occurring GnRH sequence. 
 
 
Figure 4: The amino acid structure of GnRH agonists and antagonists.  
This figure is adapted from [36].  
  
In naturally occurring GnRH structural variants, the NH2- and COOH-terminal 
residues (amino acids in positions 1-4 and 9-10) are highly conserved throughout 
different species [36]. These residues are involved in receptor binding [36]. D-amino 
acid substitution in position 6 enhances binding affinity at GnRH receptors by 
stabilising it in a folded conformation (with the receptor-binding domains spatially 
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near to each another), and reduces metabolism of the peptide [41]. All synthetic 
GnRH agonists and antagonists have this D-amino acid substitution [36]. The amino 
acid in position 8 appears to be important for ligand-selectivity and may determine 
binding affinities for different GnRH receptors [36]. Several GnRH antagonists have 
substitutions in this position. Antagonists also have D-amino acid substitutions at 
positions 1-3 and 10, and some have additional substitutions in position 5 (Figure 4). 
 
Low pulsatile doses of GnRH agonists are used effectively to treat hypogonadism 
(infertility) and delayed puberty [36]. Contrarily, high doses of agonists desensitise 
the GnRHR to decrease the production of LH and FSH in the pituitary, thus reducing 
fertility [36]. This chemical castration can be beneficial for some hormone-dependent 
diseases such as breast cancer.  
 
After activation, a GPCR is usually rapidly desensitised and internalised (through 
phosphorylation of C-terminal serine and threonine residues by GPCR-kinases and 
second messenger kinases) [42-44]. However, since the GnRH receptor does not 
have this C-terminal tail, it is somewhat resistant to this rapid desensitisation [42, 45, 
46].  Desensitisation of GnRH receptor signalling therefore requires a high dose of 
agonist, which causes an unavoidable hyperstimulation before desensitisation [33, 
36, 44]. This has clinical implications when used therapeutically: any disease 
symptoms that are dependent on GnRH signalling are likely to worsen substantially 
before they regress.  
 
Antagonists also inhibit GnRHR-mediated signalling by competing with endogenous 
GnRH [33]. However, the required doses of antagonists are much higher than that 
required for the same effect mediated by receptor desensitisation [33]. Antagonists 
would be more desirable since they avoid the need for the undesirable hyper-
stimulation that must occur for desensitisation [33, 36], but because a much higher 




Oestrogen is required for the growth of some breast cancers. To induce oestrogen 
production, GnRH must be released in pulses. GnRH agonists have been used to treat 
oestrogen-dependent breast cancer by continuously stimulating GnRHR activity in 
the pituitary [47, 48]. This causes signal inhibition and thereby prevents oestrogen 
production. 
1.2.3.1.1 Triptorelin 
Triptorelin is a GnRH agonist that differs from the physiological GnRH-I 
decapeptide by a single amino acid substitution at position 6 of Gly to D-Trp (Figure 
5). Triptorelin is a superagonist [49], and the estimated binding affinity for 








Figure 5: The amino acid structure of Triptorelin. 
The synthetic GnRH agonist Triptorelin differs from naturally occurring mammalian GnRH by 
a single amino acid substitution at position 6 of Gly to D-Trp. This figure is adapted from [36].  
 
Triptorelin is able to bind GnRHR and activate downstream signalling in both 
pituitary and extrapituitary tissues such as breast and prostate cancer cell lines [25-
32, 50, 51].  
 
Triptorelin has most extensively been used and studied for its ability to simulate 
hypothalamic GnRH in the pituitary. Triptorelin (D-Trp
6
-GnRH) has been used to 
treat prostate cancer since the 1980s [52], and more recently clinical trials have 
explored its use in other cancers such as breast cancer [53, 54]. Triptorelin is 
marketed in the UK under the brand names Decapeptyl
®
 (Ipsen) and Gonapeptyl
®
 
(Ferring Pharmaceuticals). Triptorelin is currently used to treat patients with prostate 
cancer, uterine myoma, endometriosis or precocious puberty [55]. These are all 
hormone-dependent conditions and Triptorelin works by suppressing hormone 
production. Triptorelin is administered by intramuscular injection every 4-12 weeks 
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[55]. Most side effects are as a result of the lowered level of oestrogen or 
testosterone [55]. Although unpleasant, the side effects are generally well-tolerated 
and less severe than those of other treatments such as cytotoxic therapy [20, 55].  
1.2.3.2 Current limitations of GnRH analogues in therapy 
The use of GnRH agonists, through the hormone-suppressive mechanism described 
above, can only be useful in hormone-dependent cancers, thereby failing to deal with 
a significant proportion of oestrogen receptor (ER)-negative breast cancers. 
Currently, clinical trial data does not support a role for GnRH agonists in improving 
breast cancer patient survival [48]. However, GnRH agonists are known to have 
relatively well-tolerated side-effects compared to other cancer treatments [52]. 
 
1.2.4 GnRH has antiproliferative effects in some cancer xenograft 
models and in some cancer cell lines 
It has been demonstrated that some post-menopausal breast cancer sufferers [30], and 
patients with ER-negative breast cancer [56], responded positively to GnRH agonist 
therapy. This implied a mechanism of GnRH signalling outwith its role in the 
pituitary. This new role for GnRH analogues may represent a currently unexploited 
treatment option for hormone-independent cancers. A direct anti-proliferative action 
of GnRH agonists and antagonists in vitro has now been verified by various groups 
in an array of reproductive and non-reproductive cancer cells [27, 32, 39, 50, 57-67].  
 
In 1985, Miller et al reported major inhibitory effects of the GnRH agonist Buserelin 
on the MCF7 breast cancer cell line [29]. This effect was blocked by a GnRH 
antagonist, indicating that the antiproliferative effects arose from interaction between 
the GnRH agonist and specific receptors [29]. A direct inhibitory effect of GnRH 
agonists on MCF7 cells was also demonstrated in that year by others such as 
Blankenstein et al [68]. However, Mullen et al in 1991 could only show that one out 
of four clonal variants of MCF7 cells responded to Buserelin [69]. 
 
Eidne et al confirmed the presence of specific GnRH binding sites in human breast 
cancers [70]. They showed that these binding sites were predominantly in ductal 
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breast carcinomas rather than lobular breast carcinomas, and were not observed in 
normal breast tissue [70]. The authors later confirmed an inhibitory effect of GnRH 
antagonists in several breast cancer cell lines [28].  
 
In 1988, Sharoni et al demonstrated that application of two GnRH antagonists (SB29 
and SB30) to MDA-MB-231 cells resulted in up to 40% reduction in [
3
H]thymidine 
incorporation [71]. An older antagonist had less effect and the agonist Buserelin had 
no effect on [
3
H]thymidine incorporation. Similar results were observed on cell 
growth: SB29 and 30 inhibited cell number, whereas Buserelin did not [71]. 
 
A direct interaction between GnRH and its receptor is supported by the expression of 
GnRHR in 50-64% of breast cancers [72-75], and the finding that both GnRH-I and 
GnRH-II are expressed in both normal and malignant breast cells [76]. It has long 
been speculated that GnRH may act in an autocrine or paracrine manner in breast 
cancer [28]. GnRH-I and GnRH-II have been reported to be overexpressed at the 
mRNA level in breast malignant tissue (compared to healthy tissue from the same 
individual) [76]. Emons, Grundker et al in particular have published extensively 
showing inhibitory effects of GnRH agonists and antagonists in ovarian, endometrial 
and breast cancer cell lines [60-67].  
 
More recently, Saleh-Abady et al observed that Triptorelin inhibited SKBR3 and 











]GnRH-II induced apoptosis in MCF7 and 
MDA-MB-231 cells in vitro and slowed growth of xenografts derived from these cell 
lines in vivo [78]. However, the antiproliferative effect of the GnRH-II antagonist 
persisted after GnRHR was knocked down, making it unclear how GnRH-II is 
mediating its effects [78]. Schubert et al recently demonstrated that agonists and 
antagonists of GnRH-I (Triptorelin and Cetrorelix) and GnRH-II (developed in-
house by the authors) reduced metastasis formation in MDA-MB-453 and MDA-
MB-231 cells in vivo [25]. 
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Although clinical trial data does not currently support a role for GnRH agonists or 
antagonists in the treatment of breast cancer [48], the details above indicate that 
GnRH analogues have antiproliferative effects in some breast cancer cell lines and 
with further research, GnRH signalling may represent a currently unexploited target 
for breast cancer treatment. 
 
1.2.5 Problems to overcome for the direct antiproliferative effect 
of GnRH analogues to become a viable treatment option 
Only a subset of breast cancers are thought to be responsive to the direct action of 
GnRH analogue treatment, and it is necessary to identify the factors involved in 
GnRH signalling in this context to improve prediction and efficacy of response to 
target the therapy appropriately.  
 
There has been difficulty in reproducing the antiproliferative effects of GnRH 
agonists in breast cancer cell lines between research groups. For example, in a range 
of reproductive cancer cell lines (ovary, endometrium, breast), it was found that high 
doses are required to elicit only modest antiproliferative effects [42]. There is a need 
to establish which factors are required for the response. Through increased 
understanding of the signalling mechanism, the antiproliferative effect of GnRH may 
be enhanced, for example in combination with other therapies.  
 
Although there are similarities between breast and other reproductive cancers, there 
may be crucial differences between the mechanisms of GnRHR signalling in these 
tissues. However, it is likely that at least some features of GnRH signalling will be 
common across a variety of tissues, so information from studies on a range of cell 
lines is considered to be relevant.  
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1.2.6 Factors determining the antiproliferative response to GnRH  
Possible factors determining an antiproliferative response to GnRH: 
1. Level of receptor 
2. Ligand subtype 
3. G-protein alpha subunit type 
4. Extracellular signal-regulated kinase activation 
5. Other signalling factors 
These are discussed in more detail below. 
 
1.2.6.1 Levels of GnRHR protein 
A high level of functional GnRHR (GnRH-I-R) at the cell surface appears to be 
essential for the antiproliferative effects of GnRH agonists [79]. The extent of the 
inhibitory effects of a GnRH agonist on a given cell line appears to be proportional to 
the level of functional GnRHR in that cell line [79, 80]. The authors of that study 
found that a panel of several breast cancer cell lines had levels of GnRHR 
undetectable by radioligand binding assay [80]. This may explain why a GnRH 
agonist did not inhibit proliferation in these cells. 
 
The level of GnRHR protein expression in breast cancer and its association with 
other features of breast cancer is not well defined. There is a need to define the 
expression of GnRHR in primary breast tumours in order to establish the target 
population for this application of GnRH agonists.   
 
1.2.6.2 Ligand 
1.2.6.2.1 GnRH-I vs. GnRH-II 
GnRH-I and GnRH-II have been found to have inverse potency ratios with respect to 
how well they mediate the classical GnRH-I-R signalling in the pituitary via inositol 
phosphate accumulation, and the alternative direct antiproliferative effects [81]. 
 38 




From various models built in attempts to explain the binding of ligand to the GnRH 
receptor, it appears that the receptors are in a state of equilibrium between the 
inactive and active conformations [34]. Agonists shift the balance towards the active 
state, whereas inverse agonists shift it the other way [34]. Inverse agonists can inhibit 
agonist-independent receptor activity [34]. Because inverse agonists bind to both 
conformations, they compete with agonist for binding to the active receptor [34]. 
 
1.2.6.2.3 Ligand-induced selective signalling 
The term Ligand-induced Selective Signalling has been used to suggest how different 
ligands may bind the GnRHR to induce differential intracellular responses (Figure 6) 
[36]. It is thought that different active receptor states may exist and a particular 
ligand binds a particular receptor state [36]. A signalling complex is formed that then 
stabilises this receptor conformation. Different ligands may cause the receptor to 
bind to different G-proteins to induce differential downstream effects [36]. This is 





Figure 6: Ligand-induced Selective Signalling.  
L = Ligand, R = Receptor state, SC = Signalling Complex. This figure is taken from [82]. 
 
1.2.6.3 Receptor G-protein coupling 
G-proteins are composed of three subunits: α, β and γ. When an agonist binds the 
GPCR, GDP is converted to GTP on the α subunit of the G-protein (Gα). Gα 
dissociates from the remaining subunits (Gβγ) and activates downstream effector 
molecules to mediate a functional outcome. Gα has intrinsic GTPase activity, which 
deactivates the signal by hydrolysing Gα-GTP to Gα-GDP, which re-associates with 




Figure 7: Activation of the Gα protein subunit after a ligand binds to the GPCR.   
This figure is provided by the author Sven Jähnichen (24 April 2006) [83] and permission for 
reproduction of the figure was granted under the terms of the GNU Free Documentation 
Licence.  
 
When a ligand binds to it, the GnRHR couples to a Gα-protein on the intracellular 
side of the plasma membrane to form a signalling complex. Gα subunits can be 
divided into four families with varying functions such as activation of PLC and 
adenylyl cyclase (Table 2) [34]. The Gβγ complex can also regulate downstream 
effectors such as PLC-β, K
+
 channels, adenylyl cyclase and PI3K [84, 85]. 
 
G-protein family Function 
Gαq/11 activates PLC 
Gαs activates adenylyl cyclase 
Gαi/o inhibits adenylyl cyclase 
Gα12/13 activates small GTPases 
Table 2: Functions of the four families of Gα subunits. 
 
GnRHR couples to different G-proteins depending on cell type and ligand 
stimulation. In some cells it can couple to multiple G-proteins [34]. For example, in 
GT1-7 neurons it has been shown that under a high GnRH agonist concentration the 
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receptor couples to Gαi, whereas with low GnRH agonist concentration the receptor 
couples to Gαs [34]. 
 
The Gαq subunit is known to mediate GnRHR signalling in the pituitary [86]. The G-
protein subunit to which GnRHR couples has been suggested to determine the 
functional outcome [81]. There is some evidence to suggest that Gαi mediates the 
antiproliferative effect of GnRH agonists [59, 66, 87]. However, more recently, 
White et al found that in mouse embryonic fibroblasts (MEF) and stably GnRHR-
transfected Human Embryonic Kidney-293 (Stable Cell Line number 60, SCL60) 
cells, only Gαq, and not Gαi nor Gαs coupled to the GnRHR [88]. The authors 
suggest that RTK transactivation may explain previous reports that have suggested 
receptor coupling to Gαi/o [88]. This is in light of the recent suggestion that growth 
factor RTKs can directly activate Gα subunits (Delcourt et al, 2007, as cited in [88]). 
 
1.2.6.4 Extracellular signal-regulated kinases (ERK1/2) 
A perturbation of phosphorylated ERK1/2 occurs in a number of cell lines following 
GnRH agonist treatment [79]. Although the nature of this change is not the same in 
all cell lines, it is thought to be important in mediating the antiproliferative effects of 
GnRH agonists [79]. Figure 8 outlines how GnRH is thought to signal through the 
GnRH receptor to ERK1/2.  
 
It is not clear how this change in the level of ERK1/2 activity contributes to cell fate, 
but it has been noted that the timing, duration and intensity of ERK1/2 activation are 
all important in determining cellular outcome [89]. Although ERK1/2 activation 
often drives proliferation, ERK1/2 activation has been associated with cell-death in 
many different cell types (reviewed in [89-91]). DNA-damage-induced ERK1/2 
activation causes cell cycle arrest, although the details of the mechanism are not yet 
clear (reviewed in [91]). EGFR-mediated activation of MAPK has been shown to 
cause G2 arrest [92]. Intracellular localisation of ERK1/2 may be relevant to its role 



















Figure 8: GnRH receptor signalling to ERK1/2 
 
Figure 8 outlines how GnRH (or a GnRH analogue) is thought to signal through the 
GnRH receptor to ERK1/2. GnRHR can signal through Gαq/11 to stimulate PLCβ in a 
Ca
2+
 independent manner. This induces further PLCβ activation via a Ca
2+
-dependent 
mechanism. Activation of PLCβ cleaves PIP2 to produce IP3. IP3 activates calcium 
channels in the endoplasmic reticulum to release Ca
2+
. In association with DAG, 
Ca
2+
 activates PKC [34]. Once active, PKC phosphorylates Raf which in turn 
activates MEK and downstream ERK1/2 [34].  
 
1.2.6.5 Other signalling factors implicated in GnRHR signalling 
Several of the putative GnRH receptor signalling pathway members shown in Figure 
8 have been investigated prior to this study. Morgan et al used a panel of inhibitors in 
two GnRH agonist-sensitive cell lines, B35-2 (rat neuronal cells expressing a high 
level of GnRHR) and SCL60 (HEK293 cells expressing a high level of GnRHR) to 
determine which of these suggested pathway members are required for the 
antiproliferative effect of GnRH [79] 
 
As well as the ERK1/2  pathway, the JNK and p38 MAPK pathways have been 
implicated in mediating the antiproliferative effects of GnRH [34]. JNK and p38 
MAPKs are activated by stress [94]. They affect a wide range of cellular processes 
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and, similarly to ERK1/2, their effect on cell fate is complex and they can both 
promote and inhibit cell survival and proliferation [94]. White et al sought to clarify 
which of these is required for the antiproliferative effects: JNK and p38 inhibitors 
were unable to rescue mouse embryonic fibroblast (MEF) cells from the 
growth-inhibitory effect of GnRH whereas ERK inhibitors successfully restored the 
growth of the cells to ~90% that of controls [88]. Morgan et al found that a p38 
inhibitor had no effect in either SCL60 or B35-2 cells [79]. Interestingly, the authors 
were unable to show that MEK was essential in mediating the direct antiproliferative 
effect of a GnRH agonist: A MEK inhibitor (18µM PD98059) had no effect on B35-
2 cells and only partially rescued SCL60 cells (8%), which was not statistically 
significant [79].  
 
A PKC inhibitor which inhibits PKCα and possibly other isoforms (100nM Ro 
32-0432) was able to completely rescue SCL60 cells from the antiproliferative effect 
of a GnRH agonist [79]. However, a specific PKCδ inhibitor (0.5µM Rottlerin) did 
not alter the effect of GnRH treatment [79], suggesting that whilst PKC is an 
essential factor in signalling the GnRH-mediated antiproliferative effect, the PKCδ 
isoform is not. 
 
Despite the lack of effect of the MEK inhibitor, the crucial role of PKC and the 
profound change in pERK1/2 levels in SCL60 cells following GnRHR stimulation 
makes it difficult to discount the MEK-ERK pathway. Neither of the PKC inhibitors, 
nor the MEK inhibitor, had any effect on B35-2 cell number following treatment 
with the GnRH agonist Triptorelin [79]. Only the caspase inhibitor partially rescued 
B35-2 cells from Triptorelin treatment [79]. This occurred to the same extent as in 
SCL60 cells (40%) [79]. This suggests that the GnRH receptor may mediate its 
antiproliferative effect by distinct mechanisms in different cell lines, although 
caspase-mediated cell death appears to be involved in both cases in at least a 
proportion of cells.  
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Neither a FasL antagonist nor ceramide synthesis blockage affected the response of 
either cell line to a GnRH agonist [79]. This indicated that cell death was unlikely to 




 channel blocker had no effect in either of the cell lines, whereas a Ca
2+
 
chelator had an additive effect in both cell lines [79]. It has been presumed that 
intracellular Ca
2+
 elevation is involved in GnRHR antiproliferative signalling, but 
these results do not support this.  
 
cAMP is usually activated by Gαs and inhibited by Gαi [34]. Since Gαi has been 
thought to be responsible for the direct antiproliferative effect of GnRH agonists, 
exogenous cAMP was expected to reduce this effect. However, exogenous 8-Br-
cAMP added to the antiproliferative effect of the GnRH agonist Triptorelin in 
SCL60s [79]. This was also observed in B35-2 cells (rat neuronal cells expressing 
high GnRHR) [79]. This may suggest that endogenous and exogenous cAMP do not 
influence the cell in the same way [79].  
 
1.2.6.5.1 Crosstalk with Receptor Tyrosine Kinases 
The antiproliferative effects of GnRH agonists and antagonists are thought to be at 
least partly mediated by antagonism of growth factors, such as epidermal growth 
factor (EGF) and insulin-like growth factor (IGF) [95], but the level of involvement 
and its precise role is unclear. They may also involve ligand-regulated transcription 
factors such as oestrogen receptors alpha and beta (ERα, ERβ). These may be 
activated by signalling molecules downstream of growth factor receptors such as 
PI3K and ERK1/2, and this can occur in the absence of oestrogen [96]. 
 
Growth factor receptors belong to the receptor tyrosine kinase (RTK) family. Of the 
90 members of this family, 58 are receptors, which can be divided into 20 
subfamilies based on their structural similarities [97]. RTKs have a single 
transmembrane domain, with an intracellular tyrosine kinase domain. The kinase 
region is composed of a particular combination of conserved elements that is distinct 
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to each RTK subfamily [98]. RTK ligand binding induces a conformational change 
that allows receptors to dimerise. Dimerisation increases the kinase activity of the 
receptor, and autophosphorylation of specific tyrosine residues allows proteins with 
Src homology 2 (SH2), and phosphotyrosine binding domains to bind [98]. These 
recruit Src, PLCγ, or other adaptor proteins to activate further downstream 
signalling. For example, the SHC-Grb2-Sos complex and Ras link RTKs to the 
ERK/MAPK pathway to promote proliferation [98].  
 
There is some evidence to implicate growth factor receptor signalling in mediating 
the antiproliferative effect of GnRH analogues. The GnRH agonist Buserelin 
inhibited proliferation of MCF7 cells, but this was prevented by addition of insulin or 
EGF [99]. This suggests that GnRH may exert its antiproliferative effect by 
antagonising growth factor signalling [99]. The GnRH-I analogue Triptorelin, and 
the GnRH-II analogue [D-Lys
6
]GnRH-II, both superagonists, have been shown to 
have an antiproliferative effect on the human breast cancer cell lines MCF7 and 
T47D [95]. The authors demonstrated that these agonists inhibited EGF-induced 
autophosphorylation of EGFR and inhibited MAPK and ERK1/2 activity [95]. A 
similar antiproliferative effect of Triptorelin has been shown in ovarian and 
endometrial cell lines, in which the effect was mediated by Gαi-induced activation of 
phosphotyrosine phosphatase, which then inhibited the EGF-induced 
autophosphorylation of EGFR [66]. Reduced EGFR signalling inhibited ERK1/2 
activation of c-fos and oestrogen responsive elements, thereby reducing cell 
proliferation [66]. However, other studies have shown that in some cell lines ERK1/2 
activation is (at least initially) increased following GnRHR stimulation, and this is 
thought to be important in mediating the antiproliferative effect of GnRH agonists 
and antagonists [79]. As described above, the relationship between ERK1/2 activity 
and cell fate is complex, and it is possible that activation of ERK1/2 may also lead to 
reduced cell proliferation or cell death. The mechanism by which GnRH analogues 
may exert their antiproliferative effects through signalling to ERK1/2 is not yet clear. 
G-protein coupled receptors (GPCR) have been shown to be able to transactivate 
RTKs such as EGFR by inducing cleavage of EGF-like growth factor pre-cursor via 
matrix metalloprotease activation [98]. It is possible that GnRHR may be able to 
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transactivate EGFR or another growth factor receptor in this way. Together, these 
data suggest that there may be a role for growth factor receptor signalling in the 
response to GnRH analogues.  
1.2.6.5.2 NFκB and the survival or suicide decision 
Activation of NFκB, mediated through Gαi, has been shown to occur in Triptorelin-
treated ovarian cancer cell lines, EFO-21 and EFO-27, to inhibit apoptosis [42, 65]. 
GnRH has also been shown to stimulate the rapid phosphorylation of NFκB-p65 in 
LβT2 cells [100]. This may represent another pathway that may be involved in 
mediating the antiproliferative effect of a GnRH agonist. However, this has not been 
explored in any depth in these or other models.  
 
The NFκB family consists of five members: RelA/p65, c-Rel, RelB, NFκB1 (p50) 
and NFκB2 (p52) [101]. These are transcription factors that activate a wide range of 
genes [101]. NFκB signalling plays a particularly important role in the inflammatory 
pathway, and is often constitutively active in cancers [101]. NFκB is usually held 
inactive in the cytoplasm by inhibitors of NFκB (IκB proteins): IκBα, IκBβ, IκBε, 
and IκBζ. p50 and p52, and their full length counterparts p105 and p100 also act as 
IκB proteins [101]. The main inactive form of NFκB is a trimer consisting of the p50 
and p65 subunits and IκBα [101]. This is held inactive in the cytoplasm until 
phosphorylated by an IκB kinase (IKK). Often in response to an inflammatory 
stimulus, such as TNFα, IκBα kinase (IKKα) phosphorylates IκBα, which targets it 
for ubiquitination and degradation by the proteasome [101, 102]. The degradation of 
IκBα releases p50-p65 (which is also phosphorylated by IκBα) to translocate to the 
nucleus where it activates transcription [101, 102]. The p65 subunit undergoes 
further modifications by acetylation and methylation at the site of the NFκB-
responsive promoters and the function of p65 is further enhanced by interaction with 
transcriptional coactivators [101]. This is known as the classical pathway of NFκB 
activation, and usually confers cell survival (reviewed in [102] and [103]).  
 
An alternative pathway of NFκB activation relates to another inactive form of NFκB: 
a dimer of the p52 precursor p100 and RelB [101, 102]. In response to an external 
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stimulus, such as B-cell activating factor (BAFF), p100 is phosphorylated by IKKα 
and is processed to p52 to form the p52-RelB complex [101, 102].  
 
Other pathways of NFκB activation have been reported in response to cellular 
stressors such as DNA damage, oxidative stress, heat shock, and cell cycle disruption 
[102]. These pathways may involve IKK other than IKKα; however, some IKK-
independent pathways of NFκB activation have also been reported, although these 
are uncommon and less well-described than the classical and alternative pathways 
mentioned above.  
 
1.3 Previous approaches to study GnRHR signalling 
1.3.1 Mouse Embryonic Gonadotrope Tumour Cell Lines 
Previous approaches to examine GnRH signalling have generally focused on the 
target cells of GnRH in its normal physiological role, which include the 
gonadotropes of the anterior pituitary gland. LβT2 cells are mouse embryo pituitary 
gonadotrope tumour cells that have been used to study the mechanism of GnRH in 
the pituitary. LβT2 cells have been shown to express both LHβ and FSHβ genes, as 
well as GnRHR. αT3-1 is another pituitary gonadotrope cell line that has been used 
to study GnRHR signalling [104-106]. This cell line is less widely used than the 
LβT2 cell model. The GnRHR signalling network in LβT2 pituitary cells has been 
well-described, and the resulting data has recently been collated into an online 
resource by Fink et al (see [107]).  
 
To explore the effect of a GnRH agonist on gene transcription in the pituitary, Kakar 
et al performed gene expression analysis on mouse pituitary gonadotrope tumour 
(LβT2) cells to examine the transcriptional changes resulting from GnRH agonist 
treatment [108]. The authors of that study reported a list of 68 genes whose 





]GnRH. Although the study only considered two time-points, it showed marked 
differences of GnRH agonist-regulated gene profiles at 1h and 24h after treatment 




]GnRH [108]. Genes that were changed in 
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expression encoded proteins including transcription factors, ion channel proteins, 
cytoskeletal proteins, and other signalling proteins such as those involved in 
proliferation and apoptosis [108]. This was the first microarray analysis of GnRH 
agonist-regulated gene expression and provides a useful resource for comparisons 
between the response to GnRH agonist treatment in pituitary-derived cells (which 
may be similar signalling to the normal physiological role of GnRH) and the 
antiproliferative response to GnRH agonist in extrapituitary tissue-derived cells. 
 
An earlier study by Wurmbach et al also examined gene expression changes as a 
result of GnRHR activation in LβT2 cells [109]. This study used focussed microarray 
analysis, in which 956 cDNAs were carefully selected for measurement. The authors 
showed differential expression of genes including many transcription factors, as well 
as other proteins involved in cell signalling, cytoskeletal regulation and channel 
regulators [109]. This shares similarities with the Kakar et al study, which supports 
several of the gene expression changes observed at 1h after GnRHR stimulation, 
such as Egr1, Nr4a1 and Rgs2. However, the data presented in this study is limited, 
largely by the constraints of technology at the time, and the Kakar et al study 
provides a more thorough, less biased approach to the gene expression analysis.  
 
1.3.2 SCL60 model 
The direct antiproliferative effect of GnRH agonists and antagonists in extrapituitary 
tissues has been demonstrated in several cancer cell lines, but has not been explored 
in depth in these cells and there have been difficulties in reproducing the 
antiproliferative response in some of these cell lines between research groups. To 
investigate the direct antiproliferative effect of GnRH signalling, the SCL60 model 
has been developed.  
 
SCL60 is a Human Embryonic Kidney-293 (HEK293) cell line that has been stably 
transfected with rat GnRHR cDNA. The HEK293 cell line is derived from human 
embryonic kidney epithelial cells, transformed by adenovirus E1a [110]. It is poorly 
adherent and is tumourigenic in nude mice. Radioligand binding assays have 
 49 
confirmed that SCL60 cells express high levels of functional GnRHR (similar levels 
to LβT2 cells) at the cell surface [79]. Rat GnRHR is used because rat GnRHR is 
more efficiently trafficked to the plasma membrane than human GnRHR, so 
facilitates a higher level of GnRHR protein expression at the cell membrane. The 
SCL215 model is a HEK293 cell line that has been stably transfected with a 
modified form of human GnRHR, which is inactivated by the fusion of a catfish 
GnRHR cytoplasmic tail domain [111]. The fusion protein binds GnRH but does not 
signal effectively in terms of inositol phosphate production [111]. SCL60 cells in 
vitro and SCL60-derived xenograft tumours treated with the GnRH agonist 
Triptorelin showed significantly reduced growth compared to those treated with a 
vehicle control [79, 112] at days 7 (P=0.0002), 10 (P=0.0005) and 14 (P=0.0005) 
after treatment (Figure 9). Growth of HEK293- and SCL215-derived xenografts was 










































































Figure 9: Growth of SCL60-, HEK293- and SCL215-derived xenografts treated with Triptorelin (10µg/mouse) for up to 14 days.  
The graphs show the tumour volume relative to the tumour volume at day 0, when treatment was initiated. Error bars show +/- standard error of the mean. 
The data in this figure is published in Morgan et al, 2008 Cancer Research. * indicates a significant difference (P<0.05, 2-sample t-test) between control and 
Triptorelin xenografts at days 7 (P=0.0002), 10 (P=0.0005) and 14 (P=0.0005).
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Miles et al treated SCL60 cells with the GnRH agonist Triptorelin and observed a 
very small but significant increase in the percentage of apoptotic cells by flow 
cytometry, although this could not account for the large decrease in cell number 
[112]. They also observed G2/M arrest in the cell cycle [112]. A caspase inhibitor 
partially rescued SCL60 cells from Triptorelin treatment [79], indicating that the 
GnRH receptor may mediate its antiproliferative effect at least in part by apoptosis. 
 
The cell cycle consists of four phases: Mitosis (M phase), Gap 1 (G1 phase), DNA 
synthesis (S phase), and Gap 2 (G2 phase). These phases vary in duration: typically 
G2 lasts approximately 4h, S phase 6, G1 phase approximately 10h, and mitosis lasts 
only 1-2h [113, 114]. There are checkpoints throughout the cell cycle that prevent the 
inappropriate replication of cells and these checkpoints are controlled by complexes 
of cylins and cyclin-dependent kinases [114, 115]. Cyclin D and CDK4 and 6 control 
progression from G1 to S phase; Cyclin E, A and CDK2 are responsible for the 
initiation of DNA synthesis in S phase; and the transition from G2 to M phase is 
controlled by Cyclin B and CDK1 [114, 115]. GnRHR signalling may disrupt the cell 
cycle for example at S phase by disrupting DNA replication, or at M phase by 
disrupting spindle assembly and/or alterating of the dynamics of chromosome 
segregation.  
 
As mentioned previously (on page 38), White et al found that in SCL60 cells, only 
Gαq, and not Gαi nor Gαs coupled to the GnRHR [88]. As described on page 37, 
Morgan et al demonstrated that despite an intense transient activation of pERK1/2 
observed following Triptorelin treatment, a MEK inhibitor only partially rescued 
SCL60 cells (8%), which was not statistically significant [79]. PKC appears to be an 
essential factor in signalling the GnRHR-mediated antiproliferative effect, although 
not the PKCδ isoform [79]. Neither a FasL antagonist nor ceramide synthesis 
blockage affected the response of either cell line to a GnRH agonist [79]. This 
indicated that cell death was unlikely to be occurring through the Fas death receptor 
in these cell lines. An IP3 Ca
2+
 channel blocker had no effect in either of the cell 
lines, whereas a Ca
2+
 chelator had an additive effect in both cell lines [79]. It has 
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been presumed that intracellular Ca
2+
 elevation is involved in GnRHR signalling, but 
these results do not support this.  
 
GnRH has been shown to lead to activation of lipid-directed kinases such as 
diacylglycerol kinase (DGK)-ζ [116]. Increased DGK-ζ reduced the time scale of 
ERK1/2 activation [116]. DGKs phosphorylate diacylglycerol (DAG), therefore this 
may reflect feedback metabolism of DAG generated by Gαq-PLC activation. As 
discussed earlier, the length of ERK1/2 activation could be important in determining 
the functional outcome of this signalling [89].  
 
GnRHR signalling may induce downstream signalling of the stress-activated protein 
kinases JNK and p38 [34]. These proteins have been shown to play a role in cell 
cycle arrest and apoptosis [94]. However, like ERK1/2, they can both promote and 
inhibit proliferation, and it is the duration and intensity of their activation that is 
crucial in determining the functional outcome [94].  
 
In SCL60 cells, GnRHR stimulation by GnRH-I, GnRH-II, and other agonists (but 
not antagonists) caused an increase in cell adherence and change in morphology 
[117]. This was dependent on Tyr-kinases and Src but not EGFR or JNK [117]. This 
indicated that GnRH agonists can cause cytoskeletal reorganisation and affect cell 
adherence. Inappropriate cytoskeletal changes could play a role in GnRHR-mediated 
cell death or reduced proliferation. Progression through the cell cycle, particularly 
mitosis, is dependent on carefully controlled cell adhesion. If cell adhesion is altered 
inappropriately, via signalling to adhesion molecules, the cell cycle may be halted. 
 
GnRHR signalling may lead to cell cycle arrest or apoptosis via changes at the 
transcriptional level. Inappropriate gene expression may result directly from 
GnRHR-mediated signalling, or as a consequence of cellular stress and the activation 
of p38 and JNK signalling. For example, altered transcription of one or more CDK or 
cyclins could lead to cell cycle arrest. Many diverse signalling factors interact with 
the cell cycle and apoptotic machinery within the cell and aberrant transcription of 
any of these could impact on cell survival and proliferation.  
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1.3.3 Other cell line models 
Other reproductive cancer cell lines have been used to study GnRHR signalling, such 
as EFO-21 and EFO-27 ovarian cancer cell lines [65, 66, 118], breast cancer cell 
lines including MCF-7 [31, 68, 69, 99, 119] and MDA-MB-231 [78, 120], and 
Ishikawa and Hec-1A endometrial cancer cell lines [66, 118]. Several GnRHR-
transfected cell lines have also been studied previously, such as the kidney-derived 
cells Cos-1 [45], the breast cancer cell line MCF-7 (transient transduction) [27, 121], 
and the stably transfected prostate-derived WPE-1-NB26 cells [50]. 
 
1.4 Aims of the current study 
1. To identify signalling factors that may be involved in mediating the 
antiproliferative effect of a GnRH agonist using a cell line model both in vitro 
and in vivo, and at both the transcriptomic and proteomic level.  
2. To identify the extent of GnRHR expression in breast tumours and cell lines. 
3. To develop a model to study GnRHR signalling in breast cancer. 
 
These aims will contribute to the long-term objective to identify drug treatments that 




As discussed above, the mechanism by which GnRHR activation causes a direct 
antiproliferative effect in various cell lines is not clear. There is some evidence to 
indicate the involvement of MAPK activity, and possibly cross-talk with RTKs, but 
the details remain poorly defined. A global data-driven approach was taken to 
identify candidate molecules that might be involved in mediating this effect. This 
approach focussed on the high GnRHR-expressing cell line SCL60.  
 
Section 3.1 is devoted to the molecular characterisation of the SCL60 cell line model. 
This cell line model was used to investigate the antiproliferative effect of the GnRH 
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agonist Triptorelin. The SCL60 cell line has previously been established as a model 
in which to study GnRHR-mediated antiproliferative signalling [79, 104, 112, 122], 
but this was the first attempt to comprehensively examine GnRHR signalling using a 
data-driven transcriptomic and proteomic approach, both in vitro and in vivo. In 
section 3.1 the SCL60 cell line is compared to HEK293 (untransfected) and SCL215 
cells to confirm their response to GnRHR stimulation and to explore the mechanism 
by which this may occur. Sulphorhodamine Blue (SRB) assays were used to observe 
the effect of Triptorelin on SCL60, SCL215 and HEK293 cell number; flow 
cytometry was used to assess changes to the cell cycle as a result of Triptorelin 
treatment; and immunohistochemistry was used to observe changes in markers of 
apoptosis and proliferation in SCL60 xenografts following Triptorelin treatment.  
 
To allow focus, only the GnRH agonist Triptorelin was used because it is one of the 
most potent agonists with demonstrated in vivo antiproliferation activity [79]. Effects 
on cell behaviour following treatment with Triptorelin were compared relative to 
vehicle alone (0.02% propylene glycol solution), which did not appear to have any 
effect, suggesting that the observations were caused directly or indirectly by GnRHR 
activation only.  
 
The SCL60 and HEK293 cell lines provide a useful model to study GnRHR 
signalling because the SCL60 cells express high levels of GnRHR whereas the 
HEK293 cells do not express detectable levels of GnRHR. This model was used to 
identify novel GnRH agonist-driven signalling processes. GnRHR signalling was 
explored at the transcriptomic level (section 3.2), before focusing on the proteomic 
level (section 3.3).  
 
GnRHR-induced cell cycle arrest and/or apoptosis could result from altered gene 
expression. For example, increased transcription and synthesis of pro-apoptotic 
factors or altered levels of cell cycle regulators. Events during the cell cycle require 
carefully regulated changes to the cytoskeleton. Dysregulated signalling to the 
cytoskeleton could result in cell cycle arrest. Concurrently, GnRH agonist-induced 
stress may activate cell survival responses. For example de novo synthesis of heat 
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shock proteins, which prevent cell damage by playing a role in refolding proteins 
[123]; inhibition of pro-apoptotic factors, and increased synthesis of the survival 
protein Akt, could all contribute to the cell survival response. The balance of the 
damaging events and the cell survival processes in response to GnRHR stimulation 
determine cell fate. It was therefore interesting to explore the role of de novo gene 
transcription and protein synthesis following GnRHR stimulation in SCL60 cells. 
The time course of events following GnRHR stimulation is not understood, so a 
time-series approach was beneficial. 
 
To investigate signalling that is relevant to the antiproliferative effect of GnRH 
agonists in SCL60 cells, it was interesting to explore the gene expression changes 
resulting from GnRHR expression (by comparing HEK293 and SCL60 cells, section 
3.2), and the gene expression changes in response to GnRH agonist treatment in 
SCL60 cells in vitro (section 3.2). These data were generated by conducting a time 
series gene expression study to provide an unbiased, data-driven approach to 
identifying candidates for further investigation. A time-series study allowed the 
observation of dynamic gene expression changes over the treatment period. Similar 
studies have been conducted by Kakar et al and Wurmbach et al, but these focused 
on the pituitary cell line LβT2 [108, 109]. Kakar et al showed that most of the genes 
that were increased in response to GnRH agonist treatment at 1h had returned to 
basal levels by 24h [108]. Because they used only two time points, it was not clear 
how long these genes were increased for before returning to basal levels. It was 
therefore considered useful to expand the time-course design of the Kakar et al study 
to include more time points, as it is clear from their data that the response to GnRH is 
dynamic between 0 and 24h [108]. The time series gene expression study in this 
thesis covered six time points from 0 to 24h after Triptorelin treatment to further 
understand the dynamic response to GnRHR stimulation.  
 
Phosphoproteomic antibody arrays were used to examine protein expression in 
SCL60 xenografts in vivo in response to GnRHR stimulation and 
immunohistochemistry was used to validate any protein changes identified (section 
3.3.1). From the results of the phosphoproteomic array, and from existing literature, a 
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list of candidates was populated to be explored by reverse phase protein array in 
vitro. This was used as a broad screening tool to identify candidates worthy of further 
investigation. These results are shown in section 3.3.2. The expression profiles of 
selected protein candidates were then validated by western blotting (section 0). 
 
The level of GnRHR expression in breast cancer and its association with other 
features of breast cancer is not well defined. There was a need to define the 
expression of GnRHR in primary breast tumours to establish the target population for 
this application of GnRH agonists. GnRHR expression was measured in primary 
breast cancer by quantitative immunofluorescence and association of GnRHR 
expression with key markers of breast cancer subtypes such as ER or HER2 
expression was explored using pre-existing information about their expression in 
these tumours. It was anticipated that this may help to identify a subgroup of breast 
cancers that might be most likely to respond to GnRH agonist therapy. These results 
are shown in section 3.5.  
 
To investigate GnRHR signalling in breast cancer, a model of GnRHR signalling in 
breast cancer was required. A suitable model was sought by screening a panel of cell 
lines for GnRH agonist (Triptorelin) responsiveness, and by transfecting a breast 
cancer cell line to stably express a high level of GnRHR at the cell surface. It was 
anticipated that if a suitable model can be identified or created, the GnRHR 
signalling pathway could be studied at greater depth in this breast cancer cell line 
model in the same way as for the SCL60 cell line (section 3.6). Use of targeted 
inhibitors could then help identify the involvement of growth factor driven pathways 
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2 Materials and Methods 
2.1 Materials and sources 
2.1.1 Cell Culture 
Material Source 
DMEM with Phenol Red and Glutamine Invitrogen, Paisley, UK 
Trypsin-EDTA Invitrogen, Paisley, UK 
Foetal Calf Serum Harlan Seralab, AbD Serotec, 
Kidlington, Oxford, UK 
G418 (Geneticin) Invitrogen, Paisley, UK 
Hygromycin Sigma Aldrich, Poole, Dorset, UK 
PBS Oxoid, Basingstoke, UK 
Penicillin-Streptomycin Invitrogen, Paisley, UK 
 
2.1.2 SRB Assays 
Material Source 
TCA Sigma Aldrich, Poole, Dorset, UK 
SRB dye Sigma Aldrich, Poole, Dorset, UK 
Alamar blue reagent AbD Serotec, Kidlington, Oxford, UK 
Acetic Acid VWR International, Leicestershire, UK 
 
2.1.3 Protein Detection 
Material Source 
HEPES Sigma Aldrich, Poole, Dorset, UK 
2-pad FAST
®
 slide Whatman Ltd., USA 
Acrylamide Severn Biotech, Worcestershire, UK 
Ammonium persulphate (AMPS) Sigma Aldrich, Poole, Dorset, UK 
Aprotinin Sigma Aldrich, Poole, Dorset, UK 
Blotting Pads BioRad, Hertfordshire, UK 
Bromophenol Blue Sigma Aldrich, Poole, Dorset, UK 
BSA Sigma Aldrich, Poole, Dorset, UK 
ECF substrate GE Healthcare, Buckinghamshire, UK 
EDTA Sigma Aldrich, Poole, Dorset, UK 
EGTA Sigma Aldrich, Poole, Dorset, UK 
Filter Paper Munktell, Raleigh, NC 27617, USA 
Glycerol VWR International, Leicestershire, UK 
Glycine Sigma Aldrich, Poole, Dorset, UK 
Leupeptin Sigma Aldrich, Poole, Dorset, UK 
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Methanol VWR International, Leicestershire, UK 
Mini-gel apparatus BioRad, Hertfordshire, UK 
Sodium Chloride Sigma Aldrich, Poole, Dorset, UK 
NP-40 Alternative Calbiochem, EMD Biosciences, USA 
Odyssey Blocking Buffer Li-Cor Biosciences, Lincoln, NE, USA 
Phosphatase Inhibitor Cocktail 1 Sigma Aldrich, Poole, Dorset, UK 
Phosphatase Inhibitor Cocktail 2 Sigma Aldrich, Poole, Dorset, UK 
PMSF Sigma Aldrich, Poole, Dorset, UK 
Protease Inhibitor Cocktail Tablet Sigma Aldrich, Poole, Dorset, UK 
PVDF membrane Millipore, Billerica, MA 01821, USA 
Kaleidoscope pre-stained molecular 
weight marker 
BioRad, Hertfordshire, UK  
SDS Sigma Aldrich, Poole, Dorset, UK 
TGX
® 
Tris-Glycine gels 4-15% BioRad 
Novex
®
 Tris-Glycine gels 4-20% Invitrogen, Paisley, UK 
Semi-dry transfer apparatus BioRad, Hertfordshire, UK 
Sodium Orthovanadate Sigma Aldrich, Poole, Dorset, UK 
TEMED BioRad, Hertfordshire, UK 
Tris Sigma Aldrich, Poole, Dorset, UK 
Tris base Sigma Aldrich, Poole, Dorset, UK 
Triton-X Sigma Aldrich, Poole, Dorset, UK 
Typhoon Phosphoimager Amersham Biosciences 
PBS Oxoid, Basingstoke, UK 
Tween-20 Fisher Scientific, Leicestershire, UK 
β-mercaptoethanol Sigma Aldrich, Poole, Dorset, UK 
IRDye
®
 680LT Goat Anti-Mouse Li-Cor Biosciences, USA 
IRDye
®
 800LT Goat Anti-Rabbit Li-Cor Biosciences, USA 
Primary Antibodies See Table 3 
 
2.1.4 Inositol Phosphate Assay 
Material Source 
Special DMEM Invitrogen, Paisley, UK 
3
H-myoinositol GE Healthcare, Buckinghamshire, UK 




 Dr Kevin Morgan, MRC-HRSU, UK 
HEPES Sigma Aldrich, Poole, Dorset, UK 
Lithium Chloride Sigma Aldrich, Poole, Dorset, UK 
Formic Acid Sigma Aldrich, Poole, Dorset, UK 





EGFR/ErbB2 inhibitor (#324673) Calbiochem, EMD Biosciences, USA  
Triptorelin (D-Trp
6
-GnRH) Sigma Aldrich, Poole, Dorset, UK 
IGF-I-R inhibitor II (#407248) Calbiochem, EMD Biosciences, USA 
15d-PGJ2 Biomol, Enzo Life Sciences, UK 
PI3K inhibitor (#528106) Calbiochem, EMD Biosciences, USA 
Propylene Glycol Sigma Aldrich, Poole, Dorset, UK 
 
2.1.6 Flow Assisted Cytometry 
Material Source 
Sucrose Sigma Aldrich, Poole, Dorset, UK 
Trisodium Citrate VWR International, Leicestershire, UK 
DMSO VWR International, Leicestershire, UK 
Tris Base Sigma Aldrich, Poole, Dorset, UK 
Nonidet P-40 Sigma Aldrich, Poole, Dorset, UK 
Trypsin Type IX-S Sigma Aldrich, Poole, Dorset, UK 
Trypsin Inhibitor Sigma Aldrich, Poole, Dorset, UK 
RNase A Sigma Aldrich, Poole, Dorset, UK 
Propidium Iodide Sigma Aldrich, Poole, Dorset, UK 
Spermine Tetrahydrochloride Sigma Aldrich, Poole, Dorset, UK 




 RNA Miniprep 
kit 
Agilent Technologies UK Ltd., 
Stockport, Cheshire, UK 
Illumina
®
 TotalPrep™ RNA 
Amplification Kit 
Ambion, Warrington, UK 
HumanHT-12 Expression BeadChips Illumina, Essex, UK 





DakoCytomation envision/HRP Kit DAKO, Ely, Cambridgeshire, U.K. 
Tris Base Sigma Aldrich, Poole, Dorset, UK 
EDTA Sigma Aldrich, Poole, Dorset, UK 
Tween 20 (Polysorbate 20) Fisher Scientific, Leicestershire, UK 
Sodium Citrate Sigma Aldrich, Poole, Dorset, UK 
Citric Acid Sigma Aldrich, Poole, Dorset, UK 
Mouse Anti-cytokeratin Antibody Invitrogen, Paisley, UK 
Goat anti-mouse Alexa555 antibody Invitrogen, Paisley, UK 
Goat anti-Rabbit (#A3681) Sigma Aldrich, Poole, Dorset, UK 
















Ki67 DAKO M7240 Mouse 1:250 N/A 
TE buffer 
pH9.0 1h RT 
1 in 
1000 
Myc Cell Signaling 5605 Rabbit 1:50 N/A N/A N/A N/A 
P21 Cell Signaling 2946 Mouse 1:150 N/A N/A N/A N/A 
P38MAPK Cell Signaling 9212 Rabbit 1:100 N/A N/A N/A N/A 
P53  Cell Signaling 2524 Mouse 1:50 N/A N/A N/A N/A 
pAKT Cell Signaling 9271 Rabbit 1:50 1:1000 N/A N/A N/A 
pAKT Cell Signaling 4060 Rabbit N/A N/A 
TE buffer 
pH9.0 1h RT 1 in 100 
PARP Cell Signaling 9542 Rabbit N/A 1:1000 N/A N/A N/A 
pCAV1  Cell Signaling 3251 Rabbit 1:50 N/A N/A N/A N/A 
pCAV1  Eurogentec 65411 Rabbit N/A N/A 
Sodium 
Citrate pH6.0 1h RT 1 in 50 
pCDK2 Cell Signaling 2561 Rabbit 1:50 N/A N/A N/A N/A 
pCHK2  Cell Signaling 2669 Rabbit 1:50 N/A N/A N/A N/A 
pCyclinD1 Cell Signaling 2921 Rabbit 1:50 N/A N/A N/A N/A 
pER Cell Signaling 2511 Mouse 1:100 N/A N/A N/A N/A 
pERK1/2  Cell Signaling 9101 Rabbit 1:100 1:1000 
Sodium 
Citrate pH6.0 1h RT 1 in 20 
pHistone H3 Cell Signaling 9701 Rabbit 1:100 N/A N/A N/A N/A 
PI3K 
p110alpha Cell Signaling 4249 Rabbit 1:133 1:1000 N/A N/A N/A 














pMet  Eurogentec 65559 Rabbit N/A N/A 
Sodium 
Citrate pH6.0 1h RT 1 in 50 
pmTOR Cell Signaling 2971 Rabbit 1:50 N/A N/A N/A N/A 
pNFκB Cell Signaling 3037 Rabbit 1:50 1:1000 N/A N/A N/A 
pP70S6K Cell Signaling 9206 Mouse 1:50 N/A N/A N/A N/A 
pPDK1 Cell Signaling 3061 Rabbit 1:50 N/A N/A N/A N/A 
pPTEN Cell Signaling 9554 Rabbit 1:50 N/A N/A N/A N/A 
pRAF Cell Signaling 9421 Rabbit 1:133 N/A N/A N/A N/A 
tAKT Cell Signaling 2920 Mouse 1:1000 1:2000 
Sodium 
Citrate pH6.0 1h RT 1 in 200 
tCAV1  Cell Signaling 3267 Rabbit 1:50 N/A N/A N/A N/A 
tCAV1  Eurogentec 75433 Rabbit N/A N/A 
Sodium 
Citrate pH6.0 1h RT 1 in 50 
tCyclinD1 Cell Signaling 2926 Mouse 1:300 N/A N/A N/A N/A 
tERK1/2  Cell Signaling 9107 Mouse 1:50 1:1000 N/A N/A 1 in 250 
tHER1 Cell Signaling 2239 Mouse 1:125 N/A N/A N/A N/A 
tHER2 Cell Signaling 2248 Mouse 1:50 N/A N/A N/A N/A 
tMet  Cell Signaling 3148 Mouse 1:50 1:1000 N/A N/A N/A 
tMet  Eurogentec 7551 Rabbit N/A N/A 
Sodium 
Citrate pH6.0 1h RT  
tmTOR Cell Signaling 2972 Rabbit 1:300 N/A N/A N/A N/A 
tCDK2 Cell Signaling 2546 Rabbit 1:50 N/A N/A N/A N/A 














tNFκB Eurogentec 75331 Rabbit N/A N/A 
TE buffer 
pH9.0 1h RT 1 in 200 
tPDK1 Cell Signaling 3062 Rabbit 1:50 N/A N/A N/A N/A 
tPTEN Cell Signaling 9556 Mouse 1:300 N/A N/A N/A N/A 
tRAF 
Beckton 
Dickinson R19120 Mouse 1:133 N/A N/A N/A N/A 
Vimentin Cell Signaling 3390 Mouse 1:50 N/A N/A N/A N/A 
Cleaved 













4ºC 1 in 10 
Table 3: Antibodies for RPPA, Western blotting, IHC and AQUA.  












2.2.1 Cell Culture 
All cell culture procedures were carried out at room temperature in a class II tissue 





 tissue culture flasks in a 5% CO2 atmosphere at 37°C. All cell lines were 
grown in DMEM with phenol red and glutamine, supplemented with 10% FCS and 
1% Pen-Strep. This mixture is hereafter referred to as complete media. SCL60 and 
SCL215 cells were maintained in complete media supplemented with G418 
(0.5mg/ml) and MCF-7-H14 cells were maintained in complete media supplemented 
with G418 (0.5mg/ml) and Hygromycin (0.05mg/ml). 
 
Cells were passaged when 60-80% confluent, approximately twice weekly. For a 
175cm
2
 flask, media was aspirated from the flask and cells were washed with 5ml 
PBS. Following the immediate removal of PBS, 5ml Trypsin-EDTA was added and 
the cells incubated with this for 30s-3min at 37°C. Fresh complete media was added 
to the dissociated cells and the mixture centrifuged at 1000g for 4min. The pellet was 
resuspended in 10ml fresh complete media, 20% was returned to the flask and 60ml 
fresh complete media was added. 
 
Cells were routinely stored in nitrogen at -196°C. To prepare cells for freezing, cells 
were detached as described above, centrifuged at 1000g for 4min and the pellet 
resuspended in a solution of 90% FCS and 10% DMSO. For a 175cm
2
 flask, the 
pellet was resuspended in 7ml, and 1ml aliquots were prepared in cryovials. The cells 
were frozen at -70°C overnight before transferring to nitrogen. To recover cells from 
freezing, aliquots were thawed rapidly, and immediately washed with complete 
media to remove DMSO. The cells were centrifuged at 1000g for 4min and then the 
pellet resuspended in fresh complete media. 
 
To assist cell adherence during experiments using SCL60, HEK293 and SCL215 





 in 6ml serum-free media) and incubated for 24h. Immediately 
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before very gently adding cells, excess Matrigel
®
 solution was aspirated to leave the 
dish evenly coated. 
 
2.2.2 Flow Cytometric DNA Analysis 
Cells were seeded into 6cm diameter dishes at 0.5x10
6
cells/dish. The cells were 
treated with Triptorelin (100nM) or 0.02% Propylene Glycol solution (vehicle 
control) for up to 72h. The cells were washed with PBS then detached from the dish 
surface by incubation with 1ml Trypsin-EDTA for 2min. The cells were transferred 
to 12x75mm glass tubes and centrifuged at 450 x g for 5min. Excess moisture was 
removed by inverting the tubes and the cells were then resuspended in 100µl pH7.6 
citrate buffer (Table 4). These tubes were stored at -20°C until analysis. 
 
Samples were thawed to room temperature. The cells were incubated at room 
temperature with Solution A (450µl; Table 6) for 2min with continuous agitation, 
then Solution B (375µl; Table 7) was added and after mixing the cells were incubated 
for 10min. Finally Solution C (250µl, cold; Table 8) was added and the cells were 
mixed and then incubated for 10min on ice and in the dark. The samples were 
analysed using a BD FACSAriaII SORP Flow Cytometer (Becton Dickinson) and 




Trisodium Citrate 11.76g 
Distilled Water To make final volume of 1000ml 
DMSO 50ml 
Hydrochloric Acid To adjust to pH7.6 




Trisodium Citrate 2000mg 
Tris Base 121mg 
Spermine Tetrahydrochloride 1044mg 
Nonidet NP40 2ml 
Hydrochloric Acid To adjust to pH7.6 
Table 5: Stock solution for Flow Cytometric DNA Analysis 
 
Component Quantity 
Stock solution (Table 5) 500ml 
Trypsin Type IX-S 15mg 
Table 6: Solution A for Flow Cytometric DNA Analysis 
 
Component Quantity 
Stock solution (Table 5) 500ml 
Trypsin Inhibitor 250mg 
RNase A 50mg 
Table 7: Solution B for Flow Cytometric DNA Analysis 
 
Component Quantity 
Stock solution (Table 5) 500ml 
Propidium iodide 208mg 
Spermine Tetrahydrochloride 500mg 
Table 8: Solution C for Flow Cytometric DNA Analysis 
 
2.2.3 In vitro Protein Detection 
2.2.3.1 Protein Extraction 
Cells were seeded to generate 10cm diameter dishes at 70-80% confluence. On ice, 
media was aspirated from the tissue culture dish, and the cells were washed with ice 
cold PBS. This was aspirated and 400µl complete lysis buffer A (Table 9) was added 
to cells in a 10cm diameter dish, or 800µl per 16cm dish. The dish was tilted and the 
cells scraped into the complete lysis buffer. The cells were incubated in the complete 
lysis buffer on ice for 5min before being transferred to a 1.5ml microcentrifuge tube. 
Lysates were centrifuged at 16000 x g in a microcentrifuge for 6min at 4°C. The 
supernatant was transferred to a fresh 1.5ml microcentrifuge tube and the pellet 
discarded. Lysates were stored at -70°C for up to 12 months. 
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The protein extraction method differed for experiments in chapter 3.6 as these 
experiments were performed in another laboratory: Complete lysis buffer A was 
substituted for Complete lysis buffer B (Table 10, Table 11 and Table 12). 
 
Component Quantity 
Tris (50mM, pH7.5) 1ml 
EGTA (5mM, pH8.5) 1ml 
Sodium chloride (150mM) 3ml 
Distilled water 5ml 
Triton-X (1%) 100µl 
Protease Inhibitor Cocktail Tablet 1 
Phosphatase Inhibitor Cocktail 1 100µl 
Phosphatase Inhibitor Cocktail 2 100µl 
Aprotinin 50µl 
Table 9: Complete lysis buffer A 
 
Component Quantity 
Glycerol (BDH) 5ml 
1M HEPES buffer pH7.4 (Sigma) 0.25ml 
0.5M EDTA pH8.0 (Sigma) 0.20ml 
NP-40 Alternative (Calbiochem, 
#492016) 
0.50ml 
Sodium chloride (Sigma) 0.73g 
Distilled water 44ml 
Table 10: NP40-based lysis buffer.  
Note that NP-40 alternative is used because NP40 is no longer available. 
 
Component Quantity 
NP40-based lysis buffer 1ml 
PMSF (17mg/ml in isopropanol) (Sigma, 
protease inhibitor) 
30µl 
0.2M Na Orthovanadate (Sigma, 
phosphatase inhibitor) 
30µl 
10mg/ml Leupeptin (Sigma, protease 
inhibitor) 
3µl 




10% SDS 40ml 
β-mercaptoethanol 2.5ml 
Glycerol 5ml 
1M Tris pH6.8 1.25ml 
Distilled Water 1.25ml 
Bromophenol Blue Pinch (to make the buffer blue) 
Table 12: 2x Laemmli Sample Buffer 
 
2.2.3.2 Protein Quantification 
In glass tubes (12x75mm), 5µl of each protein sample was diluted in 45µl distilled 
water and a protein standard was diluted to the following concentrations: 0, 50, 75, 
100, 250, 500, 750, and 1000µg/ml in 50µl distilled water. Then 1ml 1:50 
Bicinchoninic Acid (BCA)/Copper sulphate solution was added to each tube and the 
tubes were immediately incubated in a waterbath at 60°C for 15min. Duplicate 200µl 
samples of each tube were transferred to a flat-bottomed 96-well plate. The plate was 
read at 540nm on a Biohit BP800 spectrophotometer (BioHit Ltd., UK). 
 
2.2.3.3 Immunoblotting 
Complete lysis buffer (Table 9) was added to equalise the concentration of each 
protein sample. A 5x solution of loading buffer (Table 13) was added to protein 
lysates to make up 20% of the final volume.  
 
Lysates were electrophoretically resolved by 10% SDS–PAGE. The resolving and 
stacking gel was prepared as shown in Table 14 and Table 15. Buffers for SDS-
PAGE are described in Table 16 and Table 17. Protein lysates were denatured at 
95°C for 5min, then protein was immediately loaded onto the gel and 25µl 
Rainbow™ molecular weight marker was loaded alongside the protein samples. The 
gel was resolved at 80V for 15min then 150V for 45min. After resolving, proteins 
were transferred to a PVDF membrane at 30V overnight. The membrane was then 
blocked with 50% Li-Cor blocking buffer (diluted 1:1 with PBS) for 1h. The 
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membrane was incubated with the primary antibody in 50% blocking buffer 
overnight at 4°C. Antibodies used for western blotting are listed in Table 3. 
 
At room temperature, the membrane was washed 3x5min in PBS 0.1% Tween-20 
(PBS-T) and then incubated with the secondary antibody (Table 3) diluted in 50% 
blocking buffer for 45min. After addition of secondary antibody, exposure of the 
membrane to light was minimised. The membrane was washed again 3x5min in 
PBS-T and 3x5min in PBS. The membrane was allowed to air-dry before scanning 
on a Li-Cor Odyssey scanner (Li-Cor Biosciences, Lincoln, Nabraska, USA). 
 
For experiments in section 3.6, the immunoblotting method differed. Alterations to 
the procedure above were as follows: 
• 2x Laemmli sample buffer was added to each sample after lysis (Table 12) 
• The acrylamide gels were substituted for Novex® Tris-Glycine pre-cast 
gradient mini-gels (4-20%) (Invitrogen, Paisley, UK). 
• Transfer to PVDF membrane was by semi-dry transfer using semi-dry 
transfer buffer (Table 20). 
• Membranes were blocked using TBS-T + 0.4% BSA and TBS-T was used 
instead of PBS-T for membrane washes (Table 19). 
• Specific antibody binding was detected by enzyme-amplified 
chemifluorescence: ECF substrate was applied to the membrane for 30s; the 
membrane was dried between filter paper and then scanned on a Typhoon 








Bromophenol Blue Solution 1.664ml 
Distilled Water 23.3ml 




1M Tris, pH8.85 15ml 
10% SDS 0.4ml 
Distilled Water 11.1ml 
TEMED 0.1ml 
10% AMPS 0.1ml 
Table 14: 10% Resolving Gel 
 
Table 15: 3.6% Stacking Gel 
 
Component Quantity 
Tris Base 9.09g 
Glycine 43.26g 
10% SDS 30ml 
Distilled water To make up to 3l 





Distilled water To make up to 4l 
Table 17: Transfer buffer 
 
Component  Quantity 
Acrylamide 3.6ml 
0.375M Tris, pH6.8 10ml 
10% SDS 0.3ml 
Distilled Water 16ml 
TEMED 0.1ml 




Tris Base 60.5g 
Sodium chloride 87.6g 
Distilled water To make up to 1l 
Table 18: Tris-buffered Saline (TBS) 
 
Component Quantity 
5M Sodium chloride 300ml 
1M Tris pH7.0 100ml 
NP-40 alternative 5ml 
Tween 20 5ml 
Table 19: 10x TBS-T 
 
Component Quantity 




Distilled water 800ml 
Table 20: Semi-dry transfer buffer 
 
2.2.4 Reverse-phase Protein Array 
2.2.4.1 Preparing samples and slides 
Protein was isolated from SCL60, HEK293 and SCL215 cells following treatment 
with Triptorelin (100nM) or vehicle control (0.02% propylene glycol solution) for 0, 
0.5, 1, 2, 4, 8, or 24h. Protein was isolated in this way from three independent 
experiments. Protein was extracted and quantified as described in sections 2.2.3.1 
and 2.2.3.2. Samples were diluted to 2mg/ml in complete lysis buffer (Table 9) then 
2-fold serially diluted 4 times to produce 5 dilutions of each sample. Each dilution of 
each sample was spotted [124] in triplicate onto both pads of a 2-pad FAST
®
 
nitrocellulose-coated glass slide (Whatman Ltd., USA) such that each sample was 
spotted a total of 15 times. To avoid bias, samples were carefully distributed over the 
pads to ensure that a balance of control and treated samples were spotted by each pin. 
A total of 72 samples were spotted onto each pad by 4 pins using a BioRobotics 
Microgrid (Isogen Life Science, The Netherlands). 
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2.2.4.2 Probing slides with antibody for target protein 
Slides were blocked for 1h at room temperature with 50% Li-Cor Blocking Buffer 
(50% PBS) before being incubated with primary antibody overnight at 4°C. The 
slides were then washed with PBS-T (3x5min) before applying the fluorescently 
labelled secondary antibody (Table 3) diluted in Li-Cor blocking buffer and 
incubating at room temperature for 45min in the dark with gentle shaking. The slides 
were washed in the dark with PBS-T (3x5min), then with PBS (3x5min), and then 
dried in an oven at 50°C. 
 
The slides were scanned on a Li-Cor Odyssey scanner (Li-Cor Biosciences, Lincoln, 
Nabraska, USA) at 680nm and 780nm. The image was analysed using MicroVigene 
RPPA Analysis module software (VigeneTech Inc., Carlisle, MA, USA) to detect 
spots and quantify the spot intensities. Spot intensity is calculated from the total pixel 
intensity within the spot boundary minus background of 2 surrounding pixels. The 
means of the triplicate dilutions are used to produce a curve for each sample. The y 
intercept is used as a relative measure of protein concentration between curves. This 
quantitative measurement is used in further analysis. Measurements for 
phosphoproteins were normalised to the corresponding total protein.  
 
2.2.5 Gene Expression Analysis 
2.2.5.1 Experimental Design 
SCL60 or HEK293 cells were seeded 48h prior to treatment to allow adherence and 
proliferation to 30-40% confluence. They were treated with 100nM Triptorelin, or 
0.02% propylene glycol solution. The total media volume was 3ml; the media was 
not changed at treatment to avoid loss of loosely attached cells. RNA was collected 
at multiple time points (Table 21) from 4 independent experiments on different days. 
 
  Triptorelin Control 
SCL60 0.5h, 1h, 2h, 8h, 24h 0h, 1h, 8h, 24h 
HEK293 1h, 24h 0h, 1h, 24h 
Table 21: Gene expression study time points. 
Time points at which RNA was collected from SCL60 and HEK293 cell lines treated with 
Triptorelin or 0.02% Propylene Glycol solution (vehicle control) 
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2.2.5.2 RNA extraction and preparation for microarray 
RNA was isolated using the Absolutely
®
 RNA Miniprep kit (Stratagene) according 
to manufacturer’s instructions. Briefly, cells were lysed in a buffer containing 
guanidine thiocyanate, which denatured proteins and prevented ribonuclease 
degradation of RNA. The sample was then mixed with ethanol, and passed through 
an RNA-binding fibre matrix. Contaminating DNA was removed from the matrix 
with DNase treatment, and further washing steps remove other contaminants before 
eluting the RNA. RNA samples were quantified using the NanoDrop™ 2000 
(Thermo Scientific, USA) according to the manufacturer’s instructions [125]. 
Purified RNA was biotin-labelled using the Illumina
®
 TotalPrep™ RNA 
Amplification Kit (Ambion) according to the manufacturer’s instructions.  
 
2.2.5.3 Illumina microarrays 
Labelled RNA was hybridised to Illumina
®
 12-sample Whole Genome Array 
BeadChips (HumanHT-12 v3) [126]. These chips contain 48803 probes, representing 
37805 different features. The majority of these features are well-annotated coding 
transcripts, although there are other less well-annotated coding transcripts and a 
small number of non-coding sequences [126]. Each bead holds 10,000 copies of a 
probe, and there is an average of 30 bead types per array. The chips were scanned, 
and initial quality control measurements were carried out (using BeadStudio
®
), at the 
Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh. 
Samples were distributed carefully over the 5 chips to ensure that a balance of 
Control and Triptorelin samples were on each chip, this reduces the likelihood of 
confounding batch effects [127, 128]. Probe annotation is taken from the NCBI 
RefSeq database (Build 36.2, Release 22) [129]. After hybridisation the chips were 
scanned on an Illumina BeadArray Reader. [126]. 
 
2.2.5.4 Normalisation 
The Wellcome Trust Clinical Research Facility performed the required collation of 
individual hybridisation spots to produce a ‘raw’ dataset comprising a quantitative 
 75 
value of expression for each probe sequence, and an indication of the confidence of 
this value. 
 
Probe sequences were first filtered to remove those that were unreliably detected: 
only the probe sequences that were detected with more than 95% certainty in at least 
three samples were retained. The remaining probes were quantile-normalised to scale 
the distributions of intensities on the arrays of the five microarray chips using the 
beadarray package [130]. Cluster analysis confirmed that there was no significant 
chip or run bias. All normalisation and data analysis steps were performed using the 
statistical software package, R [131, 132] and associated Bioconductor packages 
[130, 133, 134].  
 
2.2.5.5 Further Analysis 
To identify differentially expressed genes, the normalised data were subject to Rank 
Product analysis [135]. This method of differential expression identification was 
used because it is more robust to outliers within a group than other methods such as 
Significance Analysis of Microarrays (SAM) [135]. This is important because 
outliers can particularly distort results in experiments with few samples. 
Differentially expressed genes were defined with a predicted false-positive level cut-
off of 5% (0.05). Hierarchical clustering was performed on log2-transformed, 
median-centred data using Cluster [136]. The resulting similarity matrix was viewed 
as a heatmap using Treeview [136]. The online pathway annotation tool, DAVID 
[137], was used to determine whether there was significant enrichment for any 
pathways among the genes differentially expressed between HEK293 and SCL60 
cells, or among the genes differentially expressed between Triptorelin-treated and 
control SCL60 cells. Significant enrichment was defined by an unadjusted P-value 
<0.10 from a one-tailed Fisher exact test calculated within the DAVID system. 
Analysis was performed on a standard personal computer in conjunction with the 




The flow chart below gives an overview of the gene expression microarray method. 
 
RNA collected at multiple time points from 4 independent 
experiments in which HEK293 and SCL60 cells were treated with 
Triptorelin or vehicle control for up to 24h
57 samples distributed over 5 Illumina beadarray chips
57 samples biotin-labelled
Hybridisation and scanning performed at Wellcome Trust Clinical 
Research Facility
56 RNA samples + 1 sample duplicated as a technical replicate = 
57 samples
Filtered out genes that were not detected in at least 3 samples with 
a P-value of less than 0.05
Intensity values with P-values for confidence of detection of each 
gene in 57 samples
Quality control checks (1 outlier detected, technical replicates
match, no chip bias)
Normalisation
1 outlier and 1 technical replicate removed = 55 samples remaining
Rank Products analysis to detect significant differential expression 
between the various sample groups with a false discovery rate of
5%
 
Figure 10: Flow chart for gene expression microarray study indicating steps from RNA 
collection to differential expression analysis  
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2.2.6 Radioligand Binding Assay 






I binds to Tyr
6
. 
Cells of each clone were seeded into 24-well plates using 1 row per clone as shown 
in Figure 11.  
 
Figure 11: Radioligand binding assay plate layout. 
 
After 24h, cells were 100% confluent. Cells in the control wells were washed with 
1ml PBS to remove any non-adherent cells and debris. Cells were detached by 
adding 1ml trypsin per well and resuspended by repeated pipetting. The number of 
cells was counted using a haemocytometer.  
 
Cells in the remaining wells were chilled to 4°C for 10min. The media was aspirated 
and gently replaced with either labelled (
125
I-GnRH) or both labelled and unlabelled 
GnRH in 0.5ml/well DMEM + 0.1% BSA as shown above. 
125
I-GnRH was added to 
0.5ml/well DMEM + 0.1% BSA to give approximately 30,000cpm/ml media when 
measured using an automatic gamma counter. Unlabelled GnRH was added at 1µM. 
Cells were incubated at 4°C for 90min to complete binding. 
  
On ice, media was removed and cells were gently washed 4 times with cold PBS to 
remove any unbound ligand. To solubilise the cells, 0.5ml 0.1mM NaOH was added 
per well and the cells were left on a shaking platform for 5min. The contents of each 






I-GnRH + 1µM unlabelled GnRH) 





I-GnRH + 1µM unlabelled GnRH-I were added to 2 empty glass 
tubes. Radiation was measured in the tubes using an automatic gamma counter.  
 
2.2.7 Inositol Phosphate Assay 
Incubations were at 37°C, 5% CO2 unless otherwise stated. Cells were seeded in 
complete media into 12-well plates at 50-70% confluence then incubated overnight 
to adhere. The medium was replaced with serum-free special DMEM (no inositol) 
and 0.5µci/ml 
3
H-myoinositol and the cells were incubated overnight. The medium 
was replaced with serum-free DMEM + 10mM LiCl (inositol phosphatase inhibitor) 
+ 10mM HEPES buffer pH7.5 and cells were incubated in this for 30min. The 
medium was then replaced with serum-free DMEM + 10mM LiCl (inositol 
phosphatase inhibitor) + 10mM HEPES buffer pH7.5 +/- GnRH agonist. After 90min 
the reaction was stopped by replacing the medium with 1ml/well 10mM formic acid 
and incubating for at least 30min at 4°C. The formic acid was removed and Dowex 
ion exchange chromatography was then performed as described previously [138]. 
 
2.2.8 Cell Density Assays 
2.2.8.1 Sulforhodamine Blue Assay 
Cells were seeded into 12-well plates at 40-50% confluence in complete media 
(1ml/well). After 24h the media was replaced with the relevant treatment in complete 
media (2ml/well). Cells were fixed on the day of treatment (Day 0) and selected 
time-point(s) thereafter. On ice, 25% trichloroacetic acid (TCA) solution was added 
gently to each well (500µl per ml media) to fix the cells. After 60min the wells were 
gently washed twice with water to remove any residue TCA and allowed to dry. The 
plates were incubated with 0.4% sulforhodamine blue (SRB) dye (750µl per well) for 
30min at room temperature. The SRB solution was discarded and the wells were 
washed gently 4 times with 1% glacial acetic acid and allowed to dry. Tris pH10.8 
(1ml) was added to each well to dissolve the dye and 50µl from each well was 
transferred to a 96-well plate. The absorbance was measured at 540nm using either a 
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Multiskan Transmit spectrophotometer (Labsystems Inc., MA, USA) or a BioHit 
BP800 spectrophotometer (BioHit Ltd., UK). 
 
2.2.8.2 NFκB inhibitor assay 
SCL60 cells were seeded into 12-well plates at 1x10
6
cells/ml. After 48h the cells 
were washed in serum-free media then treated with 3µM 15d-PGJ2 (NFκB inhibitor) 
or vehicle control (dimethyl sulphoxide) in serum-free media for 30min before 
addition of 100nM Triptorelin or vehicle control (0.02% Propylene glycol solution) 
in complete media. After 4 days cell proliferation was measured by (SRB) assay as 
described above. 
 
2.2.9 Proteomic (Antibody) Array 
2.2.9.1 Sample preparation (SCL60 Xenografts) and the V250 array 
Tumours were derived from the GnRH-R-transfected HEK293 cell line, SCL60, by 
subcutaneous bilateral implantation of these cells into the flank of athymic nude 
female mice. Nine mice with eleven tumours were treated with Triptorelin 
(10µg/mouse, 0.1ml). Ten mice with twelve tumours were injected with a 0.02% 
Propylene glycol solution, (0.1ml). Xenograft material was collected at day 4, 7 and 
14. 
 Control Triptorelin 
Day 4 671L, 671R, 643L 661L, 622R, 621R 
Day 7 625L, 670L, 673R 659R, 897L, 646L 
Table 22: Xenograft Samples.  
This table shows the tumour codes that were assessed by antibody array. The number 
corresponds to the mouse, and L or R indicates the left or right tumour on this mouse. 
 
Samples from 3 tumours following treatment with Triptorelin at day 4 and day 7, and 
6 corresponding controls (Table 22), were analysed using the V250 antibody array 
(Eurogentec Ltd., Southampton, UK) for protein expression. This is a forward-phase 





Figure 12: Forward-phase protein microarray.  
Antibodies are immobilised and their biotin-labelled target protein is added in solution and 
allowed to hybridise. Cy3-Streptavidin is then added, which binds to the biotin and allows the 
antibody-protein hybridisation to be detected.  
This figure is adapted from [139]. 
 
The V250 antibody array comprises 117 pairs of antibodies to detect both 
phosphorylated and non-phosphorylated forms of a range of proteins that are 
typically dysregulated in cancer-related signalling, such as proliferation and cell 
death signalling pathways. A full list of the antibodies used is shown in Appendix A 
Table 1. These antibodies, and several positive and negative controls, were 
covalently immobilised on a 3D-polymer coated glass slide. Six replicates of each 
antibody are printed onto each slide. 
 
Protein was extracted from the xenograft tissue using bespoke Eurogentec lysis 
buffers. The protein concentration was measured using a BCA Protein Assay Kit 
before the protein was biotin-labelled. The microarrays were blocked before addition 
of protein to allow conjugation to the immobilised antibodies, after which any 
unbound protein was washed off. The microarray was then incubated in the dark with 
a solution of the fluorescent dye, Cy3, conjugated to Streptavidin (which binds with 
high affinity to biotin), before several wash steps with bespoke wash buffers 
followed by distilled water. This fluorescently labelled the bound protein, allowing it 
to be detected. The microarray slide was dried with compressed nitrogen and then 
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scanned using an Axon GenePix array scanner (Axon Instruments, Molecular 
Devices Corporation, Silicon Valley, CA, USA) 
 
2.2.9.2 Data Analysis 
The data were normalised in-house by Eurogentec and are expressed as a ratio of the 
intensity detected from specific binding of antibody to a phosphorylated protein, to 
that of its non-phosphorylated counterpart. For statistical analysis the open-source 
statistical language, R, was used, with associated packages [131]. The data for day 4 
and day 7 were analysed as individual datasets with respect to their corresponding 
controls. Control and treated groups were tested for significant differences using the 
Mann-Whitney-U test. A correction for multiple testing was applied. However, since 
this returned no statistically significant differences, the uncorrected P-values were 
used, in combination with fold changes, to identify the protein changes most likely to 
be relevant to the antiproliferative effect of Triptorelin.  
 
2.2.10 Immunohistochemistry 
2.2.10.1 Tissue Microarray construction/Preparation of Slides 
2.2.10.1.1 SCL60 xenograft tissue microarray 
Tumours from SCL60 xenografts (prepared as described in [79]) were added to a 
tissue microarray as described in [140]. The tissue microarray was constructed 
containing 0.6mm cores from 9 control tumours (6 from day 4 and 3 from day 7) and 
10 Triptorelin-treated tumours (7 from day 4 and 3 from day 7), each in triplicate. 
Note that 3 control day 4 and 4 Triptorelin-treated day 7 samples were derived from 
a second xenograft experiment but the experimental protocol was identical. Paraffin 
embedded sections were prepared from the TMAs (3µm thick) using a microtome 
and then mounted onto slides. 
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2.2.10.1.2 SCL60 cell line sections 
Cells were grown to 70-80% confluence then detached using Trypsin-EDTA, washed 
and a cell pellet collected. This was fixed in formalin before being embedded into 
paraffin wax. Paraffin embedded sections were prepared from the TMAs (3µm thick) 
using a microtome and then mounted onto slides. 
 
2.2.10.1.3 Staining slides 
All washes were 2x5min with PBS-T unless otherwise indicated. All steps were 
performed at room temperature unless otherwise stated. Paraffin embedded sections 
were dewaxed by washing in xylene and then rehydrated through graded ethanol 
solutions (100% twice, then 80%, 50%; 2min each). The antigen retrieval buffer used 
was either a sodium citrate-based buffer, or a Tris-EDTA buffer, depending on 
antibody specification (Table 3).  
 
Antigen retrieval buffers were prepared as detailed in Table 23 and Table 24. The 
antigen retrieval buffer (900ml) was heated in a microwave pressure cooker for 
10min before adding the slides and heating for a further 5min. When the solution was 
cool the slides were washed, incubated for 10min with 3% hydrogen peroxide 
solution to block any endogenous peroxidase activity and then washed again. The 
slides were loaded onto a Sequenza
®
 slide rack and washed again before incubating 
with Dako Total Protein Block for 10min.  
 
Component Quantity 
0.1M Sodium Citrate 82ml 
0.1M Citric Acid 18ml 
Distilled Water 900ml 
Table 23: Sodium Citrate Buffer 
 
Component Quantity 
Tris Base 1.21g 
EDTA 0.37g 
Tween 20 (Polysorbate 20) 0.5ml 
Distilled Water 1000ml 
Table 24: Tris-EDTA Buffer 
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Primary antibodies (prepared in Dako Antibody Diluent) were applied (120µl) and 
the slides were incubated for 1h at room temperature or as otherwise advised by 
individual antibody specifications (Table 3). Slides were washed, then incubated 
with Dako Envision Labelled Polymer for 30min, then washed again. To visualise 
the bound antibody, DAB substrate was diluted 1:50 in DAB buffer and was applied 
to the slides for 10min.  
 
The slides were washed with water, counterstained in haematoxylin, and washed 
again in water to remove excess stain. The sections were dehydrated through graded 
ethanol solutions (50%, 80%, 100% twice; 2min each), and then washed in xylene. 
Slides were mounted with coverslips using di-N-butylphthalate in Xylene (DPX) 
mountant. 
 
2.2.10.1.4 Scoring and analysis 
Slides were observed at 200x magnification on a light microscope. Negative controls 
(no primary antibody added) were included for each antibody and these were 
assessed for non-specific antibody staining. 
 
For cleaved Caspase-3, the percentage of positively stained cells was visually 
estimated for each core. The mean percentage of up to three cores (some cores were 
removed due to poor quality) was calculated for each xenograft. Three ‘control day 
4’ and three ‘control day 7’ xenografts were each compared with three ‘Triptorelin 
day 4’ and three ‘Triptorelin day 7’ xenografts.  
 
For pHistone H3, an estimate of the percentage of positively stained cells in each 
core was obtained by counting all the positively and negatively stained cells in 
multiple fields per core, to reach a total cell count per core of at least 1500 cells. 
Three ‘control day 4’ and three ‘control day 7’ xenografts were each compared with 
three ‘Triptorelin day 4’ and three ‘Triptorelin day 7’ xenografts.  
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For all other markers, an immunoscore out of 300 was calculated for each TMA core. 
This was calculated by visually estimating (or counting at least 1500 cells from 
representative fields) the percentage of cells stained at each intensity level from 0 to 
3, where 0 is negative and 3 is strongly stained. The percentage of cells at each 
intensity level was multiplied by 0, 1, 2 or 3 (corresponding to the intensity level). 
The sum of these percentages gave a total score out of 300. Mean immunoscores 
were calculated for control and Triptorelin-treated tumour groups at day 4 and 7. A 
difference in mean immunoscores with a P-value of less than 0.05 from a 2-sample t-
test was considered to be significant.  
 
2.2.11 GnRHR expression assay by immunofluorescence 
2.2.11.1 TMA construction and preparation of Slides 
2.2.11.1.1 Clinical breast cancer tissue microarray 
Three tissue microarrays (TMAs) were constructed with triplicate samples from each 
of 347 primary breast carcinomas [141] as previously described [140]. The primary 
tissue was collected after surgical breast resection between 1999 and 2002 at the 
Breast Unit, Western General Hospital, Edinburgh [141]. Paraffin embedded sections 
were prepared from the TMAs (3µm thick) using a microtome and then mounted 
onto slides. Primary breast cancer TMA sections were used for antibody validation. 
This TMA is referred to as Ab-Val and is distinct from the TMAs described above. 
 
2.2.11.2 Staining for GnRHR expression 
2.2.11.2.1 Immunohistochemistry 
Sections were stained for GnRHR expression by immunohistochemistry to determine 
the optimal antibody concentration, antigen retrieval buffer and incubation times to 
use for immunofluorescence. Immunohistochemical staining was performed as 
described above using pituitary whole tissue sections (positive control for GnRHR 
expression) and primary breast cancer TMA (Ab-Val) sections. Positive GnRHR 
staining was observed with the GnRHR (A9E4) Leica Microsystems antibody, and 
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the optimal conditions for this antibody are described in Table 3. This staining was 
performed by Ilgin Cagnan, a student working under my supervision. 
 
2.2.11.2.2 AQUA® 
Sections were dewaxed and rehydrated through graded alcohols as described above. 
Antigen retrieval was performed as described above with pH6.0 0.01M sodium 
citrate buffer. Slides were washed and incubated with 3% hydrogen peroxide. 
 
Ab-Val TMA sections and pituitary whole tissue sections were used to determine 
optimal antibody concentration for immunofluorescence assays. The 
immunofluorescence assays were performed using sections from the primary breast 
cancer TMAs described above [141]. Slides incubated with antibody diluent and no 
primary antibody were included as negative controls, and formalin-fixed paraffin-
embedded pituitary was used as a positive control for GnRHR expression. 
  
Sections were prepared as for immunohistochemistry, as described in section 
2.2.10.1.3, until the primary antibody incubation step. Further steps were performed 
using the Aquantiplex™ Epithelial Masking Kit (HistoRx). Slides were incubated 
with the mouse anti-GnRHR (A9E4) antibody diluted 1:4 in antibody diluent, 
followed by mouse anti-cytokeratin antibody (diluted 1:50, 4°C overnight). The 
slides were then incubated with goat anti-mouse Alexa555 antibody (1:100; 
Invitrogen; epithelial mask visualisation). Target visualisation was performed 
according to the manufacturer’s instructions. Slides were counterstained and a 
coverslip mounted. Images (200x magnification) of the stained tissue cores were 
captured using an Olympus AX51 fluorescent microscope (as part of the HistoRx-
PM-2000
™
 imaging system) in conjuction with AQUAsition™ software. DAPI, Cy3 
and Cy5 filters were applied to obtain an image for each of the nucleus, cytokeratin 
mask, and the target protein (GnRHR). These images were analysed using 
AQUAnalysis™ software as previously described [142]. Analysis included the 
removal of image areas that either had imaging errors, corresponded to normal 
mammary ducts or ductal carcinoma in situ or constituted less than 5% epithelium. 
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Each core image was given a score in AQUA
®
 units (Au) corresponding to the level 
of GnRHR expression. Full details of the antibodies used are described in Table 3. 
This AQUA staining and scoring was performed by Ilgin Cagnan. 
 
2.2.11.2.3 Analysis 
The relationship between discrete variables (Grade or Phenotype) and GnRHR 
expression was determined by comparing the mean GnRHR expression level for each 
category (Grade 0/1/2/3 or phenotype HER2/Luminal/TNP) by one-way ANOVA. 
298 of the 347 samples were assigned to a molecular phenotype by hormone receptor 
status using the annotations given by Aitken et al [1]. Grade information was 
available for 344 of the 347 samples. 
 
The relationship between continuous variables (ER, PR, HER2, CK5/6, EGFR 
expression) and GnRHR expression was determined by non-linear regression.  
Expression values of ER, PR, HER2, CK5/6 and EGFR were available for 335, 336, 



















3.1 SCL60 response to the GnRH agonist Triptorelin in vitro 
and in vivo 
The SCL60 cell line has been established as a model in which to study GnRHR-
mediated antiproliferative signalling [79, 104, 112, 122]. The SCL60 model is a 
Human Embryonic Kidney-293 (HEK293) cell line that has been stably transfected 
with rat GnRHR. Radioligand binding assays have confirmed that these cells express 
high levels of functional GnRHR at the cell surface [79]. The SCL215 model is a 
HEK293 cell line that has been stably transfected with a modified form of GnRHR, 
which is inactivated by the presence of a C-terminal tail (personal communication – 
Dr Kevin Morgan). 
 
In this chapter, the SCL60 cell line is compared to HEK293 (untransfected) and 
SCL215 cells. Stimulation of GnRHR in SCL60 cells causes increased inositol 
phosphate production, and a reduction in SRB activity[79]. This is not observed in 
HEK293 or SCL215 cells. These cell lines provide a useful model in which to study 
GnRHR-mediated antiproliferative signalling.  
 
3.1.1 SRB Activity in Response to Triptorelin 
The experiments in this thesis focus on the GnRH agonist, Triptorelin. This agonist 
has been shown to strongly reduce SRB activity of SCL60 cells in vitro and the 
growth of SCL60-derived xenografts in vivo [79]. It is readily available and has been 
the GnRH agonist of choice in similar studies of GnRH in this context [79, 143].  
 
It is shown below that Triptorelin inhibited SCL60 but not SCL215 or HEK293 cells 
in vitro. This inhibition appeared to occur by a combination of induction of apoptosis 
and inhibition of proliferation in vivo, and involves cell cycle arrest in at least a 
proportion of cells in vitro.  
 
 89 
3.1.1.1 Triptorelin inhibits SCL60 cells in vitro 
The GnRH agonist, Triptorelin, has been shown to inhibit the proliferation of SCL60 
cells in vitro [79]. To confirm this response, SCL60 cells were treated with 100nM 
Triptorelin or an appropriate dilution of the vehicle (0.02% Propylene Glycol 
solution) as a control. Cell density was measured by sulphorhodamine blue (SRB) 
assay after 4 days. Triptorelin caused an average 42% reduction in SRB activity of 
SCL60 cells (P=0.006, paired t-test; Figure 13). HEK293 and SCL215 cells were 
unresponsive to Triptorelin (Figure 13). Figure 13 shows a representative example of 





















































































Figure 13: SRB Activity of SCL60, HEK293 and SCL215 cells 4 days after treatment with Triptorelin (100nM) or vehicle control.  
Bars show the mean of 3 replicates. Error bars show standard deviation. The effect of Triptorelin on SCL60 cells is representative of 7 independent 
experiments (mean inhibition = 42%; P=0.006, paired T-test).
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3.1.2 Exploring the mechanism by which Triptorelin reduces cell 
number in SCL60 cells in vitro 
To further understand how Triptorelin reduces cell number in vitro and tumour 
volume in vivo, it was necessary to identify whether this occurs by an inhibition of 
proliferation signalling pathways, induction of cell death signalling, or a combination 
of both processes. This is important to help identify which signalling factors are 
involved in the response to Triptorelin. To do this, the impact of Triptorelin on cell 
cycle progression in vitro and on the expression of protein biomarkers of apoptosis 
and proliferation both in vitro and in vivo was assessed.  
 
3.1.2.1 Triptorelin causes increased expression of apoptotic markers in 
SCL60 cells in vitro 
PARP is an important protein in the cellular response to DNA damage. It is cleaved 
and inactivated during caspase-mediated apoptosis. Cleaved PARP (c-PARP), 
therefore, is often used as a marker for caspase-mediated apoptosis [144].  
 
c-PARP expression was evaluated in SCL60 cells in response to Triptorelin using 
semi-quantitative western blotting. A small increase in c-PARP expression was 
detected in SCL60 cells by western blot 24-48h after treatment with Triptorelin, 
although this was much less pronounced than at 72-96h after treatment (Figure 14, 
Figure 15). By 72h the level of c-PARP expression in Triptorelin-treated cells was 
more than four times the expression in vehicle-control treated cells (Figure 15). This 
increase in c-PARP continued to be observed at 96h (Figure 14, Figure 15). These 
results support the previously published data, which identified increased c-PARP in 
SCL60 cells 72-96h after Triptorelin treatment [79]. 
 
Figure 14: Western blot showing cleaved PARP expression in SCL60 cells after 24, 48, 72 and 























































Figure 15: Quantification of the western blot for PARP and cleaved PARP.  
Values for the Triptorelin-treated samples are shown relative to the corresponding vehicle 
control-treated samples at each time point to show the change in cleaved PARP (black bars) that 
occurs as a result of Triptorelin treatment. Uncleaved PARP expression is also shown (white 
bars). This is representative of two independent experiments. 
 
3.1.2.2 Triptorelin causes cell cycle arrest in SCL60 cells in vitro 
Flow cytometric cell cycle analysis showed that after 24-48h of treatment with 
100nM Triptorelin, the percentage of SCL60 cells increased in the G2/M and S 
phases (Figure 16). The proportion of cells in each phase of the cell cycle in the 
Triptorelin-treated population normalised to the vehicle control-treated population in 
each cell line is shown in Figure 16. The unnormalised data is shown in Figure 17. It 
is important to note that these data show results from a single experiment, and 
therefore require further work before firm conclusions may be drawn. The baseline 
cell cycle distributions of HEK293 and SCL60 cells were comparable (Figure 18). In 
the HEK293 cell population, 70% were in G0/G1 phases, 21% were in S phase and 
9% were in G2/M phases. In the SCL60 cell population, 67% were in G0/G1 phases, 
24% were in S phase and 9% were in G2/M phases. The cell cycle distributions are 
similar, although there is a slightly higher proportion of SCL60 cells in S phase than 
HEK293 cells. In HEK293 and SCL215 cells no difference in the proportion of cells 
in each phase of the cell cycle between control and Triptorelin-treated cells could be 




Figure 16: Flow cytometric cell cycle analysis of SCL60, HEK293 and SCL215 cells following treatment with Triptorelin (100nM) for up to 48h.  
Bars show the proportion of cells (relative to vehicle control at the same time point) in G0/G1 (black), S (white) or G2/M (grey) phases of the cell cycle. These 









Figure 17: Flow cytometric cell cycle analysis of SCL60, HEK293 and SCL215 cells following treatment with Triptorelin (100nM) for up to 48h. 
Bars show the proportion of cells (relative to vehicle control at the same time point) in G0/G1 (black), S (red) or G2/M (blue) phases of the cell cycle in SCL60, 
HEK293 and SCL215 cells treated with 0.02% propylene glycol (solid bars) or 100nM Triptorelin (shaded bars). These data are from a single experiment.
 95 
 
Figure 18: The cell cycle distributions of HEK293 and SCL60 cells 
In the HEK293 cell population, 70% were in G0/G1 phases, 21% were in S phase and 9% were 
in G2/M phases. In the SCL60 cell population, 67% were in G0/G1 phases, 24% were in S phase 
and 9% were in G2/M phases. The cell cycle distributions are similar, although there is a slightly 




3.1.3 Exploring the mechanism by which Triptorelin reduces the 
volume of SCL60 xenografts in vivo 
Using tissue from the SCL60 xenografts treated with Triptorelin or vehicle control 
described in Section 1.3.2 (Figure 9), the level of phospho-Histone H3 and cleaved 
Caspase-3 was measured by immunohistochemistry. Phosphorylated Histone H3 is 
used as a marker of proliferation because phosphorylation at Ser10, Ser28 and Thr11 
residues of Histone H3 is specifically correlated with mitosis [145-147]. The level of 
staining for phospho-Histone H3 indicates the number of cells undergoing mitosis at 
one point in time. If the proliferation rate of the cell population is greater, one would 
expect more cells to be undergoing mitosis at any one time. Caspase-3 cleavage is an 
essential event in initiating the death cascade in caspase-dependent apoptosis [148]. 
It is therefore used as a marker of the early stages of apoptosis.  
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3.1.3.1 Triptorelin caused a reduction in the expression of the 
proliferation marker pHistone H3 in SCL60 xenografts 
pHistone H3 expression was significantly lower in Triptorelin-treated xenografts 































Figure 19: pHistone H3 expression in SCL60 xenografts as measured by immunohistochemistry. 
Bars show the percentage of cells positively stained in (triplicate cores of) 5 vehicle control-
treated tumours and 6 Triptorelin-treated tumours. Tumours were treated for either 4 or 7 
days. pHistone H3 expression was significantly lower in Triptorelin-treated tumours compared 
to vehicle control-treated tumours (P=0.006; 2-sample t-test). 
 
Figure 20: pHistone H3 immunostaining in TMA cores of SCL60 xenografts treated with (A) 
vehicle control or (B) Triptorelin for 4 days.  
Brown staining corresponds to pHistone H3 expression and blue staining corresponds to 
haematoxylin.  
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3.1.3.2 Triptorelin caused an increase in the expression of the apoptotic 
marker cleaved caspase-3 in SCL60 xenografts 
Immunohistochemical staining showed a significant 3-fold increase in cleaved 
caspase-3 expression in Triptorelin-treated SCL60 xenografts compared to those 




























Figure 21: Cleaved caspase-3 expression in SCL60 xenografts as measured by 
immunohistochemistry.  
Bars show the percentage of cells positively stained in 5 vehicle control-treated tumours and 6 
Triptorelin-treated tumours. Tumours were treated for either 4 or 7 days. A statistically 
significant increase in cleaved caspase-3 expression was observed in Triptorelin-treated tumours 
compared to vehicle control-treated tumours (P=0.0095; 2-sample t-test).  
 
 
Figure 22: Cleaved caspase-3 immunostaining in TMA cores of SCL60 xenografts treated with 
(A) vehicle control or (B) Triptorelin for 4 days.  




It has been shown above that Triptorelin reduced SCL60 but not SCL215 or HEK293 
cell numbers both in vitro [79] (Figure 13) and this has previously been shown in 
vivo [79] (Figure 9). These data support the previous finding that Triptorelin has a 
marked effect on SCL60 cell number, and that expression of functional GnRHR is 
required for a response [79]. This ability of Triptorelin to inhibit the SRB activity of 
SCL60 cells makes SCL60 cells a useful model with which to study the 
antiproliferative effect of GnRHR stimulation.  
 
The SRB activity of HEK293 and SCL215 cells was uninhibited by Triptorelin and 
this is consistent with the lack of functional GnRHR. The addition of functional 
GnRHR appeared to be sufficient to allow Triptorelin to reduce SRB activity. This 
indicated that the cells have the necessary machinery to mediate an antiproliferative 
response to a GnRH agonist, even though they do not normally express the receptor. 
This may be relevant to other cell systems that do not normally express GnRHR. 
 
To further understand how Triptorelin reduced cell number in vitro and tumour 
volume in vivo, the impact of Triptorelin on cell cycle progression (in vitro) and on 
the expression of protein biomarkers of apoptosis and proliferation (both in vitro and 
in vivo) was assessed.  
 
Triptorelin caused an increase in PARP cleavage in SCL60 cells at 72 and 96h after 
treatment with Triptorelin (Figure 14, Figure 15). This was consistent with the 
previously published data by Morgan et al [79], which described a very small 
increase in cleaved caspase-9 (upstream of c-PARP) and pFADD (death receptor 
signalling, marker of extrinsic apoptosis) expression by 24h, but did not observe any 
increase in c-PARP expression until 72h [79]. A caspase inhibitor (20µM Q-VD-
OPh) has been shown to partially rescue (40%, P<0.002) SCL60 cells from the effect 
of Triptorelin [79]. Together, these data indicate that at least a proportion of the cells 
undergo apoptosis in response to Triptorelin. 
 
 100 
Flow cytometric cell cycle analysis showed that after 24-48h of treatment with 
Triptorelin, the percentage of SCL60 (but not HEK293 or SCL215) cells increased in 
the G2/M and S phases (Figure 16). This is in agreement with previously published 
results, which showed that GnRHR stimulation caused G2/M arrest in HEK293 cells 
stably expressing either human or rat GnRHR [112]. Together, these data indicate 
that the antiproliferative effect of Triptorelin may be mediated at least in part by cell 
cycle arrest. Cell cycle arrest has been observed following GnRHR stimulation in 
other cell lines including pituitary LβT2 cells [112], breast cancer MCF7-derived 
cells [69], and ovarian cancer cells EFO-21 and EFO-27 [149], although in these 
cases there was an increase in the proportion of cells in G0/G1 phase rather than the 
G2/M phase. 
 
Immunohistochemical staining showed a significant increase in cleaved caspase-3 
expression, and a decrease in pHistone H3 expression in Triptorelin-treated 
xenografts compared to those treated with a vehicle control (Figure 19, Figure 21). 
This suggested that the antiproliferative effect of Triptorelin in vivo is mediated by a 
combination of increased apoptotic signalling and a decrease in proliferative 
signalling.  
  
In summary, Triptorelin inhibited SCL60 but not HEK293 or SCL215 cells both in 
vitro and in vivo. This occurred by a combination of induction of apoptosis and 
inhibition of proliferation, and involved cell cycle arrest in at least a proportion of 
cells in vitro. 
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3.2 Transcriptional signalling in HEK293 and SCL60 cells 
following GnRHR stimulation 
To investigate GnRHR-regulated signalling at the transcriptomic level, a global, 
data-driven approach was taken to identify genes that may be of interest in 
understanding the GnRHR-mediated antiproliferative effect. Gene expression 
analysis was conducted using RNA extracted from SCL60 and HEK293 cells 
following treatment with Triptorelin for up to 24h.  
 
Gene expression analysis allows a genome-wide snapshot of transcriptional activity. 
The genes that are most differentially expressed with treatment might feasibly 
contain some of those most relevant to mediating the direct antiproliferative effect of 
Triptorelin. The aim of this experiment was to identify gene expression changes after 
Triptorelin treatment and to use these data to generate hypotheses about genes that 
may be involved in mediating the antiproliferative effect of Triptorelin. 
 
More specifically, the aims were to examine whether genes are differentially 
expressed between (untreated) HEK293 and SCL60 cells, and whether the expression 
of any genes is influenced by Triptorelin treatment in each of these cell lines. If 
differential gene expression between any of these pairs of sample groups could be 
identified, the aim was then to determine how many genes were differentially 
expressed, by how much, and how their expression varied over 24h after treatment 
with Triptorelin. To explore these differentially expressed genes further, the most 
represented functions and pathways were defined. Differential gene expression was 
determined using Rank Product analysis with a maximum false discovery rate (FDR) 
of 0.05, as described in Materials and Methods. 
 
3.2.1 Data pre-processing 
Fifty-seven samples, including the 56 samples detailed in Materials and Methods 
(section 2.2.5.1; 4 replicates of HEK293 and SCL60 cells treated with vehicle control 
or Triptorelin for several time points up to 24h) and one sample duplicated as a 
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technical replicate, were distributed randomly over 5 Illumina HT-12 Beadchips. 
Other samples outwith this study filled the remaining 3 arrays on the chips. Values of 
the average fluorescence intensity resulting from the hybridisation of probes and 
their targets were recorded in BeadStudio (bespoke software) for 48803 probes on 
each array. In an initial similarity matrix, the technical replicates clustered together, 
and one outlier was identified. The outlier (from the group ‘SCL60 vehicle control 
1h’), and the technical replicate was removed before further analysis, leaving 55 
arrays remaining. A detection P-value was calculated in GenomeStudio (bespoke 
software), which gives a measure of confidence that a given target transcript is 
reliably expressed above the background intensity of negative control probes. Probes 
that were detected with a P-value of less than 0.05 in at least 3 samples (arrays) were 
considered to be reliably detected; all other probes were excluded from the dataset. 
These included probes with poor hybridisation or transcripts that are not represented 
in HEK293 or SCL60 cells. After this filtering process, 25820 probes were retained 
for further analyses. 
 
The dataset was quantile-normalised to scale the distributions across the 55 
beadarrays (Figure 23). Multidimensional scaling demonstrated that there was no 
significant chip or run bias, samples were randomly assigned to beadchips but 
clustered by replicate rather than by chip (Figure 24). 
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Figure 23: Boxplot showing the filtered gene expression data  
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Figure 24: Multidimensional Scaling Plot. 
The proximity of two points to one another on the graph represents how similar their expression 
profiles are. Samples cluster by cell type rather than by Beadchip or processing batch. Dark 
blue = HEK293 control; green = HEK293 Triptorelin; pink = SCL60 control; Light blue = 
SCL60 Triptorelin. Square = chip 1; circle = chip 2; cross = chip 3, triangle = chip 4; diamond = 
chip 5.  
 
 104 
3.2.2 Comparison of gene expression between vehicle control- 
and Triptorelin-treated HEK293 cells 
To identify whether any genes were differentially expressed in the untransfected 
HEK293 cells (which do not express GnRHR) as a result of Triptorelin treatment, 
four Triptorelin-treated samples were compared to four vehicle control-treated 
samples of the same time-point. Gene expression microarray analysis identified only 
four probes (representing four genes) that were increased in the Triptorelin-treated 
cells at 1h after treatment (PAK2, GRIPAP1, LOC100008589, and TNPO1), one that 
was increased at 24h (LOC100008589) and one that was decreased at 24h 
(CSNK1G2). 
 
3.2.3 Comparison of gene expression between untreated HEK293 
and SCL60 cells 
To identify whether any genes are differentially expressed as a result of GnRHR 
expression, the gene expression profile of (untreated) HEK293 cells was compared to 
that of (untreated) SCL60 cells. Four samples of each cell line were analysed by 
Illumina Beadarrays. Almost 20% (4745) of the probes that were detectably 
expressed were differentially expressed (using a 5% false positive threshold) 
between the untreated HEK293 and untreated SCL60 cells (Table 25, Appendix A 
Figure 1).  
 






Higher expression in SCL60 cells 
compared to HEK293 cells 
2583 +1.2 +19 
Lower expression in SCL60 cells 
compared to HEK293 cells 
2162 -1.2 -210 
Table 25: Differentially expressed genes between (untreated) HEK293 and (untreated) SCL60 
cells using a 5% false positive threshold.  
 
Fold changes of genes increased in SCL60 cells ranged from +1.2 (BARX2) to +19 
(SOX11), whereas genes decreased in expression with a much larger range of fold 
changes, from -1.2 (HS.574667) to -210 (HSPA1A) (Table 25).  
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The 25 probes most significantly increased and decreased in SCL60 cells compared 
to HEK293 cells are shown in Table 26 and Table 27 respectively. More details of 
these differentially expressed genes are shown Appendix A Table 2 and Appendix A 
Table 3. 
 
Probes     
SOX11 KRT19 RYR3 MAL2 FLJ12684 
BEX1 VANGL2 UCHL1 PRSS3 RAB17 
TCEAL3 
(ILMN_1734190) HLA-DRB5 HLA-B SFRP1 EEF1A2 
TCEAL3 
(ILMN_1749478) HOPX CYP4X1 LOC389641 CD44 
TACSTD1 RUNX3 MT1F TNFRSF10A PTGER4 
Table 26: The 25 probes most significantly increased in SCL60 cells compared to HEK293 cells. 
The 2583 significantly increased probes in SCL60 cells compared to HEK293 cells were ranked 
in order of significance (P-value). The 25 probes most significantly increased are shown above. 
 
Probes     





TMEM47 ZSCAN18 NEFM PCDH17 NEFL 
ZNF83 ZNF816A ZNF135 ZNF702 FABP5 
IFITM3 ZNF160 HS.572538 ZNF649 HOXB5 
LOC400713 PCDH10 SH3PXD2A ZNF682 HS.200774 
Table 27: The 25 probes most significantly decreased in SCL60 cells compared to HEK293 cells 
The 2162 significantly decreased probes in SCL60 cells compared to HEK293 cells were ranked 
in order of significance (P-value). The 25 probes most significantly decreased are shown above. 
 
Genes that had higher expression in SCL60 cells than in HEK293 cells included 
genes involved in adhesion (CD44, TACSTD1), immune response processes (HLA-
B, HLA-DRB5), and transcriptional regulation (SOX11, TCEAL3, RUNX3); whilst 
genes that had significantly lower expression in SCL60 cells compared to HEK293 
cells encode many transcription regulators (including seven zinc finger proteins) and 
several proteins involved in adhesion (PCDH17, PCDH10, SH3PXD2A). 
 
3.2.3.1 Pathways represented by genes differentially expressed 
between HEK293 and SCL60 cells 
The online pathway annotation tool, DAVID [137], was used to determine whether 
there was enrichment for any pathways among the genes differentially expressed 
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between HEK293 and SCL60 cells. This analysis used all of the 2583 significantly 
increased and 2162 significantly decreased genes. Enrichment with an unadjusted P-
value of less than 0.10 from a one-tailed Fisher exact test was deemed of interest (see 
section 2.2.5.5 on page 75). 
 
This analysis identified 30 pathways in which genes were more highly expressed in 
SCL60 cells compared to HEK293 cells, and 26 pathways in which genes were more 
lowly expressed in SCL60 cells. Most of these pathways are rather broad terms that 
relate to disease-specific mechanisms (for example, “Cancer-related signalling”), 
many of which have overlapping signalling pathways. More specific signalling 
pathways that were identified and the pathway members that were differentially 
expressed are shown in Table 28. These include Cell adhesion molecules, Cell cycle, 
Wnt signalling, ErbB signalling, RNA degradation, Regulation of actin cytoskeleton, 
and MAPK pathway signalling.  
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(A) Increased Pathways Genes P-Value FDR 
hsa04514:Cell adhesion 
molecules 
CLDN7, HLA-DRB1, HLA-DRB3, CDH1, NEO1, HLA-DMB, CDH3, SDC4, HLA-DMA, 
HLA-DRB4, HLA-DRB5, CNTNAP2, HLA-DPB1, HLA-DOA, HLA-DOB, ICAM3, HLA-A, 
HLA-C, HLA-B, HLA-F, NCAM1, SDC1, CLDN1, CNTN1, VCAN, HLA-DPA1, JAM2 
0.024 26 
hsa04110:Cell cycle CDC14B, ANAPC13, CREBBP, ANAPC4, YWHAB, SKP2, RB1, CDK7, MCM2, ORC1L, 
SMC3, CDC25B, CDKN1A, CDKN2A, CDKN2B, CCND2, CDKN2C, GSK3B, ABL1, 




WNT5A, PPP2R5C, DAAM1, DAAM2, CSNK2A2, CHD8, CSNK2A1, RAC3, NFAT5, 
FRAT1, PPP3CB, FRAT2, CAMK2B, PLCB1, VANGL2, CREBBP, FZD2, CSNK2A1P, 




MAP2K2, ERBB3, PRKCB, AKT1, LOC407835, PAK7, CBLB, CDKN1A, PLCG1, PAK2, 
GSK3B, NCK1, PLCG2, CAMK2B, MTOR, ABL1, PIK3R2 
0.095 71 
(B) Decreased Pathways Genes P-Value FDR 





PIK3CB, LOC100271831, MAP2K4, RAF1, RPS6KB1, BAD, MAPK1, EIF4EBP1, CRKL, 
PAK2, PAK4, MAPK3, ARAF, MYC 
0.075 61 
hsa04810:Regulation of actin 
cytoskeleton 
FGFR3, LOC100271831, ITGAE, LOC729841, GNA12, IQGAP2, LOC653888, CDC42, 
PFN2, PAK2, TIAM2, ARPC3, PAK4, CDC42P2, LOC729494, PDGFC, PDGFD, ACTN4, 
LIMK2, PIK3CB, RAF1, MYH9, MAPK1, ARPC1B, CRKL, CHRM3, ITGA8, ARAF, 




MEF2C, FGFR3, LOC100271831, MAPKAPK5, GNA12, HSPA1A, HSPA1B, HSPA1L, 
CDC42, TNFRSF1A, FOS, MAP3K6, PAK2, CDC42P2, HSPA6, HSPA7, PPP3CC, MYC, 
TAOK2, TAOK1, MAP2K4, TGFBR2, ATF4C, RAF1, MECOM, FLNC, STK3, MAPK1, 
DUSP4, ATF4, CRKL, RPS6KA4, MAPK3, CACNA1H, RAP1B, IKBKB 
0.089 68 
Table 28: Genes (A) increased or (B) decreased in expression in SCLl60 cells compared to HEK293 cells are enriched for various signalling pathways.  
P-value is calculated within the DAVID system using a one-tail Fisher Exact test. 
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3.2.4 Comparison of gene expression between vehicle control- 
and Triptorelin-treated SCL60 cells 
To identify which genes were differentially expressed in SCL60 cells as a result of 
Triptorelin treatment, Triptorelin-treated SCL60 cells were compared to vehicle 
control-treated or untreated SCL60 cells. Four replicates were generated at each of 
the time points (0, 0.5, 1, 2, 8 and 24h). All vehicle control and untreated (0h) 
samples were pooled and compared to all Triptorelin-treated samples.  
 
An overall comparison of all the Triptorelin-treated samples with all the untreated 
SCL60 samples revealed that 2088 probes were significantly differentially expressed 








Increased in expression with 
Triptorelin treatment 
1140 +0.92 +16 
Decreased in expression with 
Triptorelin treatment 
948 -0.80 -2.1 
Table 29: Genes that were significantly increased or decreased with Triptorelin treatment in 
SCL60 cells using a 5% false positive threshold.  
Fold change is shown to 2 significant figures. 
 
The range of expression (according to the signal intensity values from probe-target 
hybridisation) of the differentially expressed probes in untreated SCL60 cells was 37 
to 22190 fluorescence units and the range in Triptorelin-treated SCL60 cells was 41 
to 23402 fluorescence units. The minimum fold change of significantly differentially 
expressed genes was similar for increased (+0.92, CSNK1G2) and decreased (-0.80, 
EIF5A) genes. However, the maximum fold change of genes increased with 
Triptorelin treatment was much greater (+16, FOSB) than that of genes decreased (-
2.1, IGFBP5) (Table 29). 
 
An overview of the gene expression changes is shown in Figure 25. This heatmap 
shows the expression of the 2088 significantly differentially expressed in SCL60 
cells treated with Triptorelin relative to untreated (0h) SCL60 controls. There are 
four replicate samples for each time point (0, 0.5, 1, 2, 8, 24h), shown from left to 
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right. This figure shows that most of the gene changes occur between 2 and 8h after 
Triptorelin treatment. Some of these gene expression changes are prolonged up to 
24h, whereas others are shorter-lived. Further analysis of the time-dependent changes 
will be detailed later. 
 
Figure 25: Heatmap showing differentially expressed probes between control and Triptorelin-
treated SCL60 cells.  
Samples are ordered from left to right with increasing treatment time from 0 to 24h. Four 
independent experiments (columns from left to right) are shown for each treatment group. Red 
= increased expression, green = decreased, black = unchanged expression relative to the mean of 
untreated (0h) controls. The range of relative expression is approximately -5 to +5, where +5 is 
strongly increased compared to controls and -5 is strongly decreased compared to controls. The 
heatmap represents the similarity between genes’ temporal profiles. It is clustered to show genes 
that have similar temporal profiles together. 
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3.2.4.1 The most significantly differentially expressed genes in 
response to Triptorelin treatment in SCL60 cells 
To explore these differentially expressed genes in more detail, the 25 probes most 
significantly and consistently increased and decreased in expression with Triptorelin 
treatment in SCL60 cells are shown in Table 30 and Table 31 respectively. The 
expression changes are ordered in ascending probability of each being a false 
positive, which for all probes in the table is less than 0.05.  
 
The 25 most significantly increased probes (Table 30) comprise many transcription 
factors (FOS, FOSB, EGR1, ATF3, AXUD1, JUNB, LBH, ZFP36), as well as genes 
encoding IGF binding proteins (CYR61, CTGF), nuclear receptors (NR4A1, 
NR4A2) and ERK1/2 phosphatases (DUSP1, DUSP5). The genes represented by the 
25 most significantly decreased probes (Table 31) following Triptorelin treatment are 
more diverse in their functions than those that are increased. They comprise a few 
transcription factors (HOXA13, FOXD2, ZNF503), several genes whose products 
may be involved in cell adhesion (AMOT, which promotes adhesion and migration 
[150, 151]; FLRT3, which has been shown to inhibit cadherin-mediated adhesion and 
increase motility [152, 153]; and LAMA5, which has been shown to promote 
adhesion in hepatocellular carcinoma [154]), and various other genes including 
IGFBP5 (IGF binding protein), MUM1 (DNA repair), FZD4 (Wnt protein receptor) 
and SRGAP3 (Rho GTPase activating protein). 
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FOS ILMN_1669523 +12 Signal transduction, Cell 
proliferation and 
differentiation 
PTGS2 ILMN_2054297 +7.7 Prostanoid signalling 
NR4A2 ILMN_1782305 +7.3 Nuclear receptor 
CYR61 ILMN_2188264 +8.2 Secreted apoptosis/adhesion 
modulator 
FOSB ILMN_1751607 +16 Signal transduction, Cell 
proliferation and 
differentiation 
EGR1 ILMN_1762899 +7.5 Transcription factor 
CGA ILMN_1734176 +8.2 Follicle Stimulating Hormone 
subunit alpha 
ATF3 ILMN_2374865 +4.2 Transcription factor 
CTGF ILMN_1699829 +5.2 IGF binding protein. Cell 
proliferation and adhesion 
DUSP1 ILMN_1781285 +4.4 ERK2 inhibitor 
CCL2 ILMN_1720048 +3.9 Cytokine 
NR4A2 ILMN_2339955 +4.2 Nuclear receptor 
LOC387763 ILMN_1677402 +4.2 Unknown 
DUSP5 ILMN_1656501 +3.9 ERK1 inhibitor 
CTGF ILMN_2115125 +4.7 IGF binding protein. Cell 
proliferation and adhesion 
AXUD1 ILMN_1703123 +3.2 Transcription, apoptosis 
TAC1 ILMN_2384409 +5.1 Neurotransmitter 
JUNB ILMN_2086077 +3.0 Transcription factor 
LBH ILMN_2315979 +4.6 Trascription factor 
IL8 ILMN_2184373 +3.6 Chemokine 
NR4A1 ILMN_2408566 +3.4 Nuclear receptor 
ARC ILMN_1711120 +3.0 Cytoskeleton-associated 
protein 
PTGS2 ILMN_1677511 +3.0 Prostanoid signalling 
ZFP36 ILMN_1720829 +2.4 Transcripton factor 
RGS2 ILMN_2197365 +2.5 Regulator of G-protein 
signalling 
Table 30: The 25 probes with the most significant increases in expression in SCL60 Triptorelin-
treated cells compared to SCL60 control cells.  
The gene changes are ordered in ascending probability of each being a false positive, which for 
all genes in the table is less than 0.05 (not shown). Gene descriptions were taken from the 









DDIT4 ILMN_1661599 -1.7 Inhibits cell growth (downstream 
of AKT) 
IGFBP5 ILMN_1750324 -2.1 IGF binding protein. May inhibit 
or promote cell growth 
IGFBP5 ILMN_2132982 -1.9 IGF binding protein. May inhibit 
or promote cell growth 
HOXA13 ILMN_1731349 -1.6 Transcription factor. Anterior-
posterior development 
LRRC20 ILMN_1690523 -1.7 Unknown 
CBX2 ILMN_1770678 -1.6 Transcriptional repressor 
PUNC ILMN_1744635 -1.6 Immunoglobulin 
AMOT ILMN_1792409 -1.6 Tight junction maintenance 
MUM1 ILMN_1764764 -1.5 DNA repair 
C5ORF13 ILMN_1680738 -1.5 Unknown 
FOXD2 ILMN_1789400 -1.5 Transcription factor 
SESN1 ILMN_1800626 -1.5 P53-mediated inhibition of cell 
growth via AMPK and MTOR. 
FLRT3 ILMN_1805665 -1.5 Transmembrane protein. Possibly 
cell adhesion or receptor signalling 
DHRS3 ILMN_1752478 -1.5 Short-chain 
dehydrogenase/reductase 
IFIT1 ILMN_1707695 -1.5 IFN-induced protein 
FZD4 ILMN_1743367 -1.5 Receptor for Wnt proteins 
HS.208066 ILMN_1877593 -1.5 Unknown 
SRGAP3 ILMN_2400644 -1.5 Rho GTPase activating protein 
ZNF503 ILMN_1787265 -1.4 Transcription factor 
SMAD6 ILMN_1767068 -1.4 Negatively regulates BMP and 
TGF-beta signalling 
GUCY1A3 ILMN_1808590 -1.5 Catalyses GTP to cGMP 
RGMA ILMN_1717636 -1.5 Axon guidance. Possible tumour 
suppressor 
NME3 ILMN_1669456 -1.5 Synthesis of nucleotide 
triphosphates. Possibly induction 
of apoptosis 
SAMD11 ILMN_1709067 -1.4 Unknown 
LAMA5 ILMN_1773567 -1.4 Laminin subunit α5. ECM 
component, binds collagen and 
integrin α2β1. Cell adhesion and 
migration. 
Table 31: The 25 probes with the most significant decreases in expression in SCL60 Triptorelin-
treated cells compared to SCL60 control cells.  
The gene changes are ordered in ascending probability of each being a false positive, which for 
all genes in the table is less than 0.05 (not shown). Gene descriptions were taken from the 
GeneCards online database [151]. 
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3.2.4.2 Temporal profiles of genes differentially expressed with 
Triptorelin treatment in SCL60 cells 
The gene lists in Table 30 and Table 31 were produced using data from all the 
Triptorelin-treated cells (all the time-points together). However, by pooling these 
samples some information is lost because the gene expression changes do not occur 
uniformly across the 24h treatment period (Figure 25).  
 
Figure 26 shows the numbers of probes that were differentially expressed at each 
time point and it is clear from this that most of the expression changes occur around 
the 8h time-point. The number of differentially expressed probes between SCL60 
control and treated cells increases up to 8h post-treatment then begins to fall (Figure 
26). The proportion of these that are decreased is initially very low, increasing to 



































Figure 26:  The number of differentially expressed probes changed between untreated (0h) 
SCL60 cells and Triptorelin-treated SCL60 cells at five time points using a 5% false positive 
threshold. 
SC0 = SCL60 untreated (0h) control, STx = SCL60 treated with Triptorelin for x hours.  
 
The temporal profiles of the top 25 increased and decreased probes are shown in 
Figure 27 and Figure 28. The 25 probes that were increased in expression with 
Triptorelin treatment clustered into three distinct groups by their temporal profile: 
early, mid and late changes (Figure 27). Figure 28 shows that the 25 most 



















IGF binding protein. Proliferation/adhesion




Follicle Stimulating Hormone subunit alpha
Transcription factor




Time after Triptorelin treatment (h)
0.5         1           2          8          24 0 5+
Expression relative to mean of 
untreated (0h) SCL60 cells
Scale:
 
Figure 27: Heatmap to show the 25 probes most significantly increased in Triptorelin-treated SCL60 cells compared to control SCL60 cells.   
Samples are ordered from left to right with increasing treatment time from 0 to 24h. Four independent experiments (columns from left to right) are shown 
for each treatment group. Red = increased expression, black = unchanged expression relative to the mean of untreated (0h) controls. The range of relative 
expression is approximately 0 to 5+. The heatmap represents the similarity between genes’ temporal profiles. It is clustered to show genes that have similar 
temporal profiles together. These probes clustered into three distinct groups by their temporal profile: early, mid and late changes. 
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Time after Triptorelin treatment (h)
0.5         1           2          8          24
Inhibits cell growth (downstream of Akt)
Transcription factor
Negatively regulates BMP and TGF-beta signalling
Catalyses GTP to cGMP
Short-chain dehydrogenase/reductase
IFN-induced protein
IGF binding protein. May inhibit or promote cell growth
Immunoglobulin
Unknown
Nucleoside diphosphate kinase 3
IGF binding protein. May inhibit or promote cell growth
Unknown
Receptor for Wnt proteins
Tight junction maintenance
Transcriptional repressor
Transmembrane protein. Cell adhesion or receptor signalling
Rho GTPase activating protein
Unknown
Laminin subunit α5, ECM component. Cell adhesion
DNA repair
Axon guidance. Possible tumour suppressor
Transcription factor
Transcription factor
Promotes P53-mediated inhibition of cell growth via AMPK and MTOR.
Unknown
0 2+
Expression relative to mean of 
untreated (0h) SCL60 cells
Scale:
 
Figure 28: Heatmap to show the 25 probes most significantly decreased in Triptorelin-treated SCL60 cells compared to control SCL60 cells.  
Samples are ordered from left to right with increasing treatment time from 0 to 24h. Four independent experiments (columns from left to right) are shown 
for each treatment group. Red = increased expression, black = unchanged expression relative to the mean of untreated (0h) controls. The range of relative 
expression is approximately 0 to 5+. The heatmap represents the similarity between genes’ temporal profiles. It is clustered to show genes that have similar 
temporal profiles together. These probes decreased most strongly at 8 and 24h.  
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3.2.4.3 Functional annotation of genes differentially expressed with 
Triptorelin treatment in SCL60 cells 
The 25 most significantly increased and decreased probes might feasibly contain 
some of the most important genes in the transcriptional response to GnRHR 
signalling, therefore warranting the detailed annotation given above (Table 30, Table 
31, Figure 27 and Figure 28). However, 2088 probes (representing 1048 genes) were 
significantly differentially expressed between Triptorelin-treated and control SCL60 
cells and it is important to explore common functions among these genes as many of 
these are also likely to be important in helping to understand GnRHR signalling. 
 
The online pathway annotation tool, DAVID [137], was used to determine whether 
there was significant enrichment for any pathways among the genes differentially 
expressed between SCL60 control and treated cells. Using an unadjusted P-value of 
less than 0.05 from a one-tailed Fisher exact test as significant, 5 increased pathways 
(Table 32A) and 5 decreased pathways (Table 32B) were identified.  
 
Genes significantly increased with Triptorelin treatment in SCL60 cells were 
enriched for Cell cycle, p53 signalling, Nucleotide Oligomerisation Domain (NOD)-
like receptor signalling, MAPK signalling, and Retinoic acid-Inducible Gene-I (RIG-
I)-like receptor signalling pathways (Table 32A). Genes significantly decreased with 
Triptorelin treatment in SCL60 cells were enriched for Cell cycle, Notch signalling, 
ErbB signalling, Wnt signalling and Extracellular Matrix (ECM)-interaction 





 Genes P-Value FDR 
(A) Increased Pathways    
hsa04110:Cell cycle CDK1, ANAPC10P1, CDC14A, CDC14B, CCNH, ANAPC10, YWHAE, CCNE2, LOC440917, 










MAP3K7, HSP90B1, CCL2, IL8, CXCL2, CCL8, NFKBIA, TRAF6, BIRC2, CHUK, CCL7 0.002 2.8 
hsa04010:MAPK signaling 
pathway 
MAPKAPK5, NFKB2, SRF, MAP3K7, FOS, DUSP14, JUND, MAP3K8, TRAF6, MYC, 
CHUK, RELB, ATF4C, NR4A1, FLNC, DDIT3, DUSP5, ATF4, DUSP3, DUSP1, RRAS2, 




MAP3K7, DDX3X, ISG15, IL8, IL12A, NFKBIA, TRAF6, CHUK, AZI2, TANK 0.02 20 
(B) Decreased Pathways    
hsa04110:Cell cycle E2F2, LOC100133012, CDC14B, CREBBP, PRKDC, MCM2, CHEK2, YWHAE, MCM4, 





NOTCH3, CTBP1, NOTCH1, EP300, APH1A, CREBBP, JAG2, NCOR2 0.005 6.1 
hsa04012:ErbB signaling 
pathway 





WNT5A, FZD8, CTBP1, PPP2R5D, CAMK2G, CREBBP, VANGL2, FZD2, FZD4, 




SDC1, COL4A1, LAMA5, COL6A1, ITGB5, COL2A1, AGRN, COL4A6, HMMR 0.04 38 
Table 32: Genes significantly (A) increased and (B) decreased with Triptorelin treatment in SCL60 cells were enriched for various signalling pathways. 
P-value was calculated within the DAVID system using a one-tail Fisher Exact test and is shown to 1 significant figure. False Discovery Rate (FDR) was also 
calculated within the DAVID system and is shown to 2 significant figures. Genes in bold type occur in the 25 most increased or decreased probes (Figure 27, 
Figure 28, Table 26, and Table 27).
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To further explore the dynamic nature of the GnRHR-mediated signalling response, 
the most significantly differentially expressed genes were identified at each time 
point (0.5, 1, 2, 8 and 24h) compared to the previous time point following Triptorelin 
treatment in SCL60 cells (Table 33). Initial gene expression increases include 
transcription factors such as EGR1 and FOS, as well as the ERK1/2 inhibitors 
DUSP1 and DUSP5, and the IGF binding protein CYR61. Between 1 and 2h after 
treatment, expression of transcription factors EGR2, FOS and JUN, as well as 
DUSP1 is decreased. Between 2 and 8h there is a significant increase in expression 
of MMP10, which encodes a matrix metalloproteinase. The transcription factor 
DDIT3 is decreased at 8h but increased by 24h. At 24h the cytoskeletal protein 
encoding gene, ENAH, is increased whereas another cytoskeletal-associated protein 
encoding gene, ARC, is decreased (Table 33). 
 
The gene lists of differential gene expression for each time point are much more 
limited than the lists for pooled data. They are less likely, therefore, to contain 
sufficient members of a particular pathway for the gene list to be considered enriched 
for that pathway. Nevertheless, several pathways were identified in these genes lists 
including the MAPK signalling pathway and cell cycle signalling. A full list of these 









    
Increased FOS ILMN_1669523 +55 Signal transduction, Cell 
proliferation and 
differentiation 
 FOSB ILMN_1751607 +46 Signal transduction, Cell 
proliferation and 
differentiation 
 EGR1 ILMN_1762899 +14 Transcription factor 
 CYR61 ILMN_2188264 +11 IGF binding protein. Cell 
proliferation and adhesion 
 DUSP1 ILMN_1781285 +8.3 ERK2 inhibitor 
ST0.5 to 
ST1 
    
Increased NR4A1 ILMN_2408566 +4.8 Nuclear receptor 
 PTGS2 ILMN_2054297 +4.3 Prostanoid signalling 
 DUSP5 ILMN_1656501 +3.9 ERK1 inhibitor 
 EGR3 ILMN_1722781 +4.0 Transcription factor 
 NR4A2 ILMN_2339955 +3.8 Nuclear receptor 
Decreased FAM115A ILMN_2297069 -1.9 Unknown 
 LOC642333 ILMN_1696027 -1.7 Unknown 
ST1 to 
ST2 
    
Increased TAC1 ILMN_2384409 +3.5 Neurotransmitter 
 IL8 ILMN_2184373 +3.2 Chemokine 
 TAC1 ILMN_2342541 +3.0 Neurotransmitter 
 TNFRSF12A ILMN_1689004 +2.7 Tweak receptor. FGF 
inducible 
 IL8 ILMN_1666733 +2.8 Chemokine 
Decreased EGR2 ILMN_1743199 -5.5 Transcription factor 
 FOS ILMN_1669523 -5.3 Signal transduction, Cell 
proliferation and 
differentiation 
 DUSP1 ILMN_1781285 -4.6 ERK2 inhibitor 
 C10ORF10 ILMN_1767556 -3.4 Activates transcription 
factor Elk1 
 JUN ILMN_1806023 -3.3 Transcription factor 
Table 33: The top five increased and decreased Illumina probes between each time point using a 
5% false positive threshold.   
SC0 = SCL60 untreated (0h) control, STx = SCL60 treated with Triptorelin for x hours. The 
gene changes are ordered in ascending probability of each being a false positive, which for all 
genes in the table is less than 0.05 (not shown). Gene descriptions were taken from the 





Gene Illumina ID Fold 
change 
Description 
Increased MMP10 ILMN_1741847 +14 Extracellular matrix 
degradation 
 TAC1 ILMN_2384409 +11 Neurotransmitter 
 TAC1 ILMN_2342541 +9.8 Neurotransmitter 
 LOC387763 ILMN_1677402 +8.7 Unknown 
 TAC1 ILMN_1790270 +8.6 Neurotransmitter 
Decreased FOSB ILMN_1751607 -12 Signal transduction, Cell 
proliferation and 
differentiation 
 DDIT3 ILMN_1676984 -5.6 Transcription factor. Stress-
induced apoptosis 
 HERPUD1 ILMN_2374159 -4.1 Endoplasmic reticulum. 
Ubiquitin-like 
 HERPUD1 ILMN_2374164 -4.0 Endoplasmic reticulum. 
Ubiquitin-like 
 IGFBP5 ILMN_2132982 -3.2 IGF binding protein. May 




    
Increased DDIT4 ILMN_1661599 +4.6 Inhibits cell growth 
(downstream of AKT) 
 H1F0 ILMN_1757467 +3.5 Histone 
 STC2 ILMN_1691884 +3.1 Calcium and phosphate 
transport/homeostasis 
 DDIT3 ILMN_1676984 +3.4 Transcription factor. Stress-
induced apoptosis 
 ENAH ILMN_1716552 +2.7 Actin-associated. 
Cytoskeletal remodelling, 
migration 
Decreased TAC1 ILMN_2342541 -5.2 Neurotransmitter 
 ARC ILMN_1711120 -4.6 Cytoskeleton-associated 
protein 
 NR4A2 ILMN_1782305 -4.4 Nuclear receptor 
 TAC1 ILMN_2384409 -4.9 Neurotransmitter 
 LOC387763 ILMN_1677402 -4.5 Unknown 
Table 33 (continued): The top five increased and decreased Illumina probes between each time 
point using a 5% false positive threshold.  
SC0 = SCL60 untreated (0h) control, STx = SCL60 treated with Triptorelin for x hours. The 
gene changes are ordered in ascending probability of each being a false positive, which for all 
genes in the table is less than 0.05 (not shown). Gene descriptions were taken from the 




3.2.5 Comparison of genes differentially expressed as a result of 
Triptorelin treatment with genes differentially expressed in a 
similar study 
To establish whether Triptorelin-mediated gene expression changes seen in HEK293 
and SCL60 cells were more widely applicable, they were compared to a previous 
study by Kakar et al [108] that looked at gene expression in mouse pituitary 





]GnRH. Although that study only considered two time-points, it 
showed marked differences of GnRH agonist-regulated gene profiles at 1h and 24h 




]GnRH [108]. Genes that 
were changed in expression encoded proteins including transcription factors, ion 
channel proteins, cytoskeletal proteins, and other signalling proteins such as those 
involved in proliferation and apoptosis [108]. Using the online gene ID conversion 
tool, DAVID [137], human homologues could be identified for 59 of the 67 mouse 
genes reported as differentially expressed (with a fold change of 4 or greater). The 8 
mouse genes that could not be mapped were U85993, AI835098, AA682038, 
AI846236, AI428936, AW122517, 5031401C21Rik and Skir. The 59 official human 
gene symbols were converted to Illumina IDs to produce a list of 222 Illumina IDs 
(the number of Illumina IDs was greater than the number of official gene symbols 
because multiple probes exist for each gene). 
 
A subset of the GnRH-regulated genes defined by Kakar et al in LβT2 cells were 
also significantly differentially expressed between control and Triptorelin-treated 
SCL60 cells (21 out of 59) and between HEK293 and SCL60 cells (17 out of 59), 
including the early response genes EGR1, FOSB, JUNB and IER2 (Table 34). The 
remainder of the Kakar et al genes (including for example cAMP-responsive element 
modulator, CREM, and Period circadian protein homolog 1, PER1) did not appear to 
change either between HEK293 and SCL60 cells, or between control and Triptorelin-
treated SCL60 cells. However, the extent of differential gene expression in the subset 
of commonly changed genes was enough to cluster the SCL60 control and 
Triptorelin-treated sample groups apart (Appendix A Figure 2). 
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ATF3(ILMN_1791346) +1.4 +40 +2.5 ATF3(ILMN_2374865) +1.3 +40 +2.5 
ATF3(ILMN_2374865) +4.2 +40 +2.5 BTG2(ILMN_1770085) +1.4 +6.2 +2.5 
BTG2(ILMN_1770085) +2.4 +6.2 +2.5 CD68(ILMN_1714861) -1.3  +4.5 
CD68(ILMN_1714861) +1.2  +4.5 CDKN1A(ILMN_1784602) +1.6  +6.6 
CDKN1A(ILMN_1784602) +1.5  +6.6 CHERP(ILMN_1798083) -1.3 -15  
EGR1(ILMN_1762899) +7.5 +160  EGR1(ILMN_1762899) +0.7 +160  
EGR2(ILMN_1743199) +3.1 +4.9  FER(ILMN_1789618) -1.4 -6.0  
FOSB(ILMN_1751607) +16.0 +25 +2.6 FOSB(ILMN_1751607) +1.2 +25 +2.6 
FOSL1(ILMN_1771841) +1.4 +8.6 +2.5 FXYD5(ILMN_1704286) +1.8  +6.0 
GADD45B(ILMN_1718977) +2.1 +6.1  FXYD5(ILMN_2309848) +1.8  +6.0 
GLA(ILMN_1766637) +1.5  -4.8 GCNT2(ILMN_1680390) -1.3 -4.0  
IER2(ILMN_1700584) +2.0 +12  GLA(ILMN_1766637) +1.5  -4.8 
JUN(ILMN_1806023) +1.9 +9.7  HADH(ILMN_1719906) +1.3 -4.1  
JUNB(ILMN_2086077) +3.0 +28  KIFC1(ILMN_2222008) +1.3 -4.2  
KLF4(ILMN_2137789) +1.8 +6.0  MAZ(ILMN_2409793) -1.4  -4.5 
KLF6(ILMN_1735014) +1.4 +7.9 +2.2 PRSS23(ILMN_1797776) +1.5  +4.7 
KLF6(ILMN_1737406) +1.4 +7.9 +2.2 TARBP2(ILMN_1729767) -1.4 -4.6  
MNAT1(ILMN_2083243) +1.1 +4.2  TARBP2(ILMN_2310253) -1.4 -4.6  
NFKBIZ(ILMN_1719695) +1.8 +7.9 +1.7 ZFP36(ILMN_1720829) +1.3 +8.9  
NR4A1(ILMN_1661178) +1.2 +100 +12.6     
NR4A1(ILMN_2408566) +3.4 +100 +12.6     
NR4A1(ILMN_2410145) +2.9 +100 +12.6     
PPP1R15A(ILMN_1659936) +2.4 +17      
RGS2(ILMN_2197365) +2.5 +6.0 +2.9     
ZFP36(ILMN_1720829) +2.4 +8.9      
Table 34: Genes commonly significantly differentially expressed in both the SCL60 dataset and 
the Kakar et al dataset.  
(A) Kakar et al dataset and between SCL60 all control and Triptorelin-treated (0.5-24h) groups 
(B) Kakar et al dataset and between HEK293 and SCL60 cells 
Fold change is shown to 2 significant figures. Genes in bold type were differentially expressed in 




Triptorelin treatment had a minimal effect on gene expression in HEK293 cells (only 
four probes differentially expressed). This supports the hypothesis that HEK293 cells 
do not respond to Triptorelin, due to their lack of GnRHR expression. It provides 
reassurance for the model in that observed differential gene expression in other 
comparisons is likely to reflect a true biological response. Given the scale of 
differential gene expression in other comparisons such as between HEK293 and 
SCL60 cells, it is likely that the gene expression changes seen in HEK293 cells with 
Triptorelin treatment are false positives. This indicated that the parameters chosen 
for identifying differential gene expression are appropriate, since they maintain a 
minimal level of false positive detection, whilst being broad enough to minimise the 
chance of falsely excluding positive gene changes.  
 
There were 4745 probes differentially expressed (using a 5% false positive threshold) 
between the untreated HEK293 and untreated SCL60 cells (Table 25, Appendix A 
Figure 1). This large number of differentially expressed genes indicates that there are 
substantial differences at the transcriptomic level between the two cell lines. There is 
a relatively small difference between SCL60 control cells and those treated with 
Triptorelin, but there is a very substantial difference between the gene expression 
profiles of HEK293 cells and SCL60 cells. These changes in SCL60 cells compared 
to HEK293 cells may have occurred due to the presence of GnRHR (and/or the G418 
resistance gene used in the transfection), due to damage caused by its incorporation 
into the DNA or due to genetic drift as a result of random events in culture, or as a 
result of selection pressure in culture and repeated passage. Although these 
alternative explanations for the differences between the two cell lines are important 
to consider, these gene expression differences may have been caused by the addition 
of a functional GnRHR. These differentially expressed genes may therefore represent 






The presence of adhesion-related genes in both the genes increased and decreased in 
SCL60 cells compared to HEK293 cells indicates that adhesion-related signalling 
may be relevant to the antiproliferative effect of Triptorelin in SCL60 cells. A role 
for cell adhesion signalling has been previously suggested by Davidson et al [117]. 
In SCL60 cells, GnRHR stimulation by GnRH-I, GnRH-II, and other GnRH agonists 
(but not antagonists) caused an increase in cell adherence and a change in 
morphology [117]. This was dependent on Tyrosine kinases and Src but not EGFR or 
JNK [117]. This shows that GnRH can cause cytoskeletal reorganisation and affect 
cell adherence. Inappropriate cytoskeletal changes, for example during mitosis, could 
play a role in GnRHR-mediated cell death or reduced proliferation.  
 
The large number of transcriptional regulators that were differentially expressed 
indicates that GnRHR has a large influence on transcription, and that transcription 
may be relevant in the GnRHR-mediated antiproliferative effect in SCL60 cells. In 
similar gene expression studies in LβT2 cells, Kakar et al [108] and Wurmbach et al 
[109] found that a large proportion of the genes differentially expressed following 
GnRHR stimulation were transcription factors. 
 
Also significantly increased in expression in SCL60 cells compared to HEK293 cells 
was the RYR3 gene, whose product forms a calcium release channel [155]. The 
increased expression of this gene may be particularly relevant to the GnRHR-
mediated antiproliferative effect in SCL60 cells, since calcium ion release may be 
important in activating PKC, upon which the GnRHR-mediated antiproliferative 
effect is dependent [79]. However, Morgan et al could not demonstrate a dependence 
on calcium ions of the antiproliferative effect of the GnRH agonist Triptorelin with 
the use of a Ca
2+
 channel blocker or a Ca
2+
 chelator [79].  
 
Approximately 8% of detected genes (represented by 2088 probes) were 
differentially expressed between control and Triptorelin-treated SCL60 cells. This 
indicates that Triptorelin has a large impact on gene transcription in SCL60 cells.  
However, changes in expression were not uniform and most changes occurred 
between 2 and 8h after treatment (Figure 25, Figure 26). Genes with the most 
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increased expression after Triptorelin treatment clustered into three groups: early, 
mid and late changes (Figure 27), whilst repressed genes tended to decrease later in 
the 24h treatment period (Figure 28). It is possible that these genes may be decreased 
in a secondary response to some of the gene activations seen as an immediate 
response to GnRHR stimulation.  
 
The altered expression of IGF binding proteins (Table 30, Table 31) could be an 
indication of the involvement of RTK signalling pathways in the GnRHR-mediated 
response, or it may be involved in mediating changes in cellular adhesion through 
interaction with integrin [156, 157]. Interestingly, GnRHR stimulation caused an 8.2 
fold increase in expression of CGA (Table 30), which encodes the FSHα subunit 
[151]. This may indicate that there is some similarity between GnRHR signalling in 
SCL60 cells and GnRHR signalling in pituitary gonadotropes, which normally 
induces FSH and LH production.  
 
Immediately following GnRHR stimulation in SCL60 cells in vitro, there is an 
intense and rapid increase in ERK1/2 phosphorylation [79]. The increased expression 
of early response genes such as FOS and EGR1 supports this, since it has previously 
been shown that when ERK1/2 is phosphorylated it translocates to the nucleus and 
activates various transcription factors such as these [8, 9]. FOS gene family members 
encode proteins that dimerise with proteins of the JUN family to form the 
transcription factor complex AP-1 [158]. The increased expression of both FOS and 
JUN family members (Table 33) make this a possible mechanism of transcriptional 
activation in SCL60 cells.  
 
Given the intense ERK1/2 response, it was interesting to observe the increase in gene 
expression of dual specificity phosphatases, DUSP1 and DUSP5 (Table 33), whose 
protein products inhibit ERK2 and ERK1 respectively by dephosphorylation [151]. It 
is possible that these may be involved in mediating a negative feedback response to 
the initial MAPK activity. DUSP1 and DUSP5 activation following GnRHR 
stimulation is supported by the findings of Armstrong et al, who observed a marked 
increase in DUSP1, DUSP2 and DUSP5 mRNA expression following GnRH 
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treatment in cervical cancer-derived HeLa cells [159]. The increase in expression 
peaked at 1h after treatment before gradually reducing to basal levels. The authors 
also observed a slower increase in DUSP4, peaking at 4h after treatment.  
 
GnRH has been shown to activate EGR1 via ERK1/2 in HeLa cells [160]. In HeLa 
cells, GnRH causes increased mRNA expression of DUSP1 and DUSP4 [160]. 
Armstrong et al showed that the increase in DUSP1 appeared to be reliant on 
endogenous ERK1/2, whereas that of DUSP4 was not [160]. In that study by 
Armstrong et al, when DUSP1, -2, and -4 were knocked out individually or together 
there was no change in Egr1 luciferase or pERK1/2 activity [160], arguing against a 
role for these DUSPs in mediating the ERK1/2 response to GnRH. However, the 
authors also screened 16 DUSPs for involvement in regulating the ERK1/2 response 
to GnRH and found that five of these influenced the amplitude of pERK1/2 or the 
localisation of ERK2 following GnRHR stimulation [160]. This suggests that there 
may be a role for DUSPs in response to GnRHR stimulation, but it may involve 
multiple DUSPs and it may be complicated by multiple interacting signalling 
pathways.  
 
RGS2 expression was increased in SCL60 cells with Triptorelin treatment. This gene 
product is known to regulate G protein signalling [161, 162]. An increase in RGS2 
expression in response to GnRHR stimulation was also identified by Wurmbach et al 
and Kakar et al in LβT2 cells [108, 109]. Interestingly, PKC is known to 
phosphorylate and inhibit RGS2 [163]. In SCL60 cells, the antiproliferative effect of 
the GnRH agonist Triptorelin is known to be dependent on PKC [79]. RGS2 
transcript levels may increase as a result of protein inhibition by PKC.  
 
The gene SRGAP3 encodes a Rho GTPase activating protein, which may inhibit the 
activity of G-proteins associated with GnRHR. This gene was decreased in 
expression with Triptorelin treatment. If this decrease in gene expression 
corresponded to a decrease in functional protein activity, it would act to prevent the 
inhibition of GnRHR, arguing against a role for this protein product in down-
regulating GnRHR to mediate the antiproliferative effect of a GnRH agonist.  
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Genes significantly increased with Triptorelin treatment in SCL60 cells were 
enriched for Cell cycle, p53 signalling, NOD-like Receptor signalling, MAPK 
signalling and RIG-I-like receptor signalling pathways (Table 32A). Genes 
significantly decreased with Triptorelin treatment in SCL60 cells were enriched for 
Cell cycle, Notch signalling, ErbB signalling, Wnt signalling and ECM-interaction 
pathways (Table 32B).  
 
The identification of the Wnt signalling pathway was interesting, as a recent study 
(of LβT2 cells) showed that GnRH-mediated LHB (Luteinising Hormone β subunit) 
transcription requires the activity of β-Catenin, a key member of the Wnt signalling 
pathway [164]. Nuclear accumulation of β-Catenin and up-regulation of Wnt-target 
genes has been shown to occur in response to GnRH agonist treatment in SCL60 and 
LβT2 cells [165]. 
 
No previous study has implicated RIG-I like receptor signalling, NOD-like receptor 
signalling or Notch signalling in mediating the antiproliferative effects of GnRH 
agonist. RIG-I-like and NOD-like receptors are pattern recognition receptors, usually 
involved in the detection of viral RNA [166, 167], therefore their relevance here is 
uncertain. Notch signalling is usually activated through direct cell-cell contact, and is 
involved in cell fate and developmental processes [168]. Notch signalling is 
dysregulated in several cancers, and may act to inhibit or promote cell proliferation 
(reviewed in [169]).  
 
Involvement of cell cycle genes is supported by the observation of G2/M arrest 
following Triptorelin treatment in SCL60 cells (Figure 16) [50, 79]. Cell cycle 
pathway members that are increased in expression in SCL60 cells following 
treatment with Triptorelin include several that encode proteins required for mitosis 
(CDC14A, CDC14B, ANAPC10, ANAPC10P1, and ORC6L). However, MAD2L1 
is increased, which encodes a protein that forms part of the spindle assembly 
checkpoint and prevents anaphase until chromosomes are properly aligned [151]. 
BUB3 is also increased, whose product also forms part of the mitotic checkpoint to 
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prevent inappropriate transition to anaphase [170], and has a role in the attachment of 
kinetochores to microtubules [170] and dynein [171]. Also of interest is the increased 
expression of GADD45A and GADD45B. These genes have both been shown to 
activate the p38/JNK pathway to cause G2/M arrest [172, 173], and GADD45B has 
been shown to play a role in mediating Fas-induced apoptosis by enhancing the 
interaction between p38 and Rb [173]. The temporal gene expression profiles of 
these selected significantly differentially expressed probes of interest from the cell 
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Figure 29: Time-course gene expression profile of selected cell cycle pathway members. 
The graph shows gene expression relative to the mean expression of each gene in of untreated 
controls along the y axis. Time is shown along the x axis on a log scale. 
 
CCNB1 and CCNE2 are increased, and both are required for cell cycle progression 
for G1 to S and G2 to M transition respectively; also CDK1 is increased, which is 
required for cell cycle progression through G1/S and G2/M [151]. CDKN1A encodes 
an inhibitor of cyclin-CDK2 and CDK4 complexes, therefore inhibiting G1 
progression [151]. Of the cell cycle genes that are decreased, several are inhibitors of 
cell cycle progression such as CHEK2 and CDC14B, which are known to prevent 
entry into mitosis and CDKN1B and CDKN2A, which can cause cell cycle arrest in 
 129 
G1 or S phase [151]. This indicates that Triptorelin caused a decrease in cell cycle-
inhibiting genes and contrasts with the cell cycle arrest observed previously. 
However there is also a decrease in E2F2, which normally drives transcription of 
genes such as cyclin E, and thus progression through G1 to S phase [115, 151]. Some 
of the gene expression changes appear to promote the cell cycle, whilst others inhibit 
it. It is unclear which of these gene changes are the most important in mediating the 
antiproliferative response to Triptorelin, although the differential gene expression 
with Triptorelin treatment indicates that cell cycle signalling may be involved. 
 
In a study to look at the response to UVC radiation-induced DNA damage, human 
skin fibroblast cells underwent cell cycle arrest (low dose) or apoptosis (high dose) 
[174] and transcriptional events were markedly different in the two groups of cells. 
Those cells that received a low dose of radiation and underwent cell cycle arrest 
showed a transient transcriptional response followed by recovery to basal levels by 
24h [174]. Cell cycle-associated genes that exhibited altered (increased) expression 
levels included CCNE1, TOB1, ZNF263, CDKN1A, SNK and BTG2 [174]. 
CDKN1A (+1.5 fold) and BTG2 (+2.4 fold) were also significantly increased in 
SCL60 cells with Triptorelin treatment. The cells that received the high dose of 
radiation and underwent apoptosis exhibited transcriptional changes that persisted at 
24h (the authors did not study transcription after 24h). Gene expression increases in 
these cells included GADD45A (growth arrest and DNA damage inducible α) and 
ATF3 (transcriptional activator), which were also both increased in SCL60 cells 
following Triptorelin treatment.  
 
In SCL60 cells, many of the transcriptional changes induced by Triptorelin are 
transient, and the gene expression returns to basal levels by 24h. However, consistent 
with the fibroblasts described above, there are other genes whose expression is 
altered in a more prolonged manner, whereby the expression levels continue to be 
increased or decreased at 24h.  
 
Interestingly, BTG2, ATF3 and CDKN1A were also increased in expression in the 
Kakar et al dataset in response to GnRHR stimulation [108]. BTG2 negatively 
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controls G1 to S phase transition by inhibiting the Cyclin D1 promoter [175, 176]. 
CDKN1A can cause cell cycle arrest in G1 or S phase; it binds and blocks the activity 
of MDM2, and blocks transcriptional activation by MYC, E2F1. GADD45A 
transcript levels are increased after growth arrest, this protein can activate the 
p38/JNK pathway. ATF3 is a transcriptional activator. These gene changes indicate 
one way in which Triptorelin could potentially cause cell cycle arrest.  
 
To further explore how aberrant gene expression following GnRHR stimulation may 
explain the cell cycle arrest and apopotosis described in section 3.1, genes belonging 
to selected functional categories were identified from the genes that were 
significantly differentially expressed with Triptorelin treatment in SCL60 cells. 
Transcription factors, regulators of apoptosis, G1/S phase progression, G2/M phase 
progression and cytoskeletal/adhesion signalling were selected. The most strongly 
and consistently increased and decreased genes belonging to these functional 
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CREB5, MXD4,  
Figure 30: The order of differential expression of genes in selected functional categories 
following Triptorelin treatment in SCL60 cells 
Transcription factors were altered in expression at both early and later phases following 
Triptorelin treatment. Genes involved in apoptosis and G1/S signalling were altered in 
expression around 1-8h after treatment, whereas expression of cytoskeletal and G2/M related 
genes was changed around 8-24h. Red indicates increased expression with Triptorelin 
treatment, green indicates decreased expression. * indicates that the gene initially (0.5-1h after 




Genes encoding transcription factors tended to be altered in expression level very 
early (0.5-1h) after treatment with Triptorelin. Many of these transcription factors 
were increased in expression, although some decreased. Some (such as EGR2, 
EGR3, EGR4 and KLF6) were transiently increased or decreased, and some were 
initially increased in one direction followed by a profound decrease below 0h levels 
(such as HES1, HOXA5 and MYC). The expression level of other transcription 
factor genes remained elevated (such as EGR1, ATF3 and FOS) or reduced (such as 
FOXK1) for up to 24h after treatment. Genes involved in apoptosis (such as EIF5A, 
GADD45B and CABC1) and G1/S phase signalling (such as CCNA1, CGRRF1, 
POLR3GL, CHEK2 and MCM5) tended to change in expression level 1-8h after 
treatment, but were more variable in their temporal profiles. Genes encoding proteins 
normally involved in cytoskeletal signalling and adhesion processes (such as TMP4, 
ITFAV, MAPT and ITGB5) were differentially expressed later in the 24h time 
course, as were genes involved in G2/M phase progression (such as CDC2, NDEL1, 
CENPF and NDE1). 
 
The differentially expressed genes shown in Figure 30 that are involved with G2/M 
progression may help to explain how Triptorelin may dysregulate gene expression to 
cause G2/M arrest in SCL60 cells. CENPF, CENPM, TUBB4, RASSF5, RABGAP1, 
NDE1, KIF20A, and DCTN1 are either components of the kinetochore (to which 
spindle fibres attach during mitosis), or regulate the dynamics of spindle assembly 
[151]. These genes are decreased in expression with Triptorelin treatment, and due to 
their involvement in mitosis, insufficient levels of these could potentially result in 
cell cycle arrest at G2/M. CDC2, which is increased, could also be involved, as it 
inhibits the assembly of chromosomes at the spindle midzone [177].  
 
Over half of the genes represented on the Illumina HT-12 beadarray are represented 
by more than one probe, and seeing multiple probes representing the same gene in 
the lists of most differentially expressed probes can increase confidence that these 
are reproducible changes. There was good agreement between the SCL60 and LβT2 
response to GnRHR stimulation despite the use of different cell lines and GnRH 
agonists [108]. A subset of the GnRH-regulated genes defined by Kakar et al in 
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another system (LβT2 cells) [108] was significantly differentially expressed between 
control and Triptorelin-treated SCL60 cells and between HEK293 and SCL60 cells, 
including the early response genes EGR1, FOSB, JUNB and IER2 (Table 34, 
Appendix A Figure 2). This suggests that, at least at the transcriptional level, the 
mechanism by which the GnRHR mediates the antiproliferative effect of a GnRH 
agonist in SCL60 cells may share similarity to its mechanism of action in LβT2 cells.  
  
A high throughput data-driven approach was taken, and it was anticipated that this 
might be useful in finding some of the most important factors in the GnRHR-
mediated antiproliferative signalling response. Gene expression analysis has the 
advantage of looking at the entire transcriptome [126] and as such provides the basis 
for an unbiased data-driven approach to identifying important signalling factors. The 
gene expression data was useful in supporting the role of cell cycle signalling and 
MAPK pathway members in the GnRHR-mediated antiproliferative response [50, 79, 
118, 178-181]. It demonstrates that there is a complex dynamic transcriptional 
response to GnRHR stimulation and indicates that gene transcription is likely to be 
important in this response. However, because of the complexity in this gene 
expression data, it is difficult to determine which gene changes are most important. 
There is an assumption that the strongest and most consistent changes with GnRHR 
transfection or with GnRHR stimulation in SCL60 cells are the most important. 
Whilst these changes are most likely to be valid, their biological significance in the 
response is not clear. 
 
No previous study has explored the transcriptional effects of GnRHR activation in 
such depth. This study created a comprehensive dataset describing the gene 
expression changes resulting from GnRHR expression and from GnRHR stimulation 
in a model system: HEK293 cells either expressing or not expressing GnRHR 
protein. These data provide a database in which individual gene expression profiles 
can be examined to test hypotheses relating to the mechanism by which Triptorelin 
exerts its antiproliferative effect. The HEK293/SCL60 system is unlikely to reflect 
precisely the situation in breast cancer cells within patients, since the conditions in 
vivo are much more complex than in vitro culture, and this is not a breast cancer cell 
 133 
line. However, SCL60 is a useful model in which to study GnRHR signalling, facets 
of which are likely to be applicable to more complex in vivo situations. It has been 
shown above that the transcriptional response of SCL60 cells to GnRHR activation 
shares similarity with the response to GnRHR activation in LβT2 cells, and may 
therefore be relevant to GnRHR signalling in other cell types.  
 
The relevance of gene expression changes to the changes at the protein level may be 
limited since increased gene transcription does not necessarily correlate with 
increased expression or activity of the protein product. Protein activity may be 
influenced post-translation and by other proteins. It is difficult to identify which 
genes (and protein products) may be increased in expression to drive the 
antiproliferative response, and which genes may be increased in expression as part of 
a competing signalling network acting against the antiproliferative response as a 
survival response following the stimulation of the GnRHR. The functional output of 
any signalling network depends on a fine balance of positive and negative signals. 
This balance is hard to identify from such a large body of gene expression data. 
Computational modelling may help to show which of the gene changes are related to 
each other, and the likely order of activation. The genes and pathways identified 




3.3 Phosphoproteomic profiling 
3.3.1 In vivo phosphoproteomic expression profiling 
GnRH agonist-regulated changes were next examined at the proteomic level. A 
proteomic antibody array was used to explore changes in phosphoproteins in SCL60 
xenografts in vivo following treatment with the GnRH agonist Triptorelin (section 
3.3.1.1). Immunohistochemistry (section 3.3.1.2), RPPA (section 3.3.2) and western 
blots (section 0) were used to validate and further characterise some of the changes 
identified. 
 
3.3.1.1 Phosphoproteomic array 
To explore GnRHR signalling in vivo, a proteomic antibody array was conducted by 
Eurogentec, as an outsourced service, using SCL60 xenografts that had been treated 
with Triptorelin or vehicle control for 4 or 7 days. Tumours responsive to Triptorelin 
treatment were compared with vehicle control-treated tumours. The aim of this 
experiment was to generate hypotheses about which phosphoproteins might be 
involved in mediating the antiproliferative effect of Triptorelin by first identifying 
which proteins are differentially activated. The antibody array comprises 117 pairs of 
antibodies that detect both phosphorylated and non-phosphorylated forms of a range 
of proteins that are typically dysregulated in cancer-related signalling, such as 
proliferation and cell death signalling pathways. Antibodies for different 
phosphorylation sites on the same protein were also included. A full list of the 
antibodies used is shown in Appendix A Table 1. These antibodies were fixed to a 
glass slide and biotin-labelled protein from the xenografts was added in solution. 
Fluorescent Cy3-Streptavidin was used to detect the antibody-bound protein and the 
slides were scanned to measure the intensity of the fluorescent signal. Images of the 







Figure 31: Twelve antibody array slides after hybridisation of antibodies with protein and 
fluorescent labelling.   
Slides 1-3 are vehicle control day 4, 4-6 are vehicle control day 7, 7-9 are Triptorelin day 4, and 
10-12 are Triptorelin day 7. A shows an enlarged image of slide 6. Six replicates of each 




The strongest and most consistent phosphoprotein changes were identified for each 
time point using P-values from a Mann-Whitney-U test comparing Triptorelin- and 
vehicle control-treated xenografts at day 4 and day 7 after treatment. These 
phosphoproteins are shown in Figure 32. After 4 days of treatment, a decrease was 
noted in the ratio of phosphorylated to non-phosphorylated Met (growth factor 
receptor) and Caveolin-1 (membrane-associated protein) in Triptorelin-treated 
xenografts compared to control xenografts (Figure 32). In contrast, phosphorylation 
of Myc (transcription activator) was increased (Figure 32). Myc phosphorylation and 
4E-BP1 (translation repressor) phosphorylation levels were increased with 
Triptorelin treatment at both 4 and 7 days compared to vehicle control-treated 
xenografts (Figure 32). Most phosphoproteins that were differentially modulated 
following treatment in the SCL60 xenografts were quite different between days 4 and 
7. Other phosphoproteins that were increased with treatment at day 4 included the 
NFκB pathway members NFκB-p65 and IκBε. Phosphoproteins that were decreased 
at day 7 included Akt and Chk2 (Figure 32).  
 
Several cell cycle-related proteins were also differentially phosphorylated: p27 
(increased at day 4), CDC25C (increased at day 7), and Chk2 (decreased at day 7). 
Changes in the phosphorylation levels of the apoptosis regulators BCL-2 (decreased 
at day 7) and BAD (increased at day 4) were also observed. 
 137 
A: Day 4 
 
 
B: Day 7 
 
Figure 32: Proteins whose phosphorylation status was most strongly and consistently changed 
with Triptorelin treatment after (A) 4 days and (B) 7 days in SCL60 xenografts.  
Expression value is given as a ratio of phosphorylated to non-phosphorylated protein 
expression, and is then shown relative to the mean of the 3 control tumours. Three control (C) 
tumours and three Triptorelin-treated (T) tumours are shown for each day (4 and 7). Red = 
increased, green = decreased. 
 
Using the online Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
database [182-184], models were generated to suggest how these proteins might 
interact to mediate the antiproliferative effect of Triptorelin (Figure 33, Figure 34).
-0.5             0         +0.5
Expression relative to 
mean of day 7 vehicle 
control treated xenografts
Scale:
-0.5             0         +0.5
Expression relative to 





Figure 33: Model of phosphoprotein changes at day 4. 
Model to show proteins whose phosphorylation status was most strongly and significantly increased (red) or decreased (green) with Triptorelin treatment in 
SCL60 xenografts 4 days after treatment. Proteins in grey did not appear to change with Triptorelin treatment.  
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Figure 34: Model of phosphoprotein changes at day 7. 
Model to show proteins whose phosphorylation status was most strongly and significantly increased (red) or decreased (green) with Triptorelin treatment in 
SCL60 xenografts 7 days after treatment. Proteins in grey did not appear to change with Triptorelin treatment.  
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3.3.1.2 Validation of proteomic responses to GnRHR stimulation 
Immunohistochemistry was used to investigate in more detail the candidates 
identified from the in vivo proteomic array. The level of pNFκB (normalised to 
tNFκB) was significantly higher in Triptorelin-treated xenografts compared to 
vehicle control-treated xenografts compared to (P=0.009, 2-sample t-test; Figure 35). 









































Figure 35: Immunostaining for pNFκB. 
Immunostaining for pNFκB (normalised to tNFκB) was significantly lower in vehicle control-
treated xenografts compared to Triptorelin-treated xenografts (P=0.009; 2-sample t-test). The 
bars show average immunoscores for 8 Control tumours and 9 Triptorelin-treated tumours. 











































Figure 36: Immunostaining for pNFκB (day 4 and day 7). 
Immunostaining for pNFκB (normalised to tNFκB) was lower in vehicle control-treated 
xenografts compared to Triptorelin-treated xenografts. The bars show average immunoscores 
for 6 vehicle control- and 7 Triptorelin-treated tumours at day 4 and 2 vehicle control- and 2 
Triptorelin-treated tumours at day 7. Error bars show standard deviation. 
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No significant difference could be detected in the levels of pCav1, tCav1, pMet, 
tMet, pERK1/2, or tERK1/2 (p – phosphorylated, t – total) between Control and 
Triptorelin-treated xenografts when day 4 and 7 were pooled (Figure 37). Neither 
could a difference be detected between Control and Triptorelin-treated xenografts 

























































Figure 37: Immunostaining for pCav1, tCav1, pMet, tMet, pERK1/2, or tERK1/2 in SCL60 
xenografts. 
No significant difference could be detected in the levels of pCav1, tCav1, pMet, tMet, pERK1/2, 
or tERK1/2 between Control and Triptorelin-treated xenografts. The bars show average 
immunoscores for 6 vehicle control- and 7 Triptorelin-treated tumours at day 4 and 2 vehicle 
control- and 2 Triptorelin-treated tumours at day 7. Error bars show standard deviation. 
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3.3.2 RPPA 
Reverse-phase protein array (RPPA) was used as a broad screening tool to validate 
some of the candidates identified from the in vivo antibody array and existing 
literature, and to identify proteins of further interest. SCL60 cells were compared 
with their untransfected counterparts, HEK293 cells, and with another control cell 
line, SCL215, which has been transfected with an extended (non-functional) form of 
GnRHR. Protein expression following Triptorelin treatment was also investigated in 
each cell line. 
  
3.3.2.1 pNFκB, PI3K, pChk2 and pCyclinD1 differed in their baseline 
expression between SCL60, HEK293 and SCL215 cells 
The expression of several proteins was compared between HEK293, SCL215 and 
SCL60 cells. These results are shown in Figure 38. The cell cycle proteins pCHK2 
and pCyclinD1 were significantly different between at least two cell lines (Figure 
38). pCHK2 (not normalised to total) expression was significantly (39%) lower in 
SCL60 cells compared to HEK293 cells (Figure 38; P=0.027, 2-sample t-test) but not 
compared to SCL215 cells. The baseline expression of pCyclinD1 (normalised to 
total CyclinD1) was significantly (3-fold) higher in SCL215 cells than HEK293 cells 
(Figure 38; P=0.004, 2-sample t-test). PI3K-p110α was significantly (13%) reduced 
in expression in SCL60 cells compared to HEK293 cells (P=0.027, 2-sample t-test). 
pNFκB (normalised to tNFκB) was significantly (1.8 fold) higher in SCL60 cells 
compared to SCL215 cells (P=0.035, 2-sample ). 
 
No expression differences were observed between the three cell lines in the 
proliferation markers pHistone H3 and Ki67, or the tumour suppressor total p53 
(Figure 38). No difference in expression of tP21, pCAV1, pmTOR, pPTEN, pAkt, p-
cRAF, pMet, pER, tHER2, tEGFR or pERK1/2, could be detected between any of 




































































































































Figure 38: Baseline protein expression (measured by RPPA) in untreated SCL60, HEK293, and 
SCL215 cells.  
* indicates a statistically significant difference in expression (P<0.05, 2-sample t-test).  Bars 
show mean of three independent experiments. Error bars show standard deviation. Figure 
































































































































Figure 38 (continued): Baseline protein expression (measured by RPPA) in untreated SCL60, 
HEK293, and SCL215 cells.  
* indicates a statistically significant difference in expression (P<0.05, 2-sample t-test). Bars show 
mean of three independent experiments. Error bars show standard deviation. Figure continues 



















































Figure 38 (continued): Baseline protein expression (measured by RPPA) in untreated SCL60, 
HEK293, and SCL215 cells.  
* indicates a statistically significant difference in expression (P<0.05, 2-sample t-test). Bars show 
mean of three independent experiments. Error bars show standard deviation. 
 
3.3.2.2 pERK1/2 was increased in SCL60 and SCL215 cells following 
Triptorelin treatment 
Levels of selected phosphoproteins in HEK293 and SCL215 cells were largely 
unresponsive to Triptorelin treatment (Figure 39). The exception to this was a 
transient increase (approx 1.5 fold) in the level of pERK1/2 at 1h following treatment 
with Triptorelin in both SCL60 and SCL215 cells which returned to basal levels by 
24h (Figure 39). Figure 39 shows protein expression levels in SCL60, HEK293 and 
SCL215 cells at 0, 1, and 24h after treatment with Triptorelin. The data in this figure 
shows protein expression in Triptorelin treated cells relative to the expression of that 
protein in corresponding vehicle control treated cells at the same time point. Figure 
40 shows these data in more detail by showing separate values for control and 
































































































































































Figure 39: Protein expression (measured by RPPA) in SCL60, HEK293, and SCL215 cells 
following treatment with 100nM Triptorelin for 0, 1 or 24h.  
Protein expression was measured by RPPA in SCL60, HEK293 and SCL215 cells following 
treatment with 0.02% propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein 
expression was wherever possible normalised to total protein expression. The expression of each 
protein in Triptorelin-treated cells was then normalised to the expression of that protein in 
vehicle control-treated cells. Bars show normalised mean protein expression of three 
































































































































































Figure 39 (continued): Protein expression (measured by RPPA) in SCL60, HEK293, and 
SCL215 cells following treatment with 100nM Triptorelin for 0, 1 or 24h. Protein expression 
was measured by RPPA in SCL60, HEK293 and SCL215 cells following treatment with 0.02% 
propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein expression was 
wherever possible normalised to total protein expression. The expression of each protein in 
Triptorelin-treated cells was then normalised to the expression of that protein in vehicle control-
treated cells. Bars show normalised mean protein expression of three independent experiments. 













































































Figure 39 (continued): Protein expression (measured by RPPA) in SCL60, HEK293, and 
SCL215 cells following treatment with 100nM Triptorelin for 0, 1 or 24h.  
Protein expression was measured by RPPA in SCL60, HEK293 and SCL215 cells following 
treatment with 0.02% propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein 
expression was wherever possible normalised to total protein expression. The expression of each 
protein in Triptorelin-treated cells was then normalised to the expression of that protein in 
vehicle control-treated cells at the same time point. Bars show normalised mean protein 
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Figure 40: Protein expression (measured by RPPA) in SCL60, HEK293, and SCL215 cells 
following treatment with 100nM Triptorelin for 0, 1 or 24h.  
Protein expression was measured by RPPA in SCL60, HEK293 and SCL215 cells following 
treatment with 0.02% propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein 
expression was wherever possible normalised to total protein expression. Bars show mean 
protein expression of three independent experiments. Error bars show standard deviation. 
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Figure 40 (continued): Protein expression (measured by RPPA) in SCL60, HEK293, and 
SCL215 cells following treatment with 100nM Triptorelin for 0, 1 or 24h. 
Protein expression was measured by RPPA in SCL60, HEK293 and SCL215 cells following 
treatment with 0.02% propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein 
expression was wherever possible normalised to total protein expression. Bars show mean 
protein expression of three independent experiments. Error bars show standard deviation. 
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Figure 40 (continued): Protein expression (measured by RPPA) in SCL60, HEK293, and 
SCL215 cells following treatment with 100nM Triptorelin for 0, 1 or 24h.  
Protein expression was measured by RPPA in SCL60, HEK293 and SCL215 cells following 
treatment with 0.02% propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein 
expression was wherever possible normalised to total protein expression. Bars show mean 
protein expression of three independent experiments. Error bars show standard deviation.  
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3.3.2.3 Change in pERK1/2, pAkt and pNFkB expression in SCL60 cells 
from 0 to 24h 
To identify proteins that may be altered in expression as a result of GnRHR 
stimulation, RPPA was used to measure the relative levels of several proteins in 
SCL60 cells following Triptorelin treatment. Figure 41 shows the expression levels 
of these proteins in SCL60 cells. The expression levels of each phosphoprotein was 
normalised to the expression level of the corresponding total protein. Figure 41 
shows the expression of several proteins in Triptorelin treated cells relative to the 
expression of that protein in corresponding vehicle control treated cells at the same 
time point. Most proteins examined did not change in expression with Triptorelin 
treatment over 24h. However, there appeared to be some change in the level of 
PI3K-p110α, pmTOR, pPTEN, pAkt, pERK1/2, pMet, and pNFκB (Figure 41). The 
expression profiles of these proteins are shown in further detail in Figure 42. 
 
Figure 42 shows that there is a clear difference in expression of pNFκB and 
pERK1/2 between Triptorelin-treated and vehicle control-treated cells at several time 
points. pERK1/2 was initially increased in expression in Triptorelin-treated cells 
compared to vehicle control-treated cells. pERK1/2 expression was more than 2 
times higher in Triptorelin-treated cells than vehicle control-treated cells at 0.5h. 
pERK1/2 expression then decreased between 0.5 and 1h but still remained much 
higher than control levels. A higher level of pERK1/2 in Triptorelin-treated cells was 
maintained up to 8h before returning to near control level by 24h. pAkt appeared to 
be differentially expressed at 24h between control and Triptorelin-treated cells. 
pPTEN levels changed only slightly between control and treated cells at any time 
point and the data were quite variable. pmTOR and PI3K-p110α showed small 
differences in expression at at least one time point. pMet data showed changes in 
both control and Triptorelin treated cells, although they were very variable. To 
validate the changes observed here in pNFκB, pERK1/2 and pAkt, and to further 
investigate the unclear RPPA data surrounding pmTOR, pPTEN, pMet and PI3K-
p110α expression, the expression of these proteins was measured by western blot 

















































































































































Figure 41: Protein expression (measured by RPPA) in SCL60 cells following treatment with 
100nM Triptorelin for up to 24h.  
Protein expression was measured by RPPA in SCL60, HEK293 and SCL215 cells following 
treatment with 0.02% propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein 
expression was wherever possible normalised to total protein expression. The expression of each 
protein in Triptorelin-treated cells was then normalised to the expression level of that protein in 
vehicle control-treated cells at the same time point. Bars show mean protein expression of three 


















































































































































Figure 41 (continued): Protein expression (measured by RPPA) in SCL60 cells following 
treatment with 100nM Triptorelin for up to 24h.  
Protein expression was measured by RPPA in SCL60, HEK293 and SCL215 cells following 
treatment with 0.02% propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein 
expression was wherever possible normalised to total protein expression. The expression of each 
protein in Triptorelin-treated cells was then normalised to the expression level of that protein in 
vehicle control-treated cells at the same time point. Bars show mean protein expression of three 





























































Figure 41 (continued): Protein expression (measured by RPPA) in SCL60 cells following 
treatment with 100nM Triptorelin for up to 24h. 
Protein expression was measured by RPPA in SCL60, HEK293 and SCL215 cells following 
treatment with 0.02% propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein 
expression was wherever possible normalised to total protein expression. The expression of each 
protein in Triptorelin-treated cells was then normalised to the expression level of that protein in 
vehicle control-treated cells at the same time point. Bars show mean protein expression of three 









































































































































Figure 42: Protein expression (measured by RPPA) in SCL60 cells following treatment with 
100nM Triptorelin or vehicle control for up to 24h.  
Protein expression was measured by RPPA in SCL60, HEK293 and SCL215 cells following 
treatment with 0.02% propylene glycol (vehicle control) or 100nM Triptorelin. Phospho-protein 
expression was wherever possible normalised to total protein expression. Bars show mean 
protein expression of three independent experiments. Error bars show standard deviation.  
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3.3.2.4 RPPA Reproducibility 
To assess the reproducibility of the reverse phase protein array method, a 2-pad slide 
was probed for pNFkB and tNFκB as usual and then the process was repeated with 
another 2-pad slide on a different day using freshly prepared antibody solutions. The 
slides were scanned under the same conditions, and for each slide the data 
corresponding to pNFkB expression were normalised to total NFkB expression. The 
expression in Triptorelin-treated samples was then divided as before by the 
expression in the control sample of the same time point. The results of the original 





















































Figure 43: pNFkB protein expression (measured by RPPA) in SCL60 cells following treatment 
with 100nM Triptorelin for up to 24h.  
Values are shown for the original measurement (black), and a repeat measurement (white). 
Errors bars show +/- standard deviation of three replicates. 
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3.3.3 Validation of RPPA phosphoprotein expression changes by 
western blot 
Expression of the proteins identified by RPPA analysis was analysed by western blot. 
3.3.3.1 pNFκB 
pNFκB expression was higher in Triptorelin-treated cells at 1-24h after treatment 
compared to vehicle control-treated cells at the same time points (Figure 44, Figure 
45). Figure 44 shows a western blot for pNFκB and tNFκB, and Figure 45 shows the 
quantification of this western blot. The data in Figure 45 are shown as pNFκB 
expression normalised to tNFκB expression, in SCL60 cells treated with Triptorelin 
relative to that in SCL60 cells treated with a vehicle control. RPPA data showed that 
pNFκB was increased slightly at all time points except 2h. The western blot data 
shows that pNFκB was increased in expression at all six time points investigated. 
The western blot data shows that there was a gradual rise in pNFκB with a peak at 2h 
and remaining above basal level at 24h.  
pNFkB
tNFkB
0C  0.5C 0.5T   1C    1T     2C     2T     4C    4T    8C     8T 24C  24T
α-tubulin
 
Figure 44: Western blot showing pNFκB and tNFκB expression in SCL60 cells 0-24h after 

















































Figure 45: Quantification of western blot shown in Figure 44.  
The data shown is pNFκB expression (normalised to tNFκB expression) in SCL60 cells treated 
with Triptorelin relative to that in cells treated with a vehicle control at the same time point. 
This figure shows data from a single experiment. 
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3.3.3.2 pERK1/2 
Figure 46 shows a western blot for pERK1/2 and tERK1/2, and Figure 47 shows the 
quantification of this western blot. The data in Figure 47 show pERK1/2 expression 
normalised to tERK1/2 expression, in SCL60 cells treated with Triptorelin relative to 
that in SCL60 cells treated with a vehicle control. By western blot, pERK1/2 
appeared to be initially increased in expression in Triptorelin-treated cells compared 
to vehicle control-treated cells (Figure 46, Figure 47). pERK1/2 levels peaked at 4h 
after treatment and a higher level of pERK1/2 in Triptorelin-treated cells was 
maintained up to 8h after treatment before returning to nearer control level by 24h 
(Figure 46, Figure 47). Western blot-detected changes in pERK1/2 and tERK1/2 
expression levels following Triptorelin largely supported the changes detected by 
RPPA, although the magnitude of differential expression was higher in western blot 
data (Figure 47, Figure 42).  





Figure 46: Western blot showing pERK1/2 and tERK1/2 expression in SCL60 cells 0-24h after 

















































Figure 47: Quantification of western blot shown in Figure 46. 
The data shown is pERK1/2 expression (normalised to tERK1/2 expression) in SCL60 cells 
treated with Triptorelin relative to that in cells treated with a vehicle control at the same time 
point. This figure shows data from a single experiment.  
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3.3.3.3 pAkt 
Figure 48 shows a western blot for pAkt and tAkt, and Figure 49 shows the 
quantification of this western blot. By western blot, pAkt appeared to be lower in 
Triptorelin-treated cells at all time points after treatment compared to vehicle 
control-treated cells at the same time points (Figure 48, Figure 49). The data in 
Figure 49 show pAkt expression normalised to tAkt expression, in SCL60 cells 
treated with Triptorelin relative to that in SCL60 cells treated with a vehicle control.  
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Figure 48: Western blot showing pAkt and tAkt expression in SCL60 cells 0-24h after treatment 














































Figure 49: Quantification of western blot shown in Figure 48.  
The data shown is pAkt expression (normalised to tAkt expression) in SCL60 cells treated with 
Triptorelin relative to that in cells treated with a vehicle control at the same time point. These 




Figure 50 shows a western blot for PI3K-p110α, and Figure 51 shows the 
quantification of this western blot. The data in Figure 51 show PI3K-p110α 
expression in Triptorelin treated SCL60 cells relative to that in SCL60 cells treated 
with a vehicle control. The level of PI3K-p110α fluctuated in both vehicle control 
and Triptorelin-treated cells over the 24h treatment period. Western blot 
measurement of PI3K-p110α expression (Figure 50, Figure 51) did not support the 
small difference in PI3K-p110α between vehicle control and Triptorelin-treated cells 
at 24h observed by RPPA (Figure 42). 




Figure 50: Western blot showing PI3K-p110α expression in SCL60 cells 0-24h after treatment 















































Figure 51: Quantification of western blot shown in Figure 50.  
The data shown is PI3K-p110α expression in SCL60 cells treated with Triptorelin, relative to 




Figure 52 shows a western blot for pmTOR and tmTOR, and Figure 53 shows the 
quantification of this western blot. The data in Figure 53 are shown as pmTOR 
expression normalised to tmTOR expression, in SCL60 cells treated with Triptorelin 
relative to that in SCL60 cells treated with a vehicle control. pmTOR appeared to be 
higher in Triptorelin-treated cells at 0.5, 1 and 8h after treatment compared to vehicle 
control-treated cells at the same time points (Figure 52, Figure 53).  
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Figure 52: Western blot showing pmTOR and tmTOR expression in SCL60 cells 0-24h after 














































Figure 53: Quantification of western blot shown in Figure 52.  
The data shown is pmTOR expression (normalised to tmTOR expression) in SCL60 cells treated 





Figure 54 shows a western blot for pPTEN, and Figure 55 shows the quantification 
of this western blot. The data in Figure 55 show pPTEN expression in SCL60 cells 
treated with Triptorelin relative to that in SCL60 cells treated with a vehicle control. 
The level of pPTEN expression changed in both vehicle control and Triptorelin-
treated cells over the 24h treatment period. Little difference could be detected in the 
level of pPTEN between control and Triptorelin-treated cells at the same time point, 
although pPTEN did appear slightly lower with Triptorelin treatment at 24h when 
measured by western blot (Figure 54, Figure 55).  




Figure 54: Western blot showing pPTEN expression in SCL60 cells 0-24h after treatment with 


















































Figure 55: Quantification of western blot shown in Figure 54.  
The data shown is pPTEN expression in SCL60 cells treated with Triptorelin relative to that in 




Figure 56 shows a western blot for pMet and tMet, and Figure 57 shows the 
quantification of this western blot. The data in Figure 57 show pMet expression 
normalised to tMet expression, in SCL60 cells treated with Triptorelin relative to that 
in SCL60 cells treated with a vehicle control. By western blot, pMet appeared to be 
higher in Triptorelin-treated cells at 2 and 4h after treatment compared to vehicle 
control-treated cells at the same time points. However, pMet was poorly detected by 
western blot and this does not support the RPPA data. 
pMet




Figure 56: Western blot showing pMet and tMet expression in SCL60 cells 0-24h after 
















































Figure 57: Quantification of western blot shown in Figure 56.  
The data shown is pMet expression (normalised to tMet expression) in SCL60 cells treated with 





3.3.4.1 In vivo phosphoproteomic array 
The antibody array identified a number of phosphoproteins that were changed in 
response to Triptorelin in SCL60 xenografts. After 4 days of treatment, a decrease 
was noted in the ratio of phosphorylated to non-phosphorylated Met (growth factor 
receptor) and Caveolin-1 (membrane-associated protein) compared to untreated 
controls (Figure 32). In contrast, phosphorylation of Myc (multifunctional DNA 
binding proto-oncogene) was increased (Figure 32). It was interesting to note 
increases in phosphorylation of both NFκB-p65 and IκBε (Figure 32), since there is 
limited evidence in the literature that NFκB pathway members may be involved in 
GnRHR-mediated signalling [42, 65, 100, 101]. Triptorelin has been shown to induce 
NFκB activation in ovarian cancer cells (EFO-21 and EFO-27), which inhibited 
Doxorubicin-induced apoptosis in these cells [65]. GnRH has also been shown to 
stimulate the rapid phosphorylation of NFκB-p65 in LβT2 cells [100]. NFκB 
signalling may warrant further investigation as a downstream signalling pathway of 
GnRHR.  
 
The phosphoproteins that were differentially modulated following treatment in the 
SCL60 xenografts were quite different between days 4 and 7, indicative of dynamic 
changes which may be consistent with differences seen in vitro. An example of this 
was phosphorylated AMPK1, which was increased after 4 days but decreased after 7 
days (Figure 32). However, phosphorylated Myc levels remained elevated after 7 
days of Triptorelin treatment compared to untreated controls, although to a lesser 
extent (1.4 fold; Figure 32). Phosphorylated 4E-BP1 was also increased with 
Triptorelin treatment at both 4 and 7 days after treatment (Figure 32).  
 
Phosphoproteins that were decreased in vivo at day 7 included Akt (1.5 fold) and 
Chk2 (1.5 fold). Changes observed in the cell cycle proteins p27 (increased at day 4), 
CDC25C (increased at day 7), and Chk2 (decreased at day 7), may be relevant in 
understanding the disruption to cell cycle progression observed in vitro. CDC25C is 
a dual-specificity protein phosphatase that dephosphorylates and activates CDC2 to 
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allow entry into mitosis [185]. CDC25C is constitutively phosphorylated at Ser216 
(inactivated) throughout interphase and sequestered in the cytoplasm through binding 
to 14-3-3 family proteins to prevent premature entry into mitosis [186, 187]. 
CDC25C is also phosphorylated by Chk1 and Chk2 after DNA damage at the G2/M 
checkpoint [188, 189]. Phosphorylation of Chk2 at Thr68 is required for further 
phosphorylation and activation of Chk2 in response to DNA damage [190]. Changes 
in the phosphorylation levels of the apoptosis regulators BCL-2 (anti-apoptotic when 
phosphorylated at Thr56 [191, 192], decreased at day 7) and BAD (anti-apoptotic 
when phosphorylated at Ser155 [193], increased at day 4) may be relevant to 
understanding the apoptosis observed both in vitro and in vivo. 
 
It should be acknowledged that the array comprised phosphoproteins specifically 
selected because they are known to regulate cell proliferation or death and therefore 
some of these observations may not be a complete surprise, this was not a truly data-
driven approach. Nonetheless, levels of particular phosphoproteins that consistently 
or very strongly changed in this dataset may be relevant to GnRHR-mediated 
signalling. The proteins identified in this analysis were investigated further by RPPA 
in vitro or IHC in vivo. 
 
The results of the antibody array were somewhat variable due to a small sample size 
and the inherent variability in xenograft samples. Ideally more samples would have 
been included in this array. However, the antibody array was useful in that it led to 
the identification of a potential role for NFκB pathway signalling in the GnRHR-
mediated antiproliferative response, and NFκB was further shown to be important in 
the antiproliferative effects of Triptorelin (see later). 
 
The phosphoproteomic array was designed to detect changes in phosphorylation 
status of selected proteins. The method has an inherent systematic bias because each 
sample must be hybridised to a different array chip. The phosphoprotein data were 
normalised to corresponding total protein data, allowing relative changes in the ratio 
of phosphoprotein to total protein expression between samples to be analysed. 
However, it is not possible to normalise the measures of total protein. It would be 
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inappropriate to attempt to interpret a dataset that is clearly distorted by systematic 
bias, therefore these data are not shown. Comparisons between the level of total 
protein expression and the level of gene expression cannot be made for the above 
reason. 
 
Immunohistochemical staining of the xenografts revealed that the level of pNFκB 
(normalised to tNFκB) was significantly increased with Triptorelin treatment at both 
4 and 7 days after treatment (Figure 35, Figure 36). 
 
Most of the phosphoproteins examined by immunohistochemical staining of the 
SCL60 xenograft tissue did not show differential staining between SCL60 
Triptorelin-treated xenografts and vehicle control-treated xenografts. Despite being 
the most strongly and consistently differentially phosphorylated proteins according to 
the antibody array; no significant difference could be detected in the levels of pCav1, 
tCav1, pMet, or tMet between Control and Triptorelin-treated xenografts (Figure 37). 
It was also interesting to note that no difference in the expression of pERK1/2 or 
tERK1/2 could be detected between Control and Triptorelin-treated xenografts 
despite the proposed role of pERK1/2 in vitro (Figure 37) [79]. Although the sample 
size is limited, which could be a factor in not observing significant differences, the 
differences in immunostaining for the majority of targets explored were very small 
between control and treated groups. This suggests that even if the sample size were 
larger, any differences observed are unlikely to be useful in understanding the 
biology of GnRHR signalling. 
 
3.3.4.2 In vitro phosphoprotein profiling 
3.3.4.2.1 pNFκB 
The RPPA data showed that pNFκB expression was significantly (1.8 fold) higher in 
SCL60 cells compared to SCL215 cells (P=0.035, 2-sample t-test), and was 
increased slightly with Triptorelin treatment in SCL60 cells compared to vehicle 
control-treated cells at all time points from 1-24h except 2h. The western blot data 
showed that pNFκB was increased in expression at all six time points after treatment 
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compared to vehicle control-treated cells at the same time points (Figure 44, Figure 
45). The western blot data showed that there was a gradual rise in pNFκB expression 
with a peak at 2h and remaining above basal level at 24h. This increase in pNFκB 
expression in vitro was interesting because it had also been identified as 
differentially expressed in vivo. In the SCL60 xenografts, the phosphorylation of 
NFκB-p65 was increased after 4 days of treatment with Triptorelin. These data 
together gave further evidence for a role for NFκB signalling in the response to 
Triptorelin, and provided a basis for further investigation of the role of NFκB in 




A transient increase (approx 1.5 fold) was observed in the level of pERK1/2 
expression at 1h following treatment with Triptorelin in both SCL60 and SCL215 
cells which returned to basal levels by 24h (Figure 39). pERK1/2 was initially 
increased in expression in Triptorelin-treated cells compared to vehicle control-
treated cells, and an elevated level of pERK1/2 in Triptorelin-treated cells was 
maintained up to 8h before returning to near control level by 24h. 
 
ERK1/2 activation has previously been demonstrated in SCL60 cells to be transient, 
whereby increased pERK1/2 is observed within 5min of incubation with the GnRH 
agonist Triptorelin, which then decreases (although is still above basal levels) by 
30min [79]. However, the data presented above indicates that after 30min the level of 
pERK1/2 expression does not decrease entirely to basal levels, but continues to be at 
least slightly elevated for at least 8h.  
 
As mentioned in the Introduction to this thesis, there appears to be a role for ERK1/2 
activation in response to GnRHR stimulation. In SCL60 cells, there is an immediate 
intense activation of ERK1/2 following Triptorelin treatment [79]. Inappropriate 
increase in pERK1/2 has been shown to cause G2/M arrest [93, 194]. ERK1/2-
mediated G2 arrest appears to be dependent on PKC [93, 195] and MEK1 [92, 93]. 
The antiproliferative effect of Triptorelin in SCL60 cells has been shown to be 
dependent on PKC but not MEK [79].  
 
3.3.4.2.3 pAkt, PI3K-p110α and pmTOR 
pAkt appeared to be lower in Triptorelin-treated cells at all time points after 
treatment compared to vehicle control-treated cells at the same time points (Figure 
48, Figure 49). By western blot, there appeared to be a clear pattern of pAkt being 
decreased in Triptorelin-treated cells compared to vehicle control-treated cells. This 
was apparent at all time points. There was a similar level of tAkt in vehicle control 
and Triptorelin-treated cells of each time point, indicating that the variation in pAkt 
is not due to variation in the level of tAkt. A decrease in pAkt is consistent with a 
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decrease in pAkt observed in the SCL60 xenograft in vivo antibody array 7 days after 
treatment with Triptorelin.  
 
Cross-talk between the PI3K/Akt and NFκB signalling pathways has been suggested, 
and it has recently been shown that Akt inhibits FasL-dependent NFκB activity in 
human renal 293T and Jurkat T-lymphocytes [196, 197]. It could be speculated that 
the decreased Akt activity in response to Triptorelin may play a role in the increased 
NFκB activity, although further experimentation is required to understand the nature 
of any cross-talk between these pathways and the applicability of such cross-talk in 
this context. 
 
When activated, Akt promotes cell survival by inhibiting several downstream targets 
by phosphorylation, including the pro-apoptotic factors caspase 9 and BAD [196, 
198, 199]. Akt also inhibits Raf, thereby inhibiting the Raf-MEK-ERK1/2 signalling 
pathway [200]. Akt promotes progression through the cell cycle by inhibiting the 
cyclin dependent kinase inhibitors p27(Kip1) and p21 (Cip1/Waf1) [196, 201, 202] 
and maintaining cyclin D1 by inhibiting its phosphorylation and degradation by 
GSK-3β [203]. Akt also initiates a multistep signalling pathway leading to the 
activation of mTOR and ribosomal s6k to activate translation [204, 205]. It is 
plausible that the observed decrease in the level of pAkt following GnRHR 
stimulation may be partly responsible for the antiproliferative effect of Triptorelin in 
SCL60 cells.  
 
The level of PI3K-p110α appeared to decrease in Triptorelin-treated cells compared 
to vehicle control-treated cells, although it fluctuated in both sample types over the 
24h treatment period. Western blot measurement of PI3K-p110α expression (Figure 
50, Figure 51) did not support the small difference in PI3K-p110α between vehicle 
control and Triptorelin-treated cells at 24h observed by RPPA, but did indicate a 
decrease in PI3K-p110α 0.5h after Triptorelin treatment in SCL60 cells (Figure 42). 
 
PI3K-p110α also appeared to be decreased following GnRHR stimulation by 
Triptorelin in SCL60 cells. PI3K-p110α promotes the activation of Akt: PI3K 
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phosphorylates PIP2 to PIP3, which allows Akt to bind and be phosphorylated and 
activated by phosphoinositide dependent kinase 1 (PDPK1) at Thr308 and 
mammalian target of rapamycin complex 2 (mTORC2) at Ser473 [206, 207]. It is 
possible, therefore, that the decrease in PI3K-p110α mediates the decrease in pAkt. 
 
Upon stimulation, GnRHR activates the intracellular G-protein Gαq, which is known 
to inhibit PI3K-p110α and therefore Akt [208, 209]. This may be the mechanism by 
which Triptorelin causes a decrease in pAkt. More experiments are needed to explore 
the downstream effects of decreased pAkt in this context.  
 
There appeared to be a slight increase in pmTOR expression at 0.5, 1 and 8h with 
treatment, although this was not as clear as the change in pAkt. Akt is a key regulator 
of mTOR [210], but mTOR can also be activated in an Akt-independent manner 
[211]. RPPA data showed an increase in pmTOR expression with Triptorelin 
treatment at 0.5, 4, 8 and 24h. Western blot analysis supports the increased pmTOR 
expression at 0.5h but does not support the increased levels of pmTOR seen at later 
time points. Both pmTOR and tmTOR levels are variable across the 24h treatment 
period in both vehicle control-treated and Triptorelin-treated cells. It is not clear why 
pmTOR is activated in vehicle control treated cells, but this may reflect a stress-
induced response. Because of the large variability in pmTOR and tmTOR detected, 
particularly in vehicle control-treated cells, the validity of the observed differences 
between control and Triptorelin-treated cells at 0.5 and 1h is questionable. Any true 
difference is likely to be small.  
 
3.3.4.2.4 Other targets: pPTEN and pMet 
The level of pPTEN expression changed in both vehicle control and Triptorelin-
treated cells over the 24h treatment period. However, little difference could be 
detected in the level of pPTEN between control and Triptorelin-treated cells at any 
time point (Figure 54, Figure 55). It was not possible to detect tPTEN by western 
blot, and a stronger band of the incorrect molecular weight was detected, indicating 
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that this antibody unreliably detects tPTEN, therefore the level of pPTEN could not 
be normalised to the level of tPTEN. 
  
By western blot, the level of pMet expression appeared to be higher in Triptorelin-
treated cells at 2 and 4h after treatment compared to vehicle control-treated cells at 
the same time points. However, pMet was poorly detected by western blot and this 
does not support the RPPA data. 
 
3.3.4.3 Comparison of RPPA and Western blot techniques 
RPPA provided a high-throughput, quantitative method to study a large number of 
protein targets for a large number of samples. Protein expression was measured in 
SCL60 cells following GnRHR stimulation at multiple time points for three 
biological replicates (experiments performed on different days), with multiple 
protein dilutions. This high degree of replication allows for a more accurate 
quantification and indicates more reliability in the data. The disadvantage of RPPA is 
that the antibody used may detect a protein other than the protein of interest. RPPA 
may have poorer discrimination of signal from background noise compared to a 
western blot that gives an easily detectable band. RPPA therefore provided a useful 
tool for screening multiple antibodies, but western blot data is considered the more 
reliable for further interpretation. The results of the original and repeat measurements 
by RPPA showed good agreement with each other (Figure 43). Western blot data 
was highly supportive of RPPA data: where differential protein expression was 
identified by RPPA, it was generally reflected by a similar result by western blot 
analysis, although differences in expression between control and Triptorelin-treated 
cells tended to be greater in western blots. 
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3.4 NFκB signalling was altered at both the proteomic and 
transcriptomic level in SCL60 cells following GnRHR 
stimulation 
NFκB was identified as a candidate for further investigation after an antibody array 
and immunohistochemistry indicated that pNFκB-p65 was differentially expressed 
between SCL60 xenografts treated with a vehicle control or with Triptorelin. pNFκB 
was also differentially expressed between vehicle control and Triptorelin-treated 
SCL60 cells in vitro by RPPA analysis. Western blotting confirmed that pNFκB was 
increased in response to Triptorelin at all six time points (0.5, 1, 2, 4, 8, 24h) over the 
24h treatment period. A gradual rise in pNFκB was observed with a peak at 4h and 
remaining above basal level at 24h (Figure 44, Figure 45). 
 
Because NFκB had been identified as being differentially modulated by Triptorelin at 
the proteomic level both in vitro and in vivo, it was interesting to explore its 
expression at the transcriptomic level.  
 
To explore whether the expression of NFκB signalling pathway members was also 
altered at the transcriptomic level, their expression following Triptorelin treatment in 
SCL60 cells was examined. Figure 58 highlights the gene expression patterns of 
several NFκB pathway members that are perturbed in SCL60 cells following 
treatment with Triptorelin. Figure 58 shows some examples of NFκB pathway 
members, and demonstrates that there is a range of expression profiles within 
members of this pathway. Some are transiently increased (NFKBIA, IKBKB), some 
transiently decreased (IKBKG, NFKB1) and MAP3K8 has a prolonged increase in 
expression after Triptorelin treatment in SCL60 cells. NFKBIA encodes the inhibitor 
of NFκB, IκBα; IKBKB and IKBKG encode inhibitors of IκBα, IKKβ and IKKγ; 
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Figure 58: Gene expression profiles of several NFκB pathway members in SCL60 cells following 
treatment with Triptorelin for up to 24h. 
Expression at 0.5, 1, 2, 8 and 24h after Triptorelin treatment is shown relative to untreated (0h) 
cells. 
 
3.4.1 NFκB inhibition did not prevent the antiproliferative effect of 
Triptorelin in SCL60 cells 
To examine the effect of NFκB on SRB activity of SCL60 cells, the cells were 
treated with the NFκB inhibitor 15-deoxy∆
12,14
 prostaglandin J2 [212] (15d-PGJ2; 
3µM) alone and in combination with Triptorelin (100nM). Cell number was 
measured by SRB assay. After 4 days of treatment a reduction in cell number was 
observed in all three treatment groups (Figure 59) compared to vehicle control-
treated cells. The combination of GnRHR stimulation and NFκB inhibition had a 
greater impact on SRB activity than either treatment alone (Figure 59). 15d-PGJ2 did 
not inhibit HEK293 SRB activity either alone or in combination with Triptorelin 


















































Figure 59: NFκB inhibition in SCL60 cells with 3µM 15d-PGJ2. 
NFκB inhibition with 3µM 15d-PGJ2 (15-Deoxy-(Delta)12,14-Prostaglandin J2) caused 
inhibition of SCL60 SRB activity both alone and in combination with 100nM Triptorelin. Cell 
number was measured by SRB assay 4 days after treatment and is shown relative to that of the 
















































Figure 60: NFκB inhibition in HEK293 cells with 3µM 15d-PGJ2. 
NFκB inhibition with 3µM 15d-PGJ2 did not cause inhibition of HEK293 SRB activity either 
alone or in combination with 100nM Triptorelin. Cell number was measured by SRB assay 4 
days after treatment and is shown relative to that of the vehicle control-treated cells. Error bars 




The perturbation of NFκB pathway signalling at both the transcriptomic and 
proteomic level provided a basis for the hypothesis that NFκB pathway signalling 
may be involved in the antiproliferative response to GnRH agonist treatment. NFκB 
has been shown to play a role in cell survival in many model systems (reviewed in 
[103, 213]). NFκB inhibition enhanced the antiproliferative effect of Triptorelin in 
SCL60 cells (but not HEK293 cells) in vitro. NFκB activation may act in SCL60 
cells as part of a survival mechanism in response to GnRHR stimulation. 
 
Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated 
transcription factor belonging to the nuclear hormone receptor superfamily [214]. 
15d-PGJ2 is a potent ligand for PPARγ, through which its anti-inflammatory 
functions are thought to be mediated [212, 215, 216]. However, in HEK293 cells 
PPARγ-mediated gene expression is not stimulated by 15d-PGJ2 [215]. This is 
thought to be due to the very low level of PPARγ expression in HEK293 cells 
compared to other cells such as 3T3-L1 (mouse embryonic fibroblast - adipose like) 
cells [215]. One study reports that growth of HEK293 cells is inhibited by 15d-PGJ2 
in a mechanism that is independent of PPARγ [215]. This is in contrast to the finding 
above that HEK293 cells do not respond to 15d-PGJ2 (Figure 60).  
 
These data provide a useful insight into pathways that may interact with GnRH 
receptor-mediated antiproliferative signalling and suggest that NFκB pathway 
members may represent targets for enhancing the antiproliferative effect of GnRH 
agonists in some reproductive tissue cancers. 
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3.5 GnRHR Expression in Breast Cancer 
3.5.1 Introduction 
GnRH agonists and antagonists have previously been shown to have antiproliferative 
effects in some breast cancers [25, 26, 28, 29, 31, 32, 57, 68, 69, 71, 77, 95, 217], but 
further research is required to improve efficacy and prediction of response. To make 
these improvements, it is necessary to further understand the important signalling 
factors in the antiproliferative response to GnRH analogues, and to identify which 
breast cancers express GnRHR and therefore may be responsive to GnRH analogue 
treatment. 
 
It is unclear why some cell lines respond to GnRH analogues and others do not. 
There is some evidence to suggest that the level of GnRHR expression at the cell 
surface is proportional to the antiproliferative response of that cell line [79], in that 
high-GnRHR expressing cell lines have tended to be inhibited by GnRH agonists 
[79]. It could therefore be hypothesised that breast cancers expressing the highest 
level of GnRHR are those most likely to respond to GnRHR treatment. 
 
A high level of GnRHR has so far been shown to correlate with the antiproliferative 
response to GnRH agonist treatment [79], and increasing the expression of GnRHR 
can enhance the antiproliferative effect of GnRH agonists [32]. Although GnRHR 
binding sites have been found in breast cancer [28, 70, 74], other studies were unable 
to detect GnRHR in breast cancer cell lines [79, 119]. The level of GnRHR 
expression in breast cancer remains unclear. To explore this, the expression of 
GNRHR was investigated at both the transcriptional and proteomic level. 
 
3.5.2 GnRHR mRNA expression in breast cancer cell lines 
To identify breast cancer cell lines expressing high levels of GnRHR, the level of 
GnRHR was examined in existing published data. Neve et al (A Collection of Breast 
Cancer Cell Lines for the Study of Functionally Distinct Cancer Subtypes, Cancer 
Cell, 2006) [218] surveyed the expression profiles of 51 breast cancer cell lines using 
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Affymetrix U133A microarray chips. The expression profile of GnRHR was 
obtained from this dataset and the results of this are shown in Figure 61. High 
GnRHR expressing breast cancer cell lines tended to be of the Luminal subtype, 
although there was a range of GnRHR expression in each subtype.  
 
Figure 61: GNRHR gene expression in the Neve et al dataset, as identified using the selected 
probset 216341_s_at.  
The subtype of each breast cancer cell line is shown beneath the x axis as either Luminal (blue), 
Basal A (red) or Basal B (orange). This figure was provided by Andy Sims and is in agreement 
with other analyses performed by myself. 
 
3.5.3 GnRHR protein expression in breast cancer tumours 
The level of GnRHR protein expression in a series of clinical breast cancer samples 
was measured using quantitative immunofluorescence (AQUA
®
). Three tissue 
microarrays (TMAs) were constructed with triplicate samples from each of 347 
primary breast carcinomas [141]. The primary tissue was collected after surgical 
breast resection between 1999 and 2002 at the Breast Unit, Western General 
Hospital, Edinburgh [141]. Formalin-fixed paraffin-embedded pituitary was used as a 




Figure 62: Human anterior pituitary GnRHR was used as a positive control for GnRHR 
antibody staining. 
The left panel shows human pituitary incubated with antibody diluent in the absence of GnRHR 
antibody, and the right panel shows human pituitary incubated with Leica Microsystems 
A9E4GnRHR antibody (1:10 dilution). Positive staining was observed at the cell membrane and 
cytoplasm. 
 
DAPI, Cy3 and Cy5 filters were applied to obtain an image for each of the nucleus, 
cytokeratin mask, and the target protein (GnRHR) respectively (Figure 63).  
 
Figure 63: AQUA image analysis.  
An example TMA core showing compartmentalised staining with (A) DAPI for nuclear staining, 
(B) Cy3 anti-cytokeratin for epithelial tissue, (C) Cy5-tyramide for target protein (GnRHR), (D) 
all 3 markers overlaid. 
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High resolution images of the TMA cores were analysed using AQUAnalysis
®
 
software. The cytokeratin mask was used to identify epithelial areas of tissue and 
DAPI staining was used to define cytoplasmic and nuclear compartments. Image 
areas that either had imaging errors, or constituted less than 5% epithelium were 
removed. Within the epithelial mask of the cytoplasmic compartment, the Cy5 
fluorescent signal was calculated within each image pixel, totalled and then divided 
by the area of the cytoplasmic compartment to give a score in AQUA
®
 units (Au) 
corresponding to the level of GnRHR expression in that core. 
 
Initial observation of the data showed that there was a batch effect based on the year 
of tissue collection (Figure 64A). Therefore, prior to further analysis the data were 
mean-centred to account for this variation in staining intensity resulting from the 





A      B 
 
Figure 64:  Batch effect in AQUA scores of GnRHR expression. 
(A) A batch effect existed in the GnRHR AQUA scores based on the year of tissue collection.  
(B) Mean-centring the GnRHR AQUA data reduced the batch effect. 
 
The resulting data was analysed and associations between GnRHR expression and 
breast cancer subtype, grade, and expression of ER, PR, HER2, CK5/6 and EGFR 
were explored. These data were already available for the sample set.  
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The relationship between discrete variables (Grade or Phenotype) and GnRHR 
expression was determined by comparing the mean GnRHR expression level for each 
category (Grade 0/1/2/3 or phenotype HER2/Luminal/TNP) by one-way ANOVA. 
298 of the 347 samples were assigned to a molecular phenotype by hormone receptor 
status using the annotations given by Aitken et al [1]. Grade information was 
available for 344 of the 347 samples. 
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There was a range of GnRHR expression in all three breast cancer subtypes, with 
some samples showing high immunostaining (Figure 65A and Figure 65B) and 
others low immunostaining (Figure 65C and Figure 65D). 
 
Figure 65: GnRHR immunostaining in primary breast tumours. 
Representative examples of high (A and B) and low (C and D) GnRHR expression in TMA cores 
of breast cancers. A and C are immunohistochemical images with brown staining corresponding 
to GnRHR expression and blue staining to haematoxylin. B and D are immunofluorescent 
images with red staining corresponding to GnRHR expression, blue (DAPI) staining 
representing cell nuclei, and green staining for cytokeratin (carcinoma cell) staining. Arrows 
indicate areas of positive GnRHR expression.  
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Average GnRHR expression was highest in the Triple Negative Phenotype (TNP) 








































Figure 66: GnRH receptor protein expression in clinical breast cancers by breast cancer 
subtype.  
Each point represents one breast tumour sample, dashed lines show the mean of 20 HER2, 217 
Luminal and 61 TNP tumours. Protein expression was measured by quantitative 
immunofluoresence (AQUA). 
 
GnRHR expression was significantly higher in grade three tumours compared to 































Figure 67: GnRHR protein expression (measured by AQUA) by tumour grade.  
Each point represents one breast tumour sample, dashed lines show the mean GnRHR 
expression in 21 grade 1, 158 grade 2 and 165 grade 3 tumours.  
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The relationship between continuous variables (ER, PR, HER2, CK5/6, EGFR 
expression) and GnRHR expression was determined by non-linear regression.  
Expression values of ER, PR, HER2, CK5/6 and EGFR were available for 335, 336, 
339, 339 and 337 of the 347 samples respectively. 
 
High GnRHR expression was significantly associated with oestrogen receptor (ER) 
expression (P=0.002, regression) and progesterone receptor (PR) expression 
(P=0.028, regression). No significant association could be identified between 
GnRHR expression and HER2, CK5/6 or EGFR expression. 
 
By defining high- and low- ER and PR expression, using cut-points previously 
defined by Aitken et al [1] (high ER > 58Au; high PR > 43Au), it was demonstrated 
that GnRHR expression was significantly higher in tumours expressing low ER 
(P=0.024, 2-sample t-test) and low PR (P=0.002, 2-sample t-test) (Figure 68 and 
Figure 69). This is in agreement with the finding shown above that GnRHR was 
































Figure 68: GnRHR expression was higher in low-ER expressing tumours (n=132) compared to 
high-ER expressing tumours (n=203).  
Protein expression in 335 breast tumours was measured by quantitative immunofluorescence. 
Error bars show standard deviation. GnRHR expression was higher in low-ER expressing 


































Figure 69: GnRHR expression was higher in Low-PR expressing tumours (n=182) compared to 
high-PR expressing tumours (n=154).  
Protein expression in 335 breast tumours was measured by quantitative immunofluorescence. 
Error bars show standard deviation. GnRHR expression was higher in Low-PR expressing 
tumours compared to high-PR expressing tumours (P=0.002, 2-sample t-test). 
 186 
3.5.4 Effect of GnRHR stimulation in Breast Cancer Cell Lines 
Triptorelin has been reported by some groups to inhibit some breast cancer cell lines 
[57, 77]. In an attempt to identify a responsive cell line, a panel of 8 breast cancer 
cell lines were treated with Triptorelin (100nM) for up to 4 days. None of the breast 
cancer cell lines tested was inhibited by Triptorelin. Comparable results were 
observed when cells were treated once or daily, in serum-free media, and with bovine 
serum albumin-supplemented media. The SCL60 cell line is included as a positive 






































Figure 70: Effect of Triptorelin on the SRB activity of a panel of eight breast cancer cell lines.  
Cells were treated for up to 4 days with Triptorelin (100nM) or vehicle control. The GnRHR-
transfected HEK293 cell line SCL60 is included as a positive control. Data are expressed relative 
to vehicle control-treated cells. Error bars show +/- standard deviation of three 
intraexperimental replicates. These data are representative of at least 2 experiments. 
 
3.5.5 Discussion 
At the transcript level, there was a range of GnRHR expression across the breast 
cancer samples. On average, GnRHR expression appeared to be higher in luminal 
breast cancer cell lines. Protein immunostaining for the identification of GnRHR 
protein expression in breast cancers showed that there was a range of GnRHR protein 
expression in primary breast tumours, and each subgroup of breast cancer had 
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samples with high and low GnRHR expression. On average, GnRHR protein 
expression was significantly higher in the TNP subgroup and in grade 3 tumours, and 
was also associated with ER and PR expression, but not with HER2, CK5/6 or EGFR 
expression. These associations may help to define a subgroup of breast cancers that 
are most likely to express high GnRHR and therefore are most likely to respond to 
GnRH agonist therapy. 
 
A similar study by Baumann et al in 1993 measured GnRH agonist binding sites in 
235 breast cancer biopsies [74]. In contrast to the data presented above, the authors 
found no association between GnRHR and ER or PR [74]. The association with ER 
and PR did not appear to be a linear relationship, and values above and below a 
threshold of ER and PR expression may be more important than the continuous 
distribution of expression values in determining a relationship with GnRHR. 
Baumann et al used a smaller sample size, and looked for a correlation between the 
values rather than a more complex relationship. The authors were unable to show a 
significant association with breast cancer subtype, although they compared only two 
histological subtypes ductal and lobular, rather than the molecular subtypes (TNP, 
HER2 and Luminal) used above [74].  
 
Buchholz et al examined immunohistochemical expression of GnRHR in 17 TNP 
breast cancer samples and found immunoreactivity in all 17 samples [26]. They state 
that there was a large range of GnRHR expression in these samples with some 
expressing very low and some expressing high levels of GnRHR [26]. This is in line 
with the data presented above, which shows a large range of GnRHR expression 
across the primary breast tumours. The data presented by Buchholz, however, does 
not indicate an association with the TNP subtype of breast cancer because they did 
not explore GnRHR expression in other subtypes.  
 
In support of the association of GnRHR expression with triple-negative breast 
cancers, it has recently been claimed by Schubert et al that 74% of triple-negative 
breast cancers express GnRH receptors [25]. In further support of the association 
with triple-negative breast cancers, the authors of that study showed that the growth 
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of triple negative (MDA-MB-453) cell line-derived xenografts was slowed by 
treatment with the GnRH antagonist Cetrorelix [25]. Although the cells from which 
these xenograft tumours were derived are defined as triple-negative, and therefore 
should exhibit hormone-independent growth, these cells have also been reported to 
express androgen receptors [219, 220]. Androgen has been shown to induce 
transcriptional change in MDA-MB-453 cells [221, 222] and to enhance their 
proliferation [219]. Therefore there remains a possibility that the anti-proliferative 
effect of GnRH antagonist treatment is not a result of direct interaction with GnRHR 
in the xenograft cells. The GnRH antagonist is likely to be interacting with GnRHR 
in the pituitary and it is possible that some inhibition of xenograft growth may be due 
to a resultant down-regulation of androgen secretion. It would be interesting if this 
result could be supported by other studies, which might benefit from a GnRHR 
knock-out MDA-MB-453 cell line as a control, and other triple-negative cell types. 
Xenografts derived from another triple-negative breast cancer cell line (MDA-MB-
231) were also used in this study, and although the authors did not report whether 
there was an antiproliferative effect of a GnRH antagonist on these tumours, they did 
show that it had an anti-metastatic effect [25]. MDA-MB-231 cells have also been 
reported to express androgen receptors [220].  
 
This group have previously shown an apoptosis-inducing effect of a GnRH-II 
antagonist on the triple-negative MDA-MB-231 and ER-positive MCF7 cells [78]. 
However, the authors reported that the apoptotic effect of the GnRH-II antagonist 
remained present when GnRHR was knocked down [78]. It is therefore unclear how 
this antagonist mediated the antiproliferative effect without direct interaction with 
the GnRHR. Since the level of GnRHR expression has been shown to be important 
for the antiproliferative effect of GnRH agonists in other studies [79], the results 
reported by Grundker et al are interesting.  
 
This group reported inhibitory effects of an GnRH antagonist on proliferation of 
MCF7 cells [78], which contradict our and other groups’ findings that MCF7 cells do 
not express functionally relevant levels of GnRHR at the cell surface and that their 
growth is not inhibited by GnRH agonists or antagonists [27, 119, 121, 223, 224] 
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(Figure 70). In fact, it is shown above that a panel of eight breast cancer cell lines of 
different subtypes, including MCF7, MDA-MB-453 and MDA-MB-231 cells did not 
respond to the GnRH superagonist Triptorelin, despite this having a profound effect 
on the SRB activity of SCL60 (GnRHR-transfected HEK293) cells (Figure 70). 
Screening of these breast cancer cell lines by radioligand binding assay was unable to 
identify any that expressed detectable levels of GnRHR, thereby accounting for the 
lack of response to Triptorelin. Interestingly, Saleh-Abady et al recently 
demonstrated that proliferation of SKBR3 and T47D cells was inhibited by 
Triptorelin [77]. The authors of that study used a daily treatment regimen and 
supplemented the culture medium with bovine serum albumin. In the present study, 
no effect of Triptorelin on SKBR3 or T47D cell number could be detected with these 
alterations or with serum-free media. 
 
Fost et al recently showed that 31 out of 42 triple negative breast cancer specimens 
were GnRHR-positive [225]. Most of these GnRHR-positive specimens showed 
antigenicity in at least 70% of the tumour cells [225]. Fost et al used the target of 
GnRHR to direct a chemotherapeutic agent Doxorubicin. The GnRH agonist AEZS-
108 (AN-152) consists of doxorubicin linked to [D-Lys
6
]GnRH [225]. The authors 
showed that this induced apoptosis in triple negative breast cancer cell lines in vitro 
(MDA-MB-231, HCC1806 and HCC1937) and inhibited tumour growth of in vivo 
mouse models [225]. This study by Fost et al supported a previous similar report by 
Kahan et al [226]. This does not indicate that direct GnRHR signalling is involved, 
but does represent an interesting way of exploiting tissue-specific GnRHR 
expression if the doxorubicin-GnRH agonist conjugate induces apoptosis through 
binding to the GnRHR. The results presented above support the discovery of Fost et 
al that GnRHR expression appears to be higher in triple negative breast cancers and 
this group of patients may benefit from a GnRHR-directed treatment.  
 
It is also shown above that GnRHR expression appears to be higher in grade 3 
tumours compared to grade 2 tumours. An association between GnRHR expression 
and breast cancer grade has not previously been reported. Moriya et al examined the 
expression of GnRHR in 58 human breast carcinomas by immunohistochemistry 
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[73]. They defined tumours as being simply positive or negative for GnRHR 
immunoreactivity. By doing this, the authors identified an association between 
GnRHR and ER, PR and Ki-67, but were unable to demonstrate an association of 
GnRHR expression with grade [73]. The data presented above uses a much larger 
sample of breast tumours, showing that GnRHR expression is significantly higher in 
tumours with grade 3 status compared to grade 2, and that GnRHR expression is 
higher in TNP subtype of breast cancers. This information may help to further 
stratify a patient group most likely to benefit from GnRHR-targeted therapy. 
 
It is important to note that positive immunohistochemical staining for GnRHR 
protein does not necessarily correspond to functional GnRHR protein expression or 
sensitivity to GnRH agonist treatment. A high level of functional GnRHR protein 
expression at the cell surface is believed to be required for the antiproliferative 
effects of GnRH agonist [79]. The staining method used does not discriminate for the 
subcellular localisation of GnRHR. These results therefore must be interpreted in the 
context of further functional investigations of receptor activity, for example with 
radioligand binding assays and the measurement of inositol phosphate production 
after receptor stimulation. It is important to note that a large proportion of the human 
GnRHR in particular has been shown to be retained intracellularly in the 
endoplasmic reticulum, more so than other mammalian forms of GnRHR such as rat 
and mouse [37, 121, 223]. Human and mouse GnRHR has also been shown to be 
expressed at the nuclear membrane [223]. However, the overall level of GnRHR 
expression may indicate the potential for high GnRHR cell surface expression. 
 
An interesting finding by Finch et al, was that the proportion of GnRHR that is 
expressed at the plasma membrane can be increased using the GnRHR antagonists 
antide and cetrorelix [224, 227], and has also been shown to be increased with the 
non-peptide antagonist (2S)-2-[5-[2-(2-axabicyclo[2.2.2]oct-2-yl)-1,1-dimethy-2-
oxoethyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]-N-(2-pyridin-4-ylethyl)propan-1-
amine (IN3) [121, 224, 227]. The effect of cetrorelix on the cellular localisation of 
GnRHR was maximal by 24h [224]. This indicates that even in cells where GnRHR 
expression is very low at the cell surface, if there is sufficient GnRHR protein 
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expression in the whole cell, its localisation can be rapidly changed. This may also 
indicate that part of the antiproliferative effect of a GnRH analogue may be mediated 
through GnRH antagonist-induced increase of GnRHR trafficking to the plasma 
membrane, thus increasing its signalling capacity.  
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3.6 Developing a breast cancer model for studying GnRHR 
signalling 
The SCL60 model (HEK293 cells transfected with GnRHR) has been useful for 
studying signalling through the GnRHR, since it is well-characterised and responds 
well to GnRH agonists [79, 88, 104, 112, 116]. However, for it to be relevant to 
breast cancer patients it is necessary to use a cell line model that more accurately 
reflects the disease. A GnRH analogue-responsive breast cancer cell line expressing 
functional GnRHR may be more informative of GnRH signalling in breast cancer. 
 
3.6.1 Transfection of several breast cancer cell lines produced an 
MCF-7 clone expressing high GnRHR 
A panel of breast cancer cell lines was found to be unresponsive to GnRH agonist 
(Triptorelin) treatment (section 3.5.4), and endogenous GnRHR expression could not 
be identified by radiolabelled ligand binding assay in several breast cancer cell lines. 
To develop a model more relevant to breast cancer, several breast cancer cell lines 
were transfected with GnRHR. Kevin Morgan transfected these cell lines to produce 
clones with varying levels of GnRHR expression (Figure 71). It should be noted that 
in this chapter, it is assumed that the level of GnRHR is proportional to the specific 
binding that is measured by radioligand binding assay. The possibility that this is not 




Figure 71: GnRHR cell surface expression in transfected breast cancer cell line-derived clones. 
The level of GnRHR cell surface expression, as detected by radioligand binding assay, in a 
representative selection of transfected breast cancer cell line-derived clones, including the 
MCF7 subclone MCF7-h14. Also shown are the GnRHR-transfected cell lines SCL60 (derived 
from HEK293 cells), and WPE1-NB26-3 (derived from prostate epithelial cells). MCF7-h14 cells 
express a similar level of GnRHR as SCL60 cells. This figure is representative of multiple 
experiments performed by myself and Kevin Morgan. 
 
The extent of cell number reduction following GnRHR activation has been shown to 
correlate with the level of GnRHR cell surface expression [79]. To show any 
inhibition of proliferation, it appears that a cell line must have a minimum level of 
specific GnRH agonist binding (determined by radioligand binding assay) for 
GnRHR and must show receptor functionality, which can be measured by inositol 
phosphate assay [80].  
 
Endogenous GnRHR expression at the cell surface of the breast cancer cells MCF7, 
T47D and ZR75/1 could not be detected by binding assay (data not shown). 
Transfection of these cell lines with GnRHR produced 25 T47D clones with 
undetectable GnRHR levels, approximately 15 MCF7 clones with low to moderate 
levels of receptor, and approximately 30 ZR75-1 clones with low to very high levels 
of GnRHR (as measured by radioligand binding assay). The isolated ZR75-1 clones 
grew too slowly to be practically used for further experiments. Instead, one MCF7 
clone (MCF7-30) was re-transfected with GnRHR with hygromycin B 
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phosphotransferase to produce subclones with higher levels of GnRHR at the cell 
surface. The subclone MCF7-h14 showed high GnRHR cell surface expression 
(Figure 71, Figure 72), at a similar level to SCL60 cells, and this clone was used for 
further experiments. 
 
Figure 72: The level of GnRHR cell surface expression in the MCF7-30-7-H14 subclone 
compared to its parental clone, as detected by radioligand binding assay 
This figure is representative of experiments performed by myself and Kevin Morgan. 
 
MCF7 is a cell line derived from a pleural effusion of an invasive ductal carcinoma 
of a 69 year old Caucasian woman [119]. It is the most commonly used breast cancer 
cell line worldwide. MCF7 is classed as luminal [119]. It expresses ER and PR, has 
low HER2, and TP53 protein is wild type [119]. Another feature to note about the 
MCF7 cell line is that it has an activating mutation in PI3K [228]. Proliferation of 
MCF7 cells is enhanced by oestrogen and IGF-I [229, 230]. MCF7 cells proliferate 
relatively quickly in normal cell culture conditions, making them an ideal 
experimental model. 
Little is clearly understood about GnRHR signalling in MCF7 cells, and it has 
previously been difficult to identify GnRHR cell surface expression in these cells 
[119]. SCL60 has been the model used to investigate GnRHR antiproliferative 




The first aim of the experiments in this chapter, after establishing a GnRHR-
transfected breast cancer model, was to compare and contrast the response to 
GnRHR activation in MCF7-h14 and SCL60 cells. Specifically, to compare any 
change in the level of inositol phosphate production following GnRHR activation, 
any effect on cell number (SRB activity), and any change in the level of signalling 
molecules pERK1/2 and p-p38.  
 
The second aim was to compare and contrast how the response to GnRHR activation 
in these cells is affected by the inhibition of other potential components of the local 
signalling network, such as the growth factor receptors IGF-I-R, and PI3K. 
Specifically, to determine for both cell lines, whether each of these inhibitors affect 
cell number and the level of signalling molecules pERK1/2 and p-p38 following 
GnRHR activation.  
 
Two hypotheses were tested. Firstly, the mechanism of cell number reduction, 
including the effects on signalling molecules such as p-ERK1/2 and p-p38, may be 
different between these two cell types as GnRH agonists have previously been shown 
to act in a cell-type specific manner. Secondly, constitutive activity of one or more 
growth factor receptor signalling complexes (for example, IGF-I-R and PI3K) may 
compete with signalling induced by GnRHR activation. Inhibition of one or more of 
these in combination with GnRHR activation may have an addititve effect on cell 
number reduction in either cell type. 
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3.6.3 GnRH inhibits SRB activity of SCL60 cells but not MCF7h14 
or untransfected MCF7 cells 
The level of functional GnRHR activity in these cells was tested. Cells were 
stimulated with Triptorelin (100nM) and the level of inositol phosphate production 
was measured. MCF7-h14 cells showed a similar inositol phosphate response 
following GnRHR activation to that observed in SCL60 cells (Figure 73).  
 
 
Figure 73: The relative levels of inositol phosphate following GnRHR activation in each of 4 cell 
lines compared to unstimulated cells. 
ZR75-1-12 is a breast cancer cell line-derived clone expressing low levels of GnRHR, NB26-3 
and HEK293[SCL60] are shown as controls for high GnRHR-induced inositol phosphate 
production. MCF7-h14 cells show a similar level of inositol phosphate production to SCL60 
cells. This figure is representative of several experiments performed by myself and Kevin 
Morgan. 
 
GnRHR level at the cell surface has previously appeared to correlate with the extent 
of SRB activity inhibition [79], so it was predicted that MCF7-h14 cells would be 
inhibited by Triptorelin. 
 
MCF7-h14 cells did not demonstrate a response, in terms of SRB activity, to GnRHR 
stimulation with the GnRH agonist Triptorelin (Figure 74). The parental 
(untransfected) MCF7 cells were also unresponsive to GnRHR activation (Figure 
75). Exposure to GnRH for 5min was sufficient to inhibit SCL60 cell proliferation, 
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Figure 74: SRB activity of SCL60 and MCF7-h14 cells treated with 100nM Triptorelin for 
varying durations.  
SRB activity was measured at 4 days post-treatment. SRB activity is shown relative to vehicle 
control. Bars represent the mean of 3 intraexperimental replicates. Error bars indicate +/- 
standard deviation. The differential effect of Triptorelin on SCL60 and MCF-7-h14 shown here 









































Figure 75: SRB activity of untransfected MCF7 cells treated with 100nM Triptorelin.  
SRB activity was measured at 2, 3, or 5 days post-treatment. SRB activity is shown relative to 
vehicle control. Bars represent the mean of 3 intraexperimental replicates. Error bars indicate 
+/- standard deviation. These data are representative of at least 2 independent experiments. 
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In order to help understand why MCF7-h14 cells are not responsive to a GnRH 
agonist, the non-responsive MCF7-h14 cell line was compared with the responsive 
SCL60 cell line. In particular, the dependence of each cell line on the growth factor 
receptor IGF-I-R and the growth/survival signalling enzyme PI3K was examined. 
 
3.6.3.1 The effect of GnRHR activation on signalling in MCF7-h14 and 
SCL60 cells 
GnRHR activation causes a transient increase in pERK1/2 in SCL60 cells (Figure 
76A) [79] and pERK1/2 levels were also transiently increased, but to a much lesser 
degree, in MCF7-h14 cells (Figure 76B). Unlike in SCL60 cells, pERK1/2 is already 
high in resting MCF7-h14 cells (0min, Figure 76B). This may mask an increase in 
pERK1/2 caused by the addition of Triptorelin. A growth factor present in the serum 
in the MCF7 culture medium may cause this high basal pERK1/2 activity. Serum-
starved MCF7-h14 cells showed much lower basal ERK1/2 activity than those grown 
in normal culture conditions, and they showed a transient increase in pERK1/2 
similar to that seen in SCL60 cells (Figure 76C). 
 
Because the ERK1/2 response to GnRHR simulation is thought to be important in 
mediating the antiproliferative effect of Triptorelin, it was interesting to explore 
which growth factors may be competing with GnRHR signalling to ERK1/2. 
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Figure 76: pERK1/2 response to GnRHR activation.  
(A) Expression of pERK1/2 in SCL60 cells treated with Triptorelin or vehicle control for up to 
60min, as detected by western blot. 
(B) Expression of pERK1/2 in MCF7-h14 cells treated with Triptorelin or vehicle control for up 
to 60min, as detected by western blot. 
(C) Expression of pERK1/2 in serum-starved (overnight) MCF7-h14 cells treated with 
Triptorelin or vehicle control for up to 60min, as detected by western blot. These data are 
representative of at least 3 independent experiments. 
 
Phospho-p38 (p-p38) was transiently increased in SCL60 cells after treatment with 
Triptorelin (Figure 77A). To a lesser extent, p-p38 expression also appeared to 
transiently increase in MCF7-h14 cells after Triptorelin treatment (Figure 77B). 
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Figure 77: p-p38 response to GnRHR activation.  
Expression of p-p38 in (A) SCL60 and (B) MCF7-h14 cells treated with Triptorelin (100nM) or 
vehicle control for up to 60min, as detected by western blot. These data are representative of at 
least 2 independent experiments. 
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3.6.4 IGF-I-R inhibition reduced SRB activity of SCL60, MCF7-h14 
and MCF7 cells both alone and in combination with a GnRH 
agonist 
IGF-I-R inhibition prevents growth of wild-type MCF7 cells [231] and this was 











































Figure 78: SRB activity of wild type MCF7 cells treated with 2, 4, or 10µM IGF-I-R inhibitor.  
SRB activity was measured at 1, 2, and 3 days post-treatment with 2, 4, or 10µM IGF-I-R 
inhibitor II (#407248 Calbiochem, EMD Biosciences, USA). Bars represent the mean of 3 
intraexperimental replicates. Error bars indicate +/- standard deviation. The data for this figure 
was provided by Kevin Morgan. 
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IGF-I-R inhibition reduced SCL60 and MCF7-h14 cell number in a time-dependent 
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Figure 79: SRB activity of MCF7-h14 and SCL60 cells treated with 20µM IGF-I-R inhibitor for 
up to 24h.  
SRB activity was measured at 4 days post-treatment with 20µM IGF-I-R inhibitor II (#407248 
Calbiochem, EMD Biosciences, USA). Bars represent the mean of 3 intraexperimental 
replicates. Error bars indicate +/- standard deviation. These data are representative of at least 2 
independent experiments. 
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IGF-I-R inhibition reduced MCF7-h14 and SCL60 cell number in a dose-dependent 













Figure 80: SRB activity of MCF7-h14 cells in response to IGF-I-R inhibitor. 
SRB activity of MCF7-h14 cells treated with 4, 10 or 20µM IGF-I-R inhibitor for up to 5 days. 
SRB activity was measured at 1, 2, and 5 days post-treatment. Bars represent the mean of 3 
















































Figure 81: SRB activity of SCL60 cells treated with 2 or 10µM IGF-I-R inhibitor with or 
without 100nM Triptorelin, or 100nM Triptorelin alone for up to 6 days.  
SRB activity was measured at 1, 2, 3 and 6 days post-treatment. Bars represent the mean of 3 
intraexperimental replicates. Error bars indicate +/- standard deviation. These data are 
representative of at least 2 independent experiments. 
 
When the IGF-I-R inhibitor was washed out after 1h SRB activity was unaffected 










































































Figure 82: Effect of IGF-I-R inhibition on SRB activity of MCF7-h14 cells. 
SRB activity of MCF7-h14 cells treated with 15µM IGF-I-R inhibitor continuously or for 1h 
then washed out and then untreated or treated with 100nM Triptorelin continuously. SRB 
activity was measured at 4 days post-treatment. Bars represent the mean of 3 intraexperimental 
replicates. Error bars indicate +/- standard deviation. 
 
3.6.4.1 There was a sustained decrease in pERK1/2 in MCF7-h14 cells, 
but not SCL60 cells, following treatment with a IGF-I-R inhibitor 
IGF-I-R inhibition had no detectable effect on pERK1/2 levels in SCL60 cells 
(Figure 83A), but appeared to cause a sustained decrease in pERK1/2 in MCF7-h14 
cells (Figure 83B).  
 
Pre-incubation with an IGF-I-R inhibitor did not prevent GnRHR-mediated transient 
elevation in of pERK1/2 in SCL60 cells (Figure 83A). MCF7-h14 cells showed 
hyper-reactivation of ERK1/2 (far above basal) after removal of IGF-I-R inhibitor, 
and this was not altered by GnRHR stimulation (Figure 83B).  
 
 206 
IGF-I-R inhibition did not prevent GnRHR-mediated transient elevation in of p-p38 
in SCL60 cells (Figure 84A). p-p38 appeared to be transiently decreased with IGF-I-
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Figure 83: SCL60 and MCF7-h14 pERK1/2 response to Triptorelin and IGF-I-R inhibitor 
(A) Expression of pERK1/2 in SCL60 cells treated with IGF-I-R inhibitor for up to 4h then 
Triptorelin or vehicle control for up to 90min, as detected by western blot. 
(B) Expression of pERK1/2 in MCF7-h14 cells treated with IGF-I-R inhibitor for 60min then 
Triptorelin or vehicle control for up to 6h, as detected by western blot. 
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Figure 84: SCL60 and MCF7-h14 p-p38 response to Triptorelin and IGF-I-R inhibitor 
(A) Expression of p-p38 in SCL60 cells treated with IGF-I-R inhibitor for up to 6h then 
Triptorelin or vehicle control for up to 20min, as detected by western blot. 
(B) Expression of p-p38 in MCF7-h14 cells treated with IGF-I-R inhibitor up to 3h, as detected 
by western blot. 
This figure was provided by Kevin Morgan. 
 
3.6.5 PI3K inhibition caused mild inhibition of SCL60 SRB activity 
but had no effect on MCF7-h14 or WT MCF-7 cells either 
alone or in combination with GnRHR stimulation 
PI3K inhibition caused a small reduction in SRB activity of SCL60 cells in a dose-
dependent manner (Figure 85). The inhibitor used inhibits PI3K-p110γ, α, β and δ 
[232]. No additive effect was observed when cells were also treated with Triptorelin 
in combination (Figure 85). PI3K inhibition did not cause a reduction in SRB activity 
of MCF7-h14 cells (Figure 85) or untransfected MCF7 cells (Figure 86) either alone 
















































Figure 85: SRB activity of MCF7-h14 and SCL60 cells treated with 0.8, 1.6, and 7µM PI3K 
inhibitor with or without 100nM Triptorelin relative to vehicle control 
SRB activity was measured at 4 days post-treatment. Bars represent the mean of 3 
intraexperimental replicates. Error bars indicate +/- standard deviation. These data are 












































Figure 86: SRB activity of wild type MCF7 cells 7µM PI3K inhibitor with or without 100nM 
Triptorelin relative to vehicle control 
SRB activity was measured at 3 and 4 days post-treatment. Bars represent the mean of 3 
intraexperimental replicates. Error bars indicate +/- standard deviation. 
These data are representative of at least 2 independent experiments. 
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3.6.5.1 The effects of PI3K inhibition on signalling in SCL60 and MCF7-
h14 cells 
No effect could be detected on the level of pERK1/2 expression in SCL60 (Figure 
87A) or MCF7-h14 (Figure 87B) cells following PI3K inhibition. PI3K inhibition 




Figure 87: pERK1/2 response to PI3K inhibition 
(A) Expression of pERK1/2 in SCL60 cells treated with a PI3K inhibitor, as detected by western 
blot. 
 (B) Expression of pERK1/2 in MCF7-h14 cells treated with a PI3K inhibitor, as detected by 
western blot. 
These data are representative of 2 experiments. 
 
A small transient increase in p-p38 in SCL60 cells was observed following treatment 
with a PI3K-γ inhibitor (Figure 88A). This did not appear to alter the p-p38 response 
to Triptorelin observed in Figure 77 (Figure 88A). A delayed decrease in p-p38 was 
detected in MCF7-h14 cells following PI3K-γ inhibition (Figure 88B) after 60min of 
treatment with PI3K-γ inhibitor. This was sustained for a further 5 hours, at which 




Figure 88: p-p38 response to PI3K inhibition 
(A) Expression of p-p38 in SCL60 cells treated with 7µM PI3K inhibitor, as detected by western 
blot.  
(B) Expression of p-p38 in MCF7h14 cells treated with 800nM PI3K inhibitor, as detected by 
western blot.  
These data are from a single experiment. 
 
3.6.6 NFκB inhibition did not inhibit the SRB activity of MCF7h14 
cells either alone or in combination with Triptorelin. 
Because SCL60 cells had been shown to be inhibited by 15d-PGJ2, it was interesting 
to investigate whether MCF7-h14 cells might also be responsive to this NFκB 
inhibitor. MCF7-h14 cells were treated with 15d-PGJ2 (3µM) alone and in 
combination with Triptorelin (100nM). Cell number was measured by SRB assay at 
1, 4 and 6 days after treatment. No significant reduction in SRB activity could be 
observed in response to 15d-PGJ2 either alone or in combination with the GnRH 















































Figure 89: NFκB inhibition in MCF7-h14 cells with 3µM 15d-PGJ2. 
NFκB inhibition with 3µM 15d-PGJ2 did not cause reduction in SRB activity of MCF7-h14 cells 
either alone and in combination with 100nM Triptorelin. SRB activity was measured 4 days 
after treatment by SRB assay and is shown relative to that of the vehicle control-treated cells. 




Since no breast cancer cell line expressing detectable levels of endogenous GnRH 
receptor could be identified, several cell lines (ZR75/1, T47D and MCF7) were 
transfected with GnRHR. Among the clones produced was the MCF7-h14 clone, 
which showed high GnRHR cell surface expression (Figure 71, Figure 72). GnRHR 
level has previously appeared to correlate with the extent of cell number inhibition 
[79], so it was predicted that MCF7-h14 cells would be inhibited by Triptorelin. 
 
MCF7-h14 cells showed similar GnRHR expression and a similar inositol phosphate 
response following GnRHR activation to SCL60 cells (Figure 73). This indicated 
that the cells have similar levels of functional receptor activity. Despite this, MCF7-
h14 cells were not responsive to GnRHR stimulation with the GnRH agonist 
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Triptorelin. The parental (untransfected) MCF7 cells were also unresponsive to 
GnRHR activation (Figure 75).  
 
Exposure to Triptorelin for 5min was sufficient to inhibit SCL60 cell proliferation by 
approximately 40% after 4 days. This indicates that after 5min receptor stimulation, 
signalling pathway(s) downstream of the GnRHR remain active without the 
requirement for further ligand-receptor stimulation. Maximal inhibition after 4 days 
(~60%) was achieved with continuous exposure to Triptorelin for just 8h (Figure 74). 
This indicates that continuous exposure for 8h maintains the antiproliferative 
signalling.  
 
Until now, cell lines transfected with a high level of GnRHR have been shown to be 
sensitive to GnRH agonist treatment [50, 79]. It is not clear why this MCF-7-h14 
clone, that expresses a high level of GnRHR at the cell surface, is not responsive to a 
GnRH agonist.  
 
It has previously been shown that the proliferation of MCF7-h14 cells may be 
inhibited by targeting the GnRHR [32]. Everest et al were unable to detect 
endogenous GnRHR in MCF7 cells, so the authors infected the cells with adenovirus 
expressing sheep GnRHR (which has high affinity for GnRH-I). They report that 
80% of the cells then transiently expressed GnRHR and that GnRH and GnRH-I 
agonists (but not antagonists) inhibited thymidine incorporation in the MCF7 cells 
[32]. This indicated that MCF7 cells can have the required cellular machinery to 
elicit an antiproliferative response to GnRHR stimulation. This is in contrast to the 
data presented above, with the stably transfected MCF7-h14 model. The differences 
in response may be explained by a number of factors. Firstly, MCF7-h14 cells 
express rat GnRHR and were treated with the GnRH agonist Triptorelin, whereas the 
MCF7 cells in Everest et al’s study expressed sheep GnRHR and were treated with 
the GnRH agonist Buserelin. The two different receptors, or the different GnRH 
agonists, may induce differential downstream signalling. Secondly, the transfection 
process to stably express GnRHR in MCF7-h14 cells involves incorporation of 
GnRHR DNA into the host DNA. This can damage the host DNA and impact upon 
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cellular function such that the corresponding antiproliferative signalling pathway is 
not functional. Additionally, it is widely appreciated that a cell line may differ 
between laboratories due to genetic drift arising from independent culture, or subtle 
differences in the culturing environment. These differences may in part explain the 
absence of a response to Triptorelin in MCF7-h14 cells. 
 
It is assumed here that specific binding is directly proportional to the level of 
GNRHR cell surface expression. However, it is important to be aware that this may 
not necessarily be true. There may be variation in the affinity for GnRH agonist 
within the population of cell surface GnRHRs on a given cell, on different cells, and 
between cells of different cell lines. A small number of receptors with a high affinity 
may give the same level of specific binding as a high number of receptors with a low 
affinity. It is also important to consider that a the affinity of a GnRHR, or population 
of GnRHRs, for the agonist used in the ligand binding assay may differ from its 
affinity for other agonists. The level of GnRHR expression at the cell surface may 
not necessarily be the most important factor in determining receptor functionality. It 
has previously been shown that a large proportion of human GnRHR is retained 
intracellularly [223]. The rate at which GnRHR is trafficked to and from the plasma 
membrane is likely to be more important in determining the extent of GnRHR 
signalling activation. The ligand binding assays used in this study focus on one 
concentration of radioligand. A single concentration of ligand can give misleading 
results on the estimated binding affinity of the receptor population because the 
competitive equilibrium will be shifted depending on the ligand concentration. 
Multiple concentrations of radioligand have been used previously to determine the 
range of ligand concentration which gives a linear relationship to specific binding. 
3
[H]IP accumulation is used as a measure of receptor function. It should be noted that 
a limitation of this assumption is that the pool of inositol within different cells may 
be variable and if limited this may give misleading results indicating poor receptor 
functionality.  
 
MCF7-h14 cells and SCL60 cells appeared to have a comparable level of GnRHR 
(assuming that the binding affinities of GnRHR are equal between the cell lines) and 
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GnRHR-induced inositol phosphate production. Both SCL60 and MCF7-h14 cells 
express the rat GnRHR. This is used because it is more efficiently trafficked the 
plasma membrane, whereas human GnRHR is retained intracellularly. In real human 
proliferative diseases (cancer), only the human receptor may be present, and is likely 
to be intracellular. GnRHR signalling in SCL60 cells is signalling that appears to 
occur as a result of high GnRHR expression at the cell surface. In human cancers, in 
which GnRHR is largely intracellular, the nature of the signalling may differ. As 
discussed above, in human cancers it may be more important that the cells have a 
high rate of GnRHR trafficking to and from the cell membrane, as this would allow 
higher signalling even with a low proportion of the receptors at the membrane at any 
one time. Transfection may alter cells in ways additional to the presence of receptor, 
and these changes may be a requirement for (or a hindrance to) the antiproliferative 
effects of a GnRH agonist. It is possible that in MCF7-h14 cells, the transfection 
process has caused damage which may prevent the equivalent GnRHR-induced 
antiproliferative signalling pathway from being activated or propagated to the same 
outcome as in SCL60 cells. 
 
Unlike in SCL60 cells, a change in the level of pERK1/2 could not be detected in 
MCF7-h14 cells in the presence of serum, perhaps due to a higher basal level of 
pERK1/2 in MCF7-h14 relative to SCL60 (Figure 76B). A small increase in 
pERK1/2 was observed in serum-starved MCF7-h14 cells (Figure 76C), although 
transient alterations in the level of pERK1/2 have been observed in other cells that 
are inhibited by GnRHR activation even in the presence of serum, such as SCL60 
(Figure 76A) and prostate-derived WPE-NB-26-3 cells [50, 79]. The lack of change 
in pERK1/2 might account for the lack of inhibitory effect of GnRHR stimulation on 
MCF7-h14 cell number.  
 
p-p38 was also transiently increased in SCL60 cells after treatment with Triptorelin 
(Figure 77A), following a similar activation pattern to pERK1/2, although p-p38 
remained above basal level at 60min post-treatment whereas pERK1/2 returned to, or 
was even below, basal level by 30min (Figure 77A). This is in agreement with 
previously published data showing rapid activation of p38 in SCL60 cells [79]. This 
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supports the role of multiple MAPK pathways in the antiproliferative response to 
Triptorelin, although in that study by Morgan et al, a p38 inhibitor had no effect on 
cell survival following Triptorelin treatment in SCL60 cells [79].  
 
IGF-I-R inhibition reduced SCL60 and MCF7-h14 cell number in a time- (Figure 79) 
and dose-dependent manner (Figure 80, Figure 81). The two cell lines were inhibited 
to a similar extent. IGF-I-R inhibition also reduces SRB activity of wild-type MCF7 
cells [231] and this was confirmed by Kevin Morgan (Figure 78). This is consistent 
with previous literature describing the growth-stimulatory role of IGF-I in MCF7 
cells [233-237]. When the IGF-I-R inhibitor was washed out after 1h, MCF7-h14 cell 
cell number was unaffected (Figure 82), indicating that the antiproliferative effect of 
IGF-I-R inhibition is reversible up to at least 1h. Triptorelin did not appear to inhibit 
or increase the rate of cell recovery (Figure 82), although, given that the cells fully 
recovered, any positive effect may be masked. 
 
IGF-I-R inhibition had no detectable effect on pERK1/2 levels in SCL60 cells 
(Figure 83A), but caused a rapid (within 30min) decrease in pERK1/2 in MCF7-h14 
cells (Figure 83B). This discrepancy may be due to the lower level of basal pERK1/2 
activity in SCL60 cells relative to MCF7-h14 cells. Pre-incubation with an IGF-I-R 
inhibitor for 4h (and then removing the inhibitor by washing with PBS) did not 
prevent the GnRHR-mediated transient elevation in of pERK1/2 in SCL60 cells 
(Figure 83A), which has previously been shown to correlate with cell number 
inhibition [50, 79]. MCF7-h14 cells showed hyper-reactivation of ERK1/2 (far above 
basal) after removal of IGF-I-R inhibitor, and this was not altered by GnRHR 
stimulation (Figure 83B).  
 
MCF7 cells have an activating PI3K mutation, whereas SCL60 cells do not [228]. It 
is possible that this may underlie the differential signalling response to IGF-I-R 
removal in these cells. The decrease in pERK1/2 in MCF7-h14 cells may be due to 
decreased signalling from IGF-I-R to pERK1/2 via PI3K. Since PI3K is not mutated 
in SCL60 cells there is no significant decrease in pERK1/2 levels with IGF-I-R 
inhibition. In MCF7-h14 cells, when IGF-I-R inhibition is removed, the already 
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activated PI3K may interact with the IGF-I-R complex to re-phosphorylate ERK1/2, 
whereas since PI3K is not mutated in SCL60 cells and there is no significant re-
phosphorylation of ERK1/2 in these cells.  
 
Proliferation of MCF7 cells is enhanced by oestrogen [229, 230], whereas SCL60 
does not endogenously express ERα. ERα-mediated growth promoting signalling 
may act in opposition to the GnRHR-mediated antiproliferative pathway, since it has 
been shown that ERα interacts with MAPK and Akt pathways and participates in 
cross-talk with IGF-I-R [238, 239]. This may contribute to the differential effect of 
GnRHR activation in these cells. ERα is known to interact with RTK signalling such 
as IGF-I-R, EGFR and the MAPK and Akt signalling pathways [235, 236, 240]. 
 
GnRHR mediated changes in ERK1/2 may be masked by constitutive growth factor 
receptor activity which may maintain (high) levels of pERK1/2. This may explain 
why no change in pERK1/2 is seen upon GnRHR activation in MCF7-h14 cells in 
the presence of growth factors. Both SCL60 and MCF7-h14 cells were sensitive to 
IGF-I-R inhibition. This was much less pronounced in SCL60 than MCF7-h14 which 
suggests that IGF-I-R signalling plays a more dominant role in MCF7-h14 than 
SCL60 cells. This may explain why GnRHR activation is unable to overcome 
IGF-I-R-driven signalling in MCF7-h14 cells.  
 
Gαq binds PLC, which signals to activate ERK1/2 via PKC and Raf [241]. This is 
thought to be the mechanism by which GnRHR induces a transient increase in 
pERK1/2 in SCL60 cells [79]. Transient ERK1/2 activation may be relevant to the 
mechanism of GnRH agonist-induced reduction in SRB activity of SCL60 cells. Gαq 
is also able to inhibit PI3K and Akt [208, 209, 241], and the level of pERK1/2 may 
be dependent on a balance of ERK1/2 activation through Gαq-PLC and ERK1/2 
inhibition through Gαq-PI3K (Figure 91). GnRHR activation did not cause a 
reduction in SRB activity of MCF7-h14 cells. PI3K is constitutively active in MCF7 
cells and may maintain high levels of pERK1/2 [228]. Gαq can still inhibit 
constitutively active PI3K, but this may not be sufficient to induce apoptosis [209]. 
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Alternatively, a transient decrease in pERK1/2 is associated with the antiproliferative 
effect of GnRHR activation in neuroblastoma (B35) cells and in prostate cells 
WPE-1-NB26-3 [50]. Gαq is also able to inhibit PI3K and Akt [208, 209, 241], and 
this may compete with the Gαq-PLC pathway to ERK1/2. This physical interaction 
between activated Gαq and PI3K may be responsible for the transient decrease in 
pERK1/2 in B35 and WPE-NB26-3 cells. Since MCF7 cells have an activating PI3K 
mutation, this pathway may be blocked, thus preventing a GnRHR-mediated 


















Figure 90: Possible model of GnRHR signalling based on constitutive growth factor receptor 
activity 
GnRHR mediated changes in ERK1/2 may be masked by constitutive growth factor receptor 
activity which may maintain (high) levels of pERK1/2. This may explain why no change in 
pERK1/2 is seen upon GnRHR activation in MCF7-h14 cells. Both SCL60 and MCF7-h14 cells 
were sensitive to IGF-I-R inhibition. This was much less pronounced in SCL60 than MCF7-h14 
which suggests that IGF-I-R signalling plays a more dominant role in MCF7-h14 than SCL60 
cells. This may explain why GnRHR activation is unable to overcome IGF-I-R-driven signalling 



















Figure 91: Possible model of GnRHR signalling based on PI3K activity 
Transient ERK1/2 activation is thought to be the mechanism of GNRH-induced reduction in 
SCL60 cell number. The level of pErk1/2 may be dependent on a balance of Erk activation 
through Gαq-PLC and Erk inhibition through Gαq-PI3K. GnRHR activation did not cause a 
reduction in the SRB activity of MCF7-h14 cells. PI3K is constitutively active in MCF7 cells and 
may maintain high levels of pERK1/2. Gαq can still inhibit constitutively active PI3K, but this 
may not be sufficient to induce apoptosis. 
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In summary, Kevin Morgan developed a GnRHR-transfected breast cancer cell line, 
MCF7-h14. The response of MCF7-h14 cells to GnRHR stimulation was compared 
to that of SCL60 cells. Unlike SCL60 cells, MCF7-h14 cells were not inhibited by 
GnRHR activation despite the cell lines having similar levels of receptor expression. 
This may be explained by an inability of GnRHR-signalling to overcome constitutive 
PI3K activity in MCF7-h14 cells. Both cell lines appeared to be dependent on IGF-I-
R for normal proliferation. In MCF7-h14 cells a small reduction in pERK1/2 
expression was observed following IGF-I-R inhibition, but a similar effect on 
pERK1/2 expression was could not be detected in SCL60 cells. IGF-I-R inhibition 
did not affect GnRHR-mediated changes in pERK1/2 or p-p38 in SCL60 cells. PI3K 
inhibition did not affect GnRHR-mediated changes in pERK1/2 and p-p38 in either 
cell line; PI3K reduced SRB activity in SCL60 cells at 7µM. 
 
Both cell lines were sensitive to IGF-I-R inhibition, and blocking PI3K activity 
caused a mild reduction in SRB activity of SCL60 cells only. This information, 
coupled with knowledge of MAPK signalling involvement, aids the formation of 
further models which may explain the differential outcomes of GnRHR stimultation 
in these cell types (Figure 90, Figure 91), and therefore which factors may be 
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 220 
4 Final Discussion 
The GnRH agonist Triptorelin inhibited SCL60 cell number by a combination of 
apoptosis and inhibition of proliferation both in vitro and in vivo, and cell cycle arrest 
appears to be involved in vitro. A global gene expression time series in SCL60 cells 
following Triptorelin treatment implicated transcriptional changes in cell cycle, 
MAPK and adhesion-related genes, with good support from other gene expression 
studies [108, 109]. Gene expression data would benefit from computational 
modelling to understand the complex interactions at the transcriptomic level to 
identify how pathways may be interacting to mediate the antiproliferative effects of a 
GnRH agonist. The models indicated above may represent useful starting points.  
 
The level of pAkt was decreased at multiple time-points following GnRHR 
stimulation, and NFκB was activated following GnRHR stimulation. SCL60 cells 
(but not HEK293 cells) were sensitive to NFκB inhibition and the combination of 
GnRHR stimulation and NFκB inhibition enhanced the antiproliferative effect 
observed with either drug alone. This suggested that NFκB may be activated as part 
of a survival response to GnRH agonist treatment. A role for Akt and NFκB has not 


















Figure 92: Schematic diagram summarising the proteomic and transcriptomic responses to 
Triptorelin in SCL60 cells, which may contribute to the induction of G2/M arrest and apoptosis. 
At the protein level, Triptorelin appears to activate NFκB and ERK1/2, but inhibit Akt. These 
proteins may potentially drive the transcriptional responses to GnRHR stimulation. Early 
changes were observed in the expression levels of many transcription factors, some of which 
were transient and others maintained for up to 24h. Triptorelin influenced the expression of 
genes involved in apoptosis and G1/S phase progression after 1-8h of treatment, whereas the 
expression of cytoskeletal/adhesion signalling components and genes involved in G2/M phase 
progression was altered slightly later at around 8h after treatment. 
 
At the protein level, Triptorelin appears to activate NFκB and ERK1/2, but inhibit 
Akt. These proteins may drive the transcriptional responses to GnRHR stimulation, 
which consisted of early changes in the expression levels of transcription factors, 
some of which were transient and others maintained for up to 24h. Triptorelin 
influenced the expression of genes involved in apoptosis and G1/S phase progression 
after 1-8h of treatment, whereas the expression of cytoskeletal/adhesion signalling 
components and genes involved in G2/M phase progression was altered slightly later 
at 8-24h after treatment. 
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GnRHR protein expression was significantly higher in the Triple Negative 
Phenotype (TNP) subgroup of breast cancer and in grade 3 tumours. However, SRB 
activity of a breast cancer clone expressing high GnRHR (MCF7-h14) was not 
inhibited by Triptorelin despite these cells expressing a similar level of GnRHR to 
SCL60 cells, suggesting that a high level of functional GnRHR is not sufficient for 
the direct antiproliferative effects of Triptorelin. This may have implications for the 
identification of a subgroup of breast cancers that are most likely to respond to 
GnRH agonist therapy, since identifying breast tumours with high GnRHR may not 
be sufficient to predict a response.  
 
The comparison between the responsive high GnRHR-expressing SCL60 and the 
unresponsive high GnRHR-expressing MCF7-h14 cells could be expanded further. A 
high-throughput gene and protein expression profiling approach to compare these 
cells, and their responses to Triptorelin would help to identify critical signalling 
factors that are absent, or may be competing with GnRHR-mediated antiproliferative 
signalling, in MCF7h14 cells. It may also be interesting to investigate any role of 
pAkt and NFκB in MCF7h14 cells, since these appear to be important in the SCL60 
response to GnRHR stimulation. 
 
It is important to note that many of the results presented here, particularly western 
blots, are derived from single or duplicate experiments (n=1 or n=2). Any 
conclusions drawn from these therefore must be tentative and further validation, 
ideally with different methodologies, is required to affirm them. These data do 
however indicate signalling molecules of interest and provide hypotheses on which 
to base further experiments. 
 
 
The observation that proliferation of MCF7-h14 cells was not inhibited by 
Triptorelin, despite the cells expressing a high level of GnRHR, is a particularly 
important step in understanding the antiproliferative effects of GnRHR signalling. It 
demonstrates that a high level of GnRHR is insufficient for the antiproliferative 
response, and underlines the role of multiple pathways interacting with GnRHR. The 
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experiments above have indicated that growth factor signalling (such as IGF-I) 
appears to out-compete GnRHR signalling in breast cancer cells, and understanding 
how these pathways interact may help to identify a combination therapy to enhance 
the antiproliferative effects of GnRHR signalling in breast cancer. 
 
Further work may expand the current gene expression study of the SCL60 response 
to Triptorelin to explore the response to Triptorelin in vivo SCL60 xenografts. In 
addition, a comparison between the transcriptional response to Triptorelin in MCF7-
h14 cells and SCL60 cells may highlight further reasons for the differential outcome 
of GnRHR stimulation. It would be important in future work to evaluate the 
limitations and caveats discussed above, particularly with regard to GnRHR number 
and function in SCL60 and MCF7-h14 cells. It would be interesting to further 
explore the role of pNFκB and pAkt pathways at the proteomic level in response to 
GnRHR stimulation, and how this may relate to the antiproliferative effects of 
Triptorelin. This study focussed on only one GnRH agonist, but the possibility of 
differential effects of other GnRH agonists and antagonists would be interesting to 
investigate.  
 
In conclusion, GnRHR activation in SCL60 cells resulted in changes in the 
expression of cell cycle, MAPK and adhesion-related genes. At the protein level, 
pAkt expression was decreased, and NFκB was activated following Triptorelin 
treatment. NFκB inhibition enhanced the antiproliferative effect of Triptorelin in 
SCL60 cells, and may play a survival role in response to GnRHR activation. A range 
of GnRHR expression was observed in breast cancer tumours, and on average 
GnRHR expression was higher in the TNP subgroup. Despite MCF7-h14 cells 
expressing a similar high level of functional GnRHR to SCL60 cells, their SRB 
activity was unaffected by Triptorelin, indicating for the first time that a high level of 
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6 Appendix A 
14-3-3 ζ(Ab-58)   JunB(Phospho-Ser259)  
14-3-3 ζ(Phospho-Phospho-
Ser58) JunB(Phospho-Ser79)  
4E-BP1(Ab-36)  JunD(Ab-255)  
4E-BP1(Phospho-Thr36)  JunD(Phospho-Ser255)  




Akt(Phospho-Ser473)  MEK1(Ab-217)  
Akt(Phospho-Thr308)  MEK1(Ab-221)  
Akt2(Ab-474)  MEK1(Ab-291)  
Akt2(Phospho-Ser474)  MEK1(Phospho-Ser217)  
AMPK1(Ab-174)   MEK1(Phospho-Ser221)  
AMPK1(Phospho-Phospho-
Thr174) MEK1(Phospho-Thr291)  
ATM(Ab-1981)  MEK-2(Ab-394)  
BAD(Ab-112)  MEK-2(Phospho-Thr394)  
BAD(Ab-136)  Met(Ab-1349)  
BAD(Ab-155)  Met(Phospho-Tyr1349)  
BAD(Phospho-Ser112)  MKK3(Ab-189)  
BAD(Phospho-Ser136)  MKK3(Phospho-Ser189)  
BAD(Phospho-Ser155)  MSK1(Ab-376)  
BCL-2(Ab-56)  MSK1(Phospho-Ser376)  
BCL-2(Ab-70)  mTOR(Ab-2448)  
BCL-2(Phospho-Ser70)  mTOR(Phospho-Ser2448)  
BCL-2(Phospho-Thr56)  Myc(Ab-358)  
BCL-XL(Ab-62)  Myc(Ab-373)  
BCL-XL(Phospho-Ser62)  Myc(Ab-58)  
BRCA1(Ab-1423)  Myc(Ab-62)   
BRCA1(Ab-1524)  Myc(Phospho-Phospho-Ser62) 
BRCA1(Phospho-Ser1423)  Myc(Phospho-Ser373)  
BRCA1(Phospho-Ser1524)  Myc(Phospho-Thr358)  
CaMKII (Ab-286)  Myc(Phospho-Thr58)  
CaMKII (Phospho-Thr286)  NFκB-p100/p52(Ab-865)  
Caveolin-1(Ab-14)  NFκB-p100/p52(Ab-869)  
Caveolin-1(Phospho-Tyr14)  NFκB-p100/p52(Phospho-Ser869)  
CDC2(Ab-15)  NFκB-p105/p50(Ab-337)  
CDC2(Phospho-Tyr15)  NFκB-p105/p50(Ab-337)  
cdc25A (Ab-75)  NFκB-p105/p50(Ab-893)  
cdc25A (Phospho-Ser75)  NFκB-p105/p50(Ab-907)  
cdc25C(Ab-216)  NFκB-p105/p50(Phospho-Ser893)  
cdc25C(Phospho-Ser216)  NFκB-p105/p50(Phospho-Ser907)  
CDK2(Ab-160)  NFκB-p105/p50(Phospho-Ser932)  
CDK2(Phospho-Thr160)  NFκB-p65(Ab-254)  
Chk1(Ab-280)  NFκB-p65(Ab-529)  
Chk1(Ab-317)  NFκB-p65(Phospho-Ser529)  
Chk1(Ab-345)  NFκB-p65(Phospho-Thr254)  
Chk1(Phospho-Ser280)  p21Cip1(Ab-145)  
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Chk1(Phospho-Ser317)  p21Cip1(Phospho-Thr145)  
Chk1(Phospho-Ser345)  p27Kip1(Ab-10) 
Chk2(Ab-516)  p27Kip1(Ab-187) 
Chk2(Ab-68)  p27Kip1(Phospho-Ser10)  
Chk2(Phospho-Ser516)  p27Kip1(Phospho-Thr187)  
Chk2(Phospho-Thr68)  P38 MAPK(Ab-182)  
c-Jun (Phospho-Thr239)  P38 MAPK(Phospho-Thr180)  
c-Jun(Ab-239)  P38 MAPK(Phospho-Tyr182)  
c-Jun(Ab-243)  p44/42 MAP Kinase(Ab-202)  







c-Kit(Ab-721)  p53(Ab-315)  
c-Kit(Phospho-Tyr721)  p53(Ab-6)  
CREB(Ab-133)  p53(Phospho-Ser315)  
CREB(Phospho-Ser133)  p53(Phospho-Ser6)  
CrkII(Ab-221)   p70 S6 Kinase (Ab-424)  
CrkII(Phospho-Phospho-Tyr221) p70 S6 Kinase (Phospho-Ser424)  





EGFR(Ab-1110)  PDK1(Ab-241)  
EGFR(Phospho-Tyr1110)  PDK1(Phospho-Ser241)  




elF4E(Ab-209)  Pyk2(Ab-402)  
elF4E(Phospho-Ser209)  Pyk2(Phospho-Tyr402)  
Elk-1(Ab-383)  Rac1/cdc42(Ab-71)  
Elk-1(Phospho-Ser383)  Rac1/cdc42(Phospho-Ser71)  
Estrogen Receptor-α (Ab-167)  Raf1(Ab-259)  
Estrogen Receptor-α (Phospho-
Ser167)  Raf1(Phospho-Ser259)  
FAK(Ab-397)  Rb(Ab-780)  
FAK(Ab-861)  Rb(Phospho-Ser780)  
FAK(Ab-925)  Rel(Ab-503)  
FAK(Phospho-Tyr861)  Rel(Phospho-Ser503)  
FAK(Phospho-Tyr925)  SAPK/JNK(Ab-183)  
FGF Receptor 1(Ab-154)  SAPK/JNK(Phospho-Thr183)  
FGF Receptor 1(Phospho-
Tyr154)  Shc(Ab-349)   
FKHR(Ab-256)  Shc(Phospho-Phospho-Tyr349) 
FKHR(Phospho-Ser256)  SHP-2(Ab-580)   
GSK3α(Ab-21)  SHP-2(Phospho-Phospho-Tyr580) 
GSK3α(Phospho-Ser21)  Smad3(Phospho-Phospho-Ser425) 
GSK3β(Ab-9)  Src(Ab-418)  
GSK3β(Phospho-Ser9)  Src(Ab-529)  
HDAC8(Ab-39)  Src(Phospho-Tyr418)  
HDAC8(Phospho-Ser39)  Src(Phospho-Tyr529)  
HER2(Ab-877)  STAT1(Ab-701)  
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HER2(Phospho-Tyr877)  STAT1(Ab-727)  
Histone H2A.X(Ab-139)  STAT1(Phospho-Ser727)  
Histone H2A.X(Phospho-
Ser139)  STAT1(Phospho-Tyr701)  
HSF1(Ab-303)  STAT3(Ab-705)  
HSF1(Phospho-Ser303)  STAT3(Ab-727)  
HSP27(Ab-15)  STAT3(Phospho-Ser727)  
HSP27(Ab-78)  STAT3(Phospho-Tyr705)  
HSP27(Phospho-Ser15)  STAT4(Ab-693)  
HSP27(Phospho-Ser78)  STAT4(Phospho-Tyr693)  
HSP90B(Ab-254)   STAT5A (Ab-694)  
HSP90B(Phospho-Phospho-
Ser254) STAT5A (Ab-780)  
ICAM-1(Ab-512)  STAT5A (Phospho-Ser780)  
ICAM-1(Phospho-Tyr512)  STAT5A (Phospho-Tyr694)  
IGF-1R (Ab-1161)  STAT6(Ab-641)  
IGF-1R (Phospho-Tyr1161)  STAT6(Ab-645)  
IKK α(Ab-23)  STAT6(Phospho-Thr645)  
IKK α(Phospho-Thr23)  STAT6(Phospho-Tyr641)  
Integrin β3(Ab-773)  Tau(Ab-404)  
Integrin β3(Ab-785)  Tau(Phospho-Ser404)  
Integrin β3(Phospho-Tyr773)  Trk B(Ab-515)   
Integrin β3(Phospho-Tyr785)  Trk B(Phospho-Phospho-Tyr515) 
IκB-α(Ab-32/36)  TYK2(Ab-1054)  
IκB-α(Ab-42)  TYK2(Phospho-Tyr1054)  
IκB-α(Phospho-Ser32/Phospho-
Ser36)  VEGFR2(Ab-951)  
IκB-α(Phospho-Tyr42)  VEGFR2(Phospho-Tyr951)  
IκB-β(Phospho-Phospho-Ser23) β-Catenin(Ab-37)  
IκB-ε(Ab-22)   β-Catenin(Ab-41/45)  
IκB-ε(Phospho-Phospho-Ser22) β-Catenin(Phospho-Ser33)  




JAK2(Ab-1007)  Beta Actin 
JAK2(Ab-221)  Empty 
JAK2(Phospho-Tyr1007)  GAPDH 
JAK2(Phospho-Tyr221)  Negative control 
JunB(Ab-259)  Positive control 
JunB(Ab-79)    




Appendix A Figure 1: Overview heatmap showing 4745 differentially expressed genes between 
untreated HEK293 and untreated SCL60 cells.  
The heatmap shows 4 replicates for each cell line from left to right. Each horizontal line on the 
heatmap represents a gene. Red indicates a higher expression, green indicates a lower 
expression. The genes are hierarchically clustered to reveal two major, similarly sized clusters: 
one cluster showing genes increased in SCL60 compared to HEK293 cells, and one cluster 
showing genes that are decreased in SCL60 compared to HEK293 cells. 
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Gene Illumina Probe ID Fold 
Change 
Description 
SOX11 ILMN_1773459 +19 Transcriptional regulation 
KRT19 ILMN_1730777 +15 Keratin 
RYR3 ILMN_1796455 +14 Ryanodine receptor 
MAL2 ILMN_1770653 +12 Lipid raft component 
FLJ12684 ILMN_2072622 +10 Unknown 
BEX1 ILMN_2234697 +6.4 Cell cycle, NGFR signalling, can inhibit 
NFkB 
VANGL2 ILMN_1715647 +6.3 Cell polarisation 
UCHL1 ILMN_1757387 +5.9 Hydrolyses ubiquitin 
PRSS3 ILMN_1685699 +5.5 Serine protease 
RAB17 ILMN_2052373 +5.4 Small GTPase 
TCEAL3 ILMN_1734190 +5.4 Transcription regulation 
HLA-DRB5 ILMN_1697499 +5.3 MHC complex 
HLA-B ILMN_1778401 +5.3 MHC complex 
SFRP1 ILMN_2149164 +5.1 Wnt Signalling 
EEF1A2 ILMN_2108735 +5.0 Protein biosynthesis 
TCEAL3 ILMN_1749478 +4.7 Transcription regulation 
HOPX ILMN_2316236 +4.7 Interacts with serum response factor, possible 
tumour suppressor 
CYP4X1 ILMN_2175317 +4.6 Cytochrome P450 
LOC389641 ILMN_1713141 +4.6 Unknown 
CD44 ILMN_1803429 +4.5 Adhesion 
TACSTD1 ILMN_2160210 +4.5 Adhesion 
RUNX3 ILMN_1787461 +4.5 Transcriptional regulation 
MT1F ILMN_1718766 +4.4 Metallothioneins 
TNFRSF10A ILMN_1721316 +4.2 TNF Receptor, activates NFkB 
PTGER4 ILMN_1795930 +4.1 Prostaglandin E2 receptor 
Appendix A Table 2: The 25 probes with the most significantly increased expression in SCL60 
cells compared to HEK293 cells.  
The probes changes are ordered in ascending probability of each being false positive, which for 









HSPA1A ILMN_1789074 -210 Heat shock protein  
CMBL ILMN_1709634 -23 Cysteine hydrolase 
NEFH ILMN_1705153 -15 Neurofilament 
CA2 ILMN_1662795 -14 Carbonic anhydrase II 
CA2 ILMN_2199439 -14 Carbonic anhydrase II 
TMEM47 ILMN_2129234 -9.9 Transmembrane protein 
ZSCAN18 ILMN_1654946 -8.5 Transcriptional regulation 
NEFM ILMN_2215989 -8.4 Neurofilament 
PCDH17 ILMN_1781514 -8.0 Cadherin (adhesion) 
NEFL ILMN_1659086 -7.8 Neurofilament 
ZNF83 ILMN_2190414 -7.3 Transcriptional regulation 
ZNF816A ILMN_1728710 -7.3 Transcriptional regulation 
ZNF135 ILMN_1726368 -6.6 Transcriptional regulation 
ZNF702 ILMN_1663281 -5.7 Transcriptional regulation 
FABP5 ILMN_2146761 -5.7 Fatty acid binding protein 
IFITM3 ILMN_1805750 -5.1 IFN-induced antiviral protein 
ZNF160 ILMN_1777049 -5.2 Transcriptional regulation 
HS.572538 ILMN_1886769 -4.7 Unknown 
ZNF649 ILMN_1699249 -4.4 Transcriptional regulation 
HOXB5 ILMN_1674908 -4.0 Anterior-Posterior development 
LOC400713 ILMN_1773367 -3.9 Transcriptional regulation 
PCDH10 ILMN_1688500 -3.9 Cadherin (adhesion) 
SH3PXD2A ILMN_1743103 -3.7 ECM degradation, invasion 
ZNF682 ILMN_2242998 -3.6 Transcriptional regulation 
HS.200774 ILMN_1849209 -3.7 Unknown 
Appendix A Table 3: The 25 probes with the most significantly decreased expression in SCL60 
cells compared to HEK293 cells.  
The probes changes are ordered in ascending probability of each being false positive, which for 
all the probes in the table is less than 0.05. Gene descriptions were taken from the GeneCards 
database.
 249 
 Genes P-Value FDR 
Increased from SC0 to ST0.5    
hsa04010:MAPK signaling pathway DUSP5, FOS, DUSP1, JUN, GADD45B 0.008 6.8 
Increased from SC0 to ST1       
hsa04010:MAPK signaling pathway 
DUSP5, FOS, DUSP1, JUN, MAP3K8, JUND, NR4A1, 
GADD45B, SRF, GADD45A, MYC, DDIT3 1E-05 0.011 
hsa04620:Toll-like receptor signaling 
pathway FOS, IL8, JUN, MAP3K8, IL12A, NFKBIA 0.002 1.6 
hsa04115:p53 signaling pathway RRM2, CYCS, PMAIP1, GADD45B, GADD45A 0.003 2.6 
hsa04622:RIG-I-like receptor signaling 
pathway DDX3X, ISG15, IL8, IL12A, NFKBIA 0.003 3.1 
hsa04350:TGF-beta signaling pathway BMP2, ID2, ID1, ID3, MYC 0.006 6.3 
hsa04621:NOD-like receptor signaling 
pathway CCL2, IL8, CXCL2, NFKBIA 0.02 15 
Increased from SC0 to ST2       
hsa04010:MAPK signaling pathway 
RELB, NR4A1, SRF, DDIT3, DUSP5, FOS, DUSP3, ATF4, 
DUSP1, JUND, MAP3K8, GADD45B, GADD45A 1E-04 0.12 
hsa04621:NOD-like receptor signaling 
pathway CCL2, IL8, CXCL2, CCL8, NFKBIA 0.008 7.9 
hsa04115:p53 signaling pathway CASP9, PMAIP1, GADD45B, THBS1, GADD45A 0.01 11 
hsa04620:Toll-like receptor signaling 
pathway TMED7, FOS, IL8, MAP3K8, NFKBIA 0.04 35 
hsa04622:RIG-I-like receptor signaling 
pathway DDX3X, ISG15, IL8, NFKBIA 0.06 49 
Appendix A Table 4: Differentially expressed genes between untreated (0h) SCL60 controls and SCL60 cells treated with Triptorelin for up to 24h were 
enriched for several signalling pathways.  
P-value was calculated within the DAVID system using a one-tail Fisher Exact test. False Discovery Rate (FDR) was also calculated within the DAVID system 
and is shown to 2 significant figures. 
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 Genes P-Value FDR 
Increased from SC0 to ST8       
hsa04621:NOD-like receptor signaling 
pathway HSP90B1, CCL2, IL8, CCL8, CHUK, CCL7 0.01 15 
hsa04060:Cytokine-cytokine receptor 
interaction 
BMP2, CCL2, IL8, TNFRSF12A, CCL8, KITLG, CCL7, IL11, 
TNFRSF10A, CCL20, TNFRSF10D, IL12A, IFNGR1 0.02 18 
hsa04010:MAPK signaling pathway 
MAP2K4, RELB, NR4A1, DUSP5, FOS, RPS6KA3, DUSP1, JUN, 
HSPA6, GADD45B, GADD45A, DUSP8, CHUK 0.02 20 
hsa04115:p53 signaling pathway CDKN1A, CASP9, PMAIP1, GADD45B, THBS1, GADD45A 0.02 20 
hsa04620:Toll-like receptor signaling 
pathway TMED7, FOS, IL8, JUN, MAP2K4, IL12A, CHUK 0.03 28 
Decreased from SC0 to ST8       
hsa03410:Base excision repair MUTYH, PARP4, XRCC1, SMUG1, NTHL1 0.01 14 
hsa03030:DNA replication PRIM1, POLA2, MCM2, MCM5 0.07 57 
        
Increased from SC0 to ST24       
hsa04060:Cytokine-cytokine receptor 
interaction 
CCL2, IL8, CCL20, TNFRSF12A, CCL8, CD70, CCL7, IL11, 
CCL26, ACVR1 0.04 35 
hsa04621:NOD-like receptor signaling 
pathway CCL2, IL8, CCL8, CCL7 0.09 66 
Decreased from SC0 to ST24       
hsa04115:p53 signaling pathway CDKN2A, BAX, LRDD, DDB2, CHEK2, SESN1 0.01 12 
hsa00562:Inositol phosphate metabolism ALDH6A1, ISYNA1, IMPA2, PLCG2 0.09 66 
Appendix A Table 4 (continued): Differentially expressed genes between untreated (0h) SCL60 controls and SCL60 cells treated with Triptorelin for up to 
24h were enriched for several signalling pathways.  P-value was calculated within the DAVID system using a one-tail Fisher Exact test. False Discovery Rate 




Appendix A Figure 2: The Kakar et al gene signature clustered the SCL60 dataset into control 
and Triptorelin-treated groups.  
SCL60 (S) cells treated with Triptorelin (T) or vehicle control (C) for up to 24h. SCx = SCL60 
treated with vehicle control for x hours, STx = SCL60 treated with Triptorelin for x hours. Four 
replicates are shown for each time point from left to right (except for SC1, for which there are 3 



















7 Appendix B 
Further supplementary material is available on the enclosed CD.  
 
The CD contains the file Colette Meyer PhD Thesis – Supplementary File 1.xls, 
which contains further details of the differentially expressed genes between HEK293 
and SCL60 cells and in SCL60 cells with Triptorelin treatment. It also details the 
conversion of Kakar et al genes to Illumina IDs and the full list of expression values 
observed in the phosphoproteomic antibody array (V250). 
 
The CD also contains the published BMC cancer paper below (BMC Cancer Morgan 
et al 2011.pdf), which is also available online at 
http://www.biomedcentral.com/1471-2407/11/476. 
 
GnRH receptor activation competes at a low level with growth signaling in stably 
transfected human breast cell lines. 
Morgan K, Meyer C, Miller N, Sims AH, Cagnan I, Faratian D, Harrison DJ, Millar 
RP, Langdon SP. 
